0000313143-26-000050 | 10-K | XBRL Viewer

Print Document

SEGMENT AND ENTERPRISE-WIDE INFORMATION - Segment Information By Geographic Region (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]
Total long-lived assets	$ 305,761	$ 284,052
Net revenues	1,334,027	1,360,824	$ 1,309,055
United States
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]
Total long-lived assets	224,699	217,212
Net revenues	982,176	1,010,918	970,007
Japan
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]
Total long-lived assets	916	1,250
Net revenues	68,200	62,408	58,087
Europe
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]
Total long-lived assets	32,080	20,024
Net revenues	185,019	175,655	160,142
Rest of Asia
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]
Total long-lived assets	30,833	28,705
Net revenues	87,212	92,305	107,536
Other
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]
Total long-lived assets	17,233	16,861
Net revenues	$ 11,420	$ 19,538	$ 13,283

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

+ Details

LEASES - Supplemental Balance Sheet Information Operating Leases (Details) - USD ($) $ in Thousands	Mar. 28, 2026	Mar. 29, 2025
Leases [Abstract]
Right-of-use assets	$ 39,619	$ 47,492
Operating lease, liability, current	9,243	8,107
Operating lease, liability, noncurrent	$ 40,898	$ 50,454
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other long-term assets	Other long-term assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other current liabilities	Other current liabilities
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other long-term liabilities	Other long-term liabilities

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)	3 Months Ended	12 Months Ended
	Mar. 28, 2026 USD ($) unit	Mar. 28, 2026 USD ($) unit	Mar. 29, 2025 USD ($)	Mar. 30, 2024 USD ($)
Summary of Significant Accounting Pronouncements [Line Items]
Optional exemption term	1 year	1 year
Cash and cash equivalents maximum maturity period		3 months
Number of business units \| unit		3
Goodwill, reporting unit, quantitative assessment, number \| unit	1	1
Reporting unit, carrying value	$ 821,600,000	$ 821,600,000
Reporting unit, percentage of fair value in excess of carrying amount	6.00%	6.00%
Fair value measurement, input measurement, discount rate		10.50%
Impairment of intangible assets		$ 86,546,000	$ 2,391,000	$ 10,419,000
Amortization expense		1,400,000	1,400,000	900,000
Capitalized implementation costs	$ 62,400,000	62,400,000	44,000,000.0
Impairment charges related to the discontinuance of certain capitalized software projects		0	0	0
Advertising expense		7,400,000	7,700,000	7,100,000
Foreign currency transaction gain (loss), before tax		$ (3,200,000)	$ (900,000)	$ (4,000,000.0)
Ten Largest Customers \| Net Revenues \| Customer Concentration Risk
Summary of Significant Accounting Pronouncements [Line Items]
Concentration risk		44.00%	42.00%	48.00%
Plasma Customer, CSL Limited (CSL), Two Customers \| Net Revenues \| Customer Concentration Risk
Summary of Significant Accounting Pronouncements [Line Items]
Concentration risk		13.00%
Minimum
Summary of Significant Accounting Pronouncements [Line Items]
Software capitalization term		5 years
Maximum
Summary of Significant Accounting Pronouncements [Line Items]
Software capitalization term		10 years
Attune Medical
Summary of Significant Accounting Pronouncements [Line Items]
Fair value measurement, input measurement, discount rate		19.80%
Business combination, asset, fair value	12,300,000	$ 12,300,000
Business combination, asset, carrying value	89,500,000	89,500,000
Impairment of intangible assets	77,200,000
Hospital
Summary of Significant Accounting Pronouncements [Line Items]
Reporting unit, fair value	$ 867,800,000	$ 867,800,000

CAPITAL STOCK (Schedule of Summary of Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options Outstanding, (in shares), Beginning Balance	993,587
Options Outstanding, (in shares), Granted	227,425
Options Outstanding, (in shares), Exercised	(36,267)
Options Outstanding, (in shares), Forfeited	(166,850)
Options Outstanding, (in shares), Ending Balance	1,017,895	993,587
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price (in dollars per share), Beginning Balance	$ 81.75
Weighted Average Exercise Price (in dollars per share), Granted	70.05
Weighted Average Exercise Price (in dollars per share), Exercised	57.90
Weighted Average Exercise Price (in dollars per share), Forfeited	89.42
Weighted Average Exercise Price (in dollars per share), Ending Balance	$ 78.74	$ 81.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted Average Remaining Life, Balance	3 years 6 months	3 years 6 months
Aggregate Intrinsic Value, Balance	$ 45	$ 2,249
Options Outstanding, (in shares), Exercisable and End of Period	599,839
Weighted Average Exercise Price (in dollars per share), Exercisable at End of Period	$ 79.67
Weighted Average Remaining Life, Exercisable at End of Period	2 years 2 months 12 days
Aggregate Intrinsic Value, Exercisable at End of Period	$ 33
Options Outstanding, (in shares), Vested and Expected to Vest at End of Period	945,805
Weighted Average Exercise Price (in dollars per share), Vested or Expected to Vest at End of Period	$ 78.87
Weighted Average Remaining Life, Vested or Expected to Vest at End of Period	3 years
Aggregate Intrinsic Value, Vested and Expected to Vest at End of Period	$ 45
Performance Share Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Shares, Vested (in shares)	162,066
Performance shares target, percentage	100.00%
Performance Share Units (PSUs) \| Performance Period One
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Shares, Vested (in shares)	162,066
Performance shares target, percentage	128.00%

DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION	12 Months Ended
DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION	Mar. 28, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION	DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Haemonetics’ innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. When used in this report, the terms “we,” “us,” “our,” “Haemonetics” and the “Company” mean Haemonetics Corporation. Haemonetics manages its business in three principal reporting segments: Plasma, Blood Center and Hospital. For that purpose, “Plasma” includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. “Blood Center” includes blood collection and processing devices and disposables for plasma, red cells and platelets. “Hospital” is comprised of Interventional Technologies, which includes Vascular Closure, Sensor-Guided Technologies and Esophageal Protection product lines, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management product lines. The accompanying consolidated financial statements present separately the Company’s consolidated financial position, results of operations, cash flows and changes in shareholders’ equity. The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). All amounts presented, except per share amounts, are stated in thousands of U.S. dollars, unless otherwise indicated. The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Cash Flows from Operating Activities:
Net income	$ 97,308	$ 167,679	$ 117,558
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	111,717	115,586	97,215
Amortization of fair value inventory step-up	5,814	14,956	3,347
Share-based compensation expense	33,827	29,636	28,332
Impairment of intangible assets	86,546	2,391	10,419
Gain on repurchase of convertible senior notes, net	0	(12,600)	0
Gains on sales of property, plant and equipment	(714)	(15,698)	(1,013)
Remeasurement of contingent consideration	(1,879)	(23,022)	0
Deferred income taxes	(26,471)	(5,219)	(11,039)
Other non-cash operating activities	10,726	9,978	11,633
Change in operating assets and liabilities:
Change in accounts receivable	(14,881)	6,956	(24,193)
Change in inventories	47,361	(64,704)	(60,061)
Change in prepaid income taxes	(4,534)	226	(983)
Change in other assets and other liabilities	(35,028)	(25,232)	(34,046)
Change in accounts payable and accrued expenses	(16,571)	(19,208)	44,582
Net cash provided by operating activities	293,221	181,725	181,751
Cash Flows from Investing Activities:
Capital expenditures	(32,780)	(39,278)	(38,125)
Proceeds from divestiture and sale of assets	0	43,291	1,500
Proceeds from sale of property, plant and equipment	1,375	23,253	1,810
Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment	(51,891)	(21,112)	(28,171)
Acquisitions	60,180	150,906	243,852
Other investments	(36,071)	(17,143)	(15,551)
Net cash used in investing activities	(179,547)	(161,895)	(322,389)
Cash Flows from Financing Activities:
Proceeds from issuance of convertible notes	0	700,000	0
Repayment and repurchase of convertible notes	(300,000)	(185,500)	0
Purchase of capped call related to convertible notes	0	(88,200)	0
Term loan borrowings	0	250,000	0
Term loan redemption	0	(262,500)	0
Repayment of term loan borrowings	(6,250)	(4,688)	(12,250)
Proceeds from revolving facility	300,000	0	110,000
Payments on revolving facility	0	(50,000)	(60,000)
Debt issuance costs	0	(23,135)	0
Proceeds from employee stock purchase plan	7,893	8,333	7,214
Cash used to net share settle employee equity awards	(5,001)	(10,243)	(5,885)
Share repurchases	(175,000)	(225,000)	0
Other financing activities	(102)	(249)	(922)
Net cash (used in) provided by financing activities	(178,460)	108,818	38,157
Effect of exchange rates on cash and cash equivalents	3,463	(685)	(3,185)
Net Change in Cash and Cash Equivalents	(61,323)	127,963	(105,666)
Cash and Cash Equivalents at Beginning of Year	306,763	178,800	284,466
Cash and Cash Equivalents at End of Year	245,440	306,763	178,800
Supplemental Disclosures of Cash Flow Information:
Interest paid	17,465	16,534	20,901
Income taxes paid	60,665	49,293	52,706
Fair value of previously held equity interest settled in connection with acquisition	47,258	0	0
Settlement of pre-existing loan in connection with acquisition	$ 35,812	$ 0	$ 0

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain on cash flow hedges, net of tax	$ 2,097	$ (935)	$ 4,912
Designated as Hedging Instrument \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain on cash flow hedges, net of tax	2,540
Amount of Gain (Loss) Reclassified from AOCL into Earnings	1,145
Amount of Gain (Loss) Excluded from Effectiveness Testing	2,637
Designated as Hedging Instrument \| Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain on cash flow hedges, net of tax	(443)
Amount of Gain (Loss) Reclassified from AOCL into Earnings	(5)
Amount of Gain (Loss) Excluded from Effectiveness Testing	0
Not Designated as Hedging Instrument \| Cash Flow Hedging \| Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain on cash flow hedges, net of tax	0
Amount of Gain (Loss) Reclassified from AOCL into Earnings	0
Amount of Gain (Loss) Excluded from Effectiveness Testing	$ (5,111)

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 182
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-182

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(5)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(6)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CCC
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CCC
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CCC
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CC
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E

+ Details

EARNINGS PER SHARE (Schedule of Earnings Per Share Reconciliation) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Earnings Per Share [Abstract]
Net income	$ 97,308	$ 167,679	$ 117,558
Basic weighted average shares (in shares)	47,179	50,330	50,706
Net effect of common stock equivalents (in shares)	175	400	691
Diluted weighted average shares (in shares)	47,354	50,730	51,397
Basic income per share (in dollars per share)	$ 2.06	$ 3.33	$ 2.32
Diluted income per share (in dollars per share)	$ 2.05	$ 3.31	$ 2.29
Anti-dilutive shares (in shares)	936,000	768,000	606,000

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482705/350-40-65-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479719/606-10-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482705/350-40-65-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479719/606-10-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482705/350-40-65-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479719/606-10-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 45: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 50: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 51: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 52: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 28, 2026	Mar. 29, 2025
Amortizable:
Gross Carrying Amount	$ 805,515	$ 762,866
Accumulated Amortization	363,763	316,313
Net Carrying Amount	441,752	446,553
Non-amortizable:
Non-amortizable intangibles	5,903	9,190
Developed technology
Amortizable:
Gross Carrying Amount	556,631	506,144
Accumulated Amortization	193,114	156,123
Net Carrying Amount	$ 363,517	$ 350,021
Weighted average useful life	11 years 7 months 6 days	12 years 1 month 6 days
Customer contracts and related relationships
Amortizable:
Gross Carrying Amount	$ 130,862	$ 135,561
Accumulated Amortization	76,489	70,842
Net Carrying Amount	$ 54,373	$ 64,719
Weighted average useful life	11 years 3 months 18 days	12 years 7 months 6 days
Capitalized software
Amortizable:
Gross Carrying Amount	$ 95,880	$ 85,528
Accumulated Amortization	82,284	76,185
Net Carrying Amount	$ 13,596	$ 9,343
Weighted average useful life	2 years 10 months 24 days	6 years 10 months 24 days
Patents and other
Amortizable:
Gross Carrying Amount	$ 7,422	$ 19,678
Accumulated Amortization	4,613	6,796
Net Carrying Amount	$ 2,809	$ 12,882
Weighted average useful life	5 years 6 months	8 years 6 months
Trade names
Amortizable:
Gross Carrying Amount	$ 14,720	$ 15,955
Accumulated Amortization	7,263	6,367
Net Carrying Amount	$ 7,457	$ 9,588
Weighted average useful life	10 years 4 months 24 days	12 years 3 months 18 days
In-process research and development
Non-amortizable:
Non-amortizable intangibles	$ 5,903	$ 9,190

RETIREMENT PLANS (Narrative) (Details) - USD ($)	12 Months Ended
RETIREMENT PLANS (Narrative) (Details) - USD ($)	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Reinsurance contracts asset value	$ 7,300,000	$ 7,000,000.0
Benefit obligation, plan funded by company	7,100,000	7,400,000
Accumulated benefit obligation	32,000,000.0	29,100,000
Amount expected to be amortized from accumulated other comprehensive loss in next fiscal year	300,000
Subsidiaries
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions	1,100,000	1,000,000.0	$ 700,000
Savings Plus Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions	8,900,000	8,200,000	8,100,000
401k Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions	$ 0	$ 0	$ 0

LEASES - Schedule of Maturity of Operating Lease Liabilities (Details) $ in Thousands	Mar. 28, 2026 USD ($)
Leases [Abstract]
Fiscal 2027	$ 11,631
Fiscal 2028	9,567
Fiscal 2029	7,621
Fiscal 2030	7,261
Fiscal 2031	7,029
Thereafter	16,895
Total future minimum operating lease payments	60,004
Less: imputed interest	(9,863)
Present value of operating lease liabilities	$ 50,141

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant, and Equipment Useful Life (Details)	Mar. 28, 2026
Minimum \| Building
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, useful life	30 years
Minimum \| Building improvements
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Minimum \| Plant equipment and machinery
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Minimum \| Office equipment and information technology
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Minimum \| Haemonetics equipment
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Maximum \| Building
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, useful life	40 years
Maximum \| Building improvements
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, useful life	20 years
Maximum \| Plant equipment and machinery
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, useful life	15 years
Maximum \| Office equipment and information technology
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, useful life	10 years
Maximum \| Haemonetics equipment
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, useful life	7 years

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 905
-SubTopic 360
-Name Accounting Standards Codification
-Section 25
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478704/905-360-25-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 05
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482338/360-10-05-3

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482222/360-10-30-2

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 05
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482338/360-10-05-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 05
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482338/360-10-05-3

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 05
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482338/360-10-05-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482558/350-40-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A

+ Details

INCOME TAXES

12 Months Ended

Mar. 28, 2026

Income Tax Disclosure [Abstract]

INCOME TAXES

Domestic and foreign income before provision for income tax is as follows:


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Domestic	$	87,236	$	161,800	$	112,563
Foreign	40,794		50,271		39,302
Total	$	128,030	$	212,071	$	151,865

The income tax provision (benefit) from continuing operations contains the following components:


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Current
Federal	$	35,794	$	29,818	$	29,113
State	9,078		8,112		6,539
Foreign	12,251		12,085		9,532
Total current	$	57,123	$	50,015	$	45,184
Deferred
Federal	(17,960)		(6,555)		(6,165)
State	(3,175)		1,774		2,132
Foreign	(5,266)		(842)		(6,844)
Total deferred	$	(26,401)	$	(5,623)	$	(10,877)
Total	$	30,722	$	44,392	$	34,307

The Company conducts business globally and reports its results of operations in a number of foreign jurisdictions in addition to the United States. The Company’s reported tax rate differs from the statutory tax rate due to the jurisdictional mix of earnings in any given period as the foreign jurisdictions in which it operates have tax rates that differ from the U.S. statutory tax rate. The Company’s effective tax rate is adversely impacted by non-deductible expenses including executive compensation and transaction costs, and is favorably impacted by changes in contingent consideration revaluation, the expiration of the statute of limitations with respect to certain uncertain tax position reserves, jurisdictional mix of earnings, impact of foreign tax law changes and research credits generated.

Tax effected, significant temporary differences comprising the net deferred tax liability are as follows:


	March 28, 2026		March 29, 2025
	(Dollars in Thousands)
Deferred tax assets:
Depreciation	$	304	$	97
Amortization of intangibles	4,286		4,796
Inventory	5,357		2,846

Accruals, reserves and other deferred tax assets	14,941		14,801
Net operating loss carry-forward	29,453		8,842
Stock based compensation	5,116		4,897
Operating lease liabilities	12,614		14,906
Tax credit carry-forward, net	7,734		6,713
Capitalized research expenses	39,958		39,219
Gross deferred tax assets	119,763		97,117
Less valuation allowance	(14,238)		(11,930)
Total deferred tax assets (after valuation allowance)	105,525		85,187
Deferred tax liabilities:
Depreciation	(37,368)		(35,006)
Amortization of goodwill and intangibles	(79,850)		(87,905)
Unremitted earnings	(2,726)		(1,497)
Operating lease assets	(9,823)		(12,033)

Other deferred tax liabilities	(4,285)		(3,518)
Total deferred tax liabilities	(134,052)		(139,959)
Net deferred tax liabilities	$	(28,527)	$	(54,772)

The valuation allowance increase of $2.3 million during fiscal 2026 is primarily due to an increase in valuation allowances established against acquired attributes offset by a decrease in the valuation allowance against foreign deferred tax assets and other income tax attributes utilized during the fiscal year. The Company has assessed, on a jurisdictional basis, the available means of recovering deferred tax assets, including the ability to carry-back net operating losses, the existence of reversing temporary differences, the availability of tax planning strategies and available sources of future taxable income. It has also considered the ability to implement certain strategies that would, if necessary, be implemented to accelerate taxable income and use expiring deferred tax assets. The Company has concluded that future taxable income can be considered a source of income to realize a benefit for deferred tax assets in certain jurisdictions. The Company believes it is able to support the deferred tax assets recognized as of the end of the year based on all of the available evidence. The worldwide net deferred tax liability as of March 28, 2026 includes deferred tax liabilities related to amortizable tax basis in goodwill and other indefinite lived assets, which can only be used as a source of income to benefit other indefinite lived deferred tax assets.

As of March 28, 2026, the Company maintains a valuation allowance against certain U.S. foreign tax credit carryforwards and U.S. state net operating loss and tax credit carryforwards that are not more-likely-than-not realizable, as well as a valuation allowance against the deferred tax assets of certain foreign subsidiaries.

In connection with certain acquisitions, the Company has acquired net operating loss and tax credit carryforwards, which may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50 percent as defined under Section 382 and 383 of the U.S. Internal Revenue Code of 1986, respectively, as well as similar state provisions. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. The Company conducted Section 382 studies covering the periods of inception through the respective acquisition dates. The studies concluded that ownership changes occurred during those periods which limit the amount of the Company’s net operating losses and tax credit carryforwards that can be utilized before expiring. The remaining carryforwards disclosed in the deferred tax table above represent the amount of attributes that can be utilized based on the results of the studies. The Company does not believe it has had any additional ownership change that would result in additional limitations. Subsequent ownership changes may further affect the limitation in future years. In fiscal 2026, the Company acquired approximately $135.5 million of net operating losses in Ireland as a result of the acquisition of Vivasure. The Company has preliminarily concluded that the transaction does not result in the net operating losses being subject to any utilization limitations associated with the acquisition itself.

As of March 28, 2026, the Company has U.S. federal net operating loss carryforwards of $6.6 million, all of which will begin to expire in fiscal 2027. The Company has U.S. state net operating losses of $51.5 million of which $51.0 million will expire at various times between fiscal 2027 and fiscal 2044 and $0.5 million can be carried forward indefinitely. The Company has federal tax credits of $0.6 million that will begin to expire in fiscal 2030 and state tax credits of $6.6 million that began to expire in fiscal 2029.

As of March 28, 2026, the Company has Canadian federal and provincial net operating loss carryforwards of $21.5 million and $18.2 million, respectively, which will expire from fiscal 2036 through fiscal 2045. Additionally, the Company has Irish net operating loss carryforwards of $140.0 million that can be carried forward indefinitely. The Company has other foreign net operating losses of approximately $6.8 million that are available to reduce future income which can be carried forward indefinitely. The Company has foreign research tax credits of $2.0 million which will begin to expire in fiscal 2035.

As of March 28, 2026, substantially all of the unremitted earnings of the Company have been taxed in the U.S. The accumulated earnings in the foreign subsidiaries are primarily utilized to fund working capital requirements as its subsidiaries continue to expand their operations and to fund future foreign acquisitions. The Company does not believe it is practicable to estimate the amount of income taxes payable on the earnings that are indefinitely reinvested in foreign operations, however a significant portion of the unremitted earnings could be remitted without a future tax cost.

In accordance with the adoption of ASC Update No. 2023-09, income tax provision differs from the tax provision computed at the U.S. federal statutory income tax rate due to the following:


	Year Ended March 28, 2026
	(Dollars in Thousands)
Tax at federal statutory rate	$	26,886	21.0	%
State income taxes net of federal benefit(1)	4,610		3.6	%
Foreign tax effects
Switzerland
Statutory tax rate difference	(5,051)		(3.9)	%
Local income tax	2,246		1.8	%
Other items	21		—	%
Canada
Local income tax	(1,838)		(1.5)	%
Other items	(1,071)		(0.8)	%
Ireland	1,341		1.0	%
Other foreign jurisdictions	3,267		2.6	%
Effect of cross-border tax laws	(770)		(0.6)	%
Nontaxable or nondeductible items
Other nontaxable or nondeductible items	1,496		1.2	%
Limitation on executive compensation	3,434		2.7	%
Tax credits
Federal research credits	(3,089)		(2.4)	%
Other tax credits	(852)		(0.7)	%
Changes in valuation allowances	37		—	%
Changes in unrecognized tax benefits	54		—	%
Other, net	1		—	%
Income tax provision	$	30,722	24.0	%

_________

(1) The jurisdictions which account for the majority of the tax effect in this category include California, Texas, Florida, New York, Pennsylvania, Illinois and Georgia.

Prior to the adoption of ASC Update No. 2023-09, income tax provision differed from the tax provision computed at the U.S. federal statutory income tax rate due to the following:


		Year Ended
	2025			2024
		(Dollars in Thousands)
Tax at federal statutory rate		$	44,535	21.0	%	$	31,892	21.0	%

Impact of foreign operations		(732)		(0.3)	%	(3,631)		(2.4)	%
State income taxes net of federal benefit		7,505		3.5	%	7,037		4.6	%
Change in uncertain tax positions		(1,227)		(0.6)	%	(107)		(0.1)	%

Global intangible low taxed income		(1,380)		(0.7)	%	(555)		(0.4)	%
Unremitted earnings		163		0.1	%	171		0.1	%
Deferred statutory rate changes		543		0.3	%	(159)		(0.1)	%

Non-deductible executive compensation		5,130		2.4	%	3,256		2.1	%
Non-deductible expenses		2,845		1.3	%	2,355		1.6	%
Stock compensation benefits		(4,469)		(2.1)	%	(1,841)		(1.2)	%
Research credits		(2,411)		(1.1)	%	(1,378)		(0.9)	%
Contingent consideration		(4,774)		(2.3)	%	—		—	%
Impact of foreign tax law changes		(2,707)		(1.3)	%	(2,739)		(1.8)	%


Valuation allowance		1,744		0.9	%	(393)		(0.2)	%
Other, net		(373)		(0.2)	%	399		0.3	%
Income tax provision		$	44,392	20.9	%	$	34,307	22.6	%

The Company recorded an income tax expense in fiscal 2026 of $30.7 million, representing an effective tax rate of 24.0%. The effective tax rate is unfavorably impacted by state taxes and non-deductible executive compensation, offset by the favorable impact of changes in jurisdictional mix of earnings and research credits generated.

The 15% global minimum tax under the Organization for Economic Cooperation and Development’s (“OECD”) Pillar Two Global Anti-Base Erosion Rule is currently effective in certain jurisdictions in which the Company operates. The OECD continues to issue guidance on the Pillar Two framework and various countries continue to enact legislation with respect to their application of the framework. The Company has considered the Pillar Two rules in effect in the countries in which it operates and have reflected the effect of the rules in the foreign tax effects. The impact is not material in fiscal 2026.

Unrecognized Tax Benefits

Unrecognized tax benefits represent uncertain tax positions for which reserves have been established. As of March 28, 2026, the Company had $1.6 million of unrecognized tax benefits, of which $0.7 million would impact the effective tax rate, if recognized. As of March 29, 2025, the Company had $2.8 million of unrecognized tax benefits, of which $1.8 million would impact the effective tax rate, if recognized. As of March 30, 2024, the Company had $3.7 million of unrecognized tax benefits, of which $3.1 million would impact the effective tax rate, if recognized.

The following table summarizes the activity related to its gross unrecognized tax benefits for the fiscal years ended March 28, 2026, March 29, 2025 and March 30, 2024:


	March 28, 2026		March 29, 2025		March 30, 2024
	(Dollars in Thousands)
Beginning Balance	$	2,822	$	3,743	$	3,941
Additions for tax positions of fiscal 2026	140		315		234
Additions for tax positions of a prior fiscal year	9		1,242		—
Additions for tax positions related to acquired businesses	—		91		—
Reductions of tax positions	(111)		(64)		(198)
Settlements of tax positions	(1,242)		—		—
Expiration of statute of limitations	(24)		(2,505)		(234)
Ending Balance	$	1,594	$	2,822	$	3,743

The Company’s historical practice has been and continues to be to recognize interest and penalties related to federal, state and foreign income tax matters in income tax expense. Approximately $0.1 million of gross interest and penalties was accrued as of March 28, 2026 and March 29, 2025, respectively, and are not included in the amounts above. Additionally, an expense of $0.1 million, a benefit of $0.3 million, and an expense of $0.1 million of accrued interest and penalties were included in the income tax provision for each of the years ended March 28, 2026, March 29, 2025 and March 30, 2024, respectively.

The Company conducts business globally and, as a result, files federal, state and foreign income tax returns in multiple jurisdictions. In the normal course of business, it is subject to examination by taxing authorities throughout the world. With a few exceptions, the Company is no longer subject to U.S. federal, state, or local income tax examinations for years before fiscal 2023 and foreign income tax examinations for years before fiscal 2021. To the extent that the Company has tax attribute carry-forwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, state, or foreign tax authorities to the extent utilized in a future period.

The following is a summary of cash income taxes paid, net of refunds:


	Year Ended
	2026
	(Dollars in Thousands)
Federal	$	41,750
State	10,082
Foreign	8,833
Total	$	60,665

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

ACCUMULATED OTHER COMPREHENSIVE LOSS

12 Months Ended

Mar. 28, 2026

Stockholders' Equity Note [Abstract]

ACCUMULATED OTHER COMPREHENSIVE LOSS

The following is a roll-forward of the components of AOCL, net of tax, for the years ended March 28, 2026 and March 29, 2025:


	Foreign currency		Defined benefit plans		Net Unrealized Gain (Loss) on Derivatives		Total
	(Dollars in Thousands)
Balance, March 30, 2024	$	(38,274)	$	1,748	$	894	$	(35,632)
Other comprehensive loss before reclassifications	(17,974)		(599)		(935)		(19,508)
Amounts reclassified from AOCL(1)	—		—		56		56
Balance, March 29, 2025	$	(56,248)	$	1,149	$	15	$	(55,084)
Other comprehensive income before reclassifications	16,916		(403)		2,097		18,610
Amounts reclassified from AOCL(1)	—		—		(1,140)		(1,140)
Balance, March 28, 2026	$	(39,332)	$	746	$	972	$	(37,614)

__________

(1) Presented net of income taxes, the amounts of which are insignificant.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481520/505-30-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 1.D.2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479921/505-20-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-3

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 1.B.3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480148/855-10-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-5

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Mar. 28, 2026

Accounting Standards Update and Change in Accounting Principle [Abstract]

Fiscal Year

Haemonetics’ fiscal year ends on the Saturday closest to the last day of March. Fiscal years 2026, 2025 and 2024 include 52 weeks with each quarter having 13 weeks.

Principles of Consolidation

The accompanying consolidated financial statements include all accounts including those of its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. In addition, the Company assesses its strategic investments to determine whether they meet the definition of a variable interest entity (“VIE”), and if so, whether the Company has controlling financial interest. Controlling financial interest occurs if the Company has both the power to direct activities of the VIE that most significantly impact the VIE’s economic performance and an obligation to absorb losses of or the right to receive benefits from the VIE that could potentially be significant to the VIE. The Company’s strategic investments did not meet the controlling financial interest criteria, as such no VIEs were consolidated during fiscal 2026, 2025 or 2024.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could vary from the amounts derived from its estimates and assumptions. The Company considers estimates to be critical if they are required to make assumptions about material matters that are uncertain at the time of estimation or if materially different estimates could have been made or it is reasonably likely that the accounting estimate will change from period to period. The following are areas considered to be critical and require management’s judgment: revenue recognition, inventory provisions, intangible asset and goodwill valuation, legal and other judgmental accruals and income taxes.

Contingencies

The Company is currently involved and may become involved in various legal proceedings and claims, including, without limitation, patent infringement, product liability, breach of contract and employee-related matters. Accruals recorded for various contingencies including legal proceedings, employee related litigation, self-insurance and other claims are based on judgment, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarially determined estimates. When a loss is probable and a range of loss is established but a best estimate cannot be made, the Company records the minimum loss contingency amount, which could be zero. These estimates are often initially developed substantially earlier than the ultimate loss is known and the estimates are reevaluated each accounting period, as additional information is available. As information becomes known, an additional loss provision is recorded when either a best estimate can be made or the minimum loss amount is increased. When events result in an expectation of a more favorable outcome than previously expected, the best estimate is changed to a lower amount.

Revenue Recognition

The Company's revenue recognition policy is to recognize revenues from product sales, software and services in accordance with the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) Update No. 2014-19, Revenue from Contracts with Customers (Topic 606). Revenue is recognized when obligations under the terms of a contract with a customer are satisfied; this occurs with the transfer of control of the Company’s goods or services. The Company considers revenue to be earned when all of the following criteria are met: it has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the consideration the Company expects to receive for transferring goods or providing services, is determinable and it has transferred control of the promised items to the customer. A promise in a contract to transfer a distinct good or service to the customer is identified as a performance obligation. A contract’s transaction price is allocated to each performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Some of the Company’s contracts have multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation based on the estimated standalone selling prices of the good or service in the contract. For goods or services for which observable standalone selling prices are not available, the Company uses an expected cost plus a margin approach to estimate the standalone selling price of each performance obligation. In software contracts with multiple performance obligations, the Company accounts for individual performance obligations separately if they are distinct. The Company allocates the transaction price to each performance obligation based on its relative standalone selling price out of total consideration of the contract. Standalone selling price is determined utilizing observable prices to the extent available. If the standalone selling price for a performance obligation is not directly observable, the Company estimates it maximizing the use of observable inputs. For maintenance and support, the Company determines the standalone selling price based on the price at which we separately sell a renewal contract and the economic relationship between licenses and maintenance.

Product Revenues

The majority of the Company’s performance obligations related to product sales are satisfied at a point in time. Product revenue consists of the sale of its disposable products and the related equipment. The Company’s performance obligation related to product sales is satisfied upon shipment or delivery to the customer based on the specified terms set forth in the customer contract. Shipping and handling activities performed after a customer obtains control of the good are treated as fulfillment activities and are not considered to be a separate performance obligation. Revenue is recognized over time for maintenance plans provided to customers that provide services beyond the Company’s standard warranty period. Payment terms between customers related to product sales vary by the type of customer, country of sale, and the products or services offered and could result in an unbilled receivable or deferred revenue balance depending on whether the performance obligation has been satisfied (or partially satisfied).

For product sales to distributors, the Company recognizes revenue for both equipment and disposables upon shipment to distributors, which is when its performance obligations are complete. The Company’s standard contracts with its distributors state that title to the equipment passes to the distributors at point of shipment to a distributor’s location. The distributors are responsible for shipment to the end customer along with any installation, training and acceptance of the equipment by the end customer. Payments from distributors are not contingent upon resale of the product.

The Company also places equipment at customer sites. While the Company retains ownership of this equipment, the customer has the right to use it for a period of time provided they meet certain agreed to conditions. The Company recovers the cost of providing the equipment from the sale of its disposables.

Software and Other Revenues

To a lesser extent, the Company enters into other types of contracts including certain software licensing arrangements to provide software solutions to support its plasma, blood collection and hospital customers. A portion of its software sales are perpetual licenses typically accompanied by implementation services related to software customization as well as other professional and technical services. The Company generally recognizes revenue from the sale of perpetual licenses and related customization services over time (the Company is creating or enhancing an asset that the customer controls) using an input method which requires it to make estimates of the extent of progress toward completion of the contract. When the Company provides other services, including in some instances hosting, technical support and maintenance, it recognizes these fees and charges over time (the customer simultaneously receives and consumes benefits), as performance obligations for these services are satisfied during the contract period. Certain of the Company’s software licensing arrangements are term-based licenses that include a per-collection or a usage-based fee related to the use of the license and the related technical support and hosting services. For these usage-based arrangements, the Company applies the revenue recognition exception resulting in revenue recognition occurring upon the later of actual usage or satisfaction of the related performance obligations. The payment terms for software licensing arrangements vary by customer pursuant to the terms set forth in the customer contract and result in an unbilled receivable or deferred revenue balance depending on whether the performance obligation has been satisfied (or partially satisfied).

Significant Judgments

Revenues from product sales are recorded at the net sales price, which includes estimates of variable consideration related to rebates, product returns and volume discounts. These reserves, which are based on estimates of the amounts earned or to be claimed on the related sales, are recorded as a reduction of revenue and a current liability. The Company’s estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the net sales price is limited to the amount that is probable not to result in a significant reversal in the amount of the cumulative revenue recognized in a future period. Revenue recognized in the current period related to performance obligations satisfied in prior periods was not material. If the Company is unable to estimate the expected rebates reasonably, it records a liability for the maximum potential rebate or discount that could be earned. In circumstances where the Company provides upfront rebate payments to customers, it capitalizes the rebate payments and amortizes the resulting asset as a reduction of revenue using a systematic method over the life of the contract.

Contract Balances

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables and contract assets, as well as customer advances, customer deposits and deferred revenue (contract liabilities) on the consolidated balance sheets. The difference in timing between billing and revenue recognition primarily occurs in software licensing arrangements, resulting in contract assets and contract liabilities.

Practical Expedients

The Company elected not to disclose the value of transaction price allocated to unsatisfied performance obligations for contracts with an original expected length of one year or less. When applicable, the Company has also elected to use the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component if it is expected, at contract inception, that the period between when the Company transfers a promised good or service to a customer and when the customer pays for that good or service, will be one year or less.

Translation of Foreign Currencies

All assets and liabilities of foreign subsidiaries are translated at the rate of exchange at year-end while sales and expenses are translated at an average rate in effect during the year. The net effect of these translation adjustments is shown in the accompanying consolidated financial statements as a component of stockholders’ equity. Foreign currency transaction gains and losses, including those resulting from intercompany transactions, are charged directly to earnings and included in other expense, net on the consolidated statements of income. The impact of foreign exchange on long-term intercompany loans, for which repayment has not been scheduled or planned, are recorded in accumulated other comprehensive loss (“AOCL”) on the consolidated balance sheets.

Cash and Cash Equivalents

Cash equivalents include various instruments such as money market funds, U.S. government obligations and commercial paper with maturities of three months or less at date of acquisition. Cash and cash equivalents are recorded at cost, which approximates fair market value. As of March 28, 2026, cash and cash equivalents consisted primarily of investments in United States Government Agency and institutional money market funds.

Allowance for Credit Losses

The Company establishes a specific allowance for customers when it is probable that they will not be able to meet their financial obligations. Customer accounts are reviewed individually on a regular basis and reserves are established as deemed appropriate. The Company also maintains a general reserve using a percentage that is established based upon the age of its receivables and its collection history. The Company establishes allowances for balances not yet due and past due accounts based on past experience.

Inventories

Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method. The Company has based its provisions for excess, expired and obsolete inventory primarily on its estimates of forecasted net sales. Significant changes in the timing or level of demand for the Company’s products result in recording additional provisions for excess, expired and obsolete inventory. Additionally, uncertain timing of next-generation product approvals, variability in product launch strategies, non-cancelable purchase commitments, product recalls and variation in product utilization all affect the Company’s estimates related to excess, expired and obsolete inventory.

Property, Plant and Equipment

Property, plant and equipment is recorded at historical cost. The Company provides for depreciation and amortization by charges to operations using the straight-line method in amounts estimated to recover the cost of the building and improvements, equipment and furniture and fixtures over their estimated useful lives as follows:


Asset Classification						Estimated Useful Lives
Building						30 – 40 Years
Building improvements						5 – 20 Years
Plant equipment and machinery						3 – 15 Years
Office equipment and information technology						3 – 10 Years
Haemonetics equipment						3 – 7 Years

The Company evaluates the depreciation periods of property, plant and equipment to determine whether events or circumstances warrant revised estimates of useful lives. All property, plant and equipment are also tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.

The Company’s installed base of devices includes devices owned by the Company and devices sold to the customer. The asset on its consolidated balance sheets classified as Haemonetics equipment consists of medical devices installed at customer sites but owned by Haemonetics. Generally, the customer has the right to use it for a period of time during which they separately purchase disposables.

Consistent with the impairment tests noted below for other intangible assets subject to amortization, the Company reviews Haemonetics equipment and the related useful lives of such equipment at least once a year, or more frequently if certain conditions arise, to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. To conduct these reviews, the Company estimates the future amount and timing of demand for disposables used with these devices, from which it generates revenues. The Company also considers product life cycle in its evaluation of useful life and recoverability. Changes in expected demand can result in additional depreciation expense, which is classified as cost of goods sold. Any significant unanticipated changes in demand could impact the value of the Company’s devices and its reported operating results.

Leasehold improvements are depreciated over the lesser of their useful lives or the term of the lease. Maintenance and repairs are generally expensed to operations as incurred. When the repair or maintenance costs significantly extend the life of the asset, these costs may be capitalized. When equipment and improvements are sold or otherwise disposed of, the asset cost and accumulated depreciation are removed from the accounts and the resulting gain or loss, if any, is included in the consolidated statements of income.

Goodwill and Intangible Assets

Goodwill represents the excess purchase price over the fair value of the net tangible and other identifiable intangible assets acquired. Goodwill is not amortized and is instead reviewed for impairment at least annually, or on an interim basis between annual tests when events or circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying value. The Company performs its annual impairment test on the first day of the fiscal fourth quarter for each of its reporting units.

A reporting unit is defined as an operating segment or one level below an operating segment, referred to as a component. The Company determines its reporting units by first identifying its operating segments and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company aggregates components within an operating segment that have similar economic characteristics. The Company’s operating segments are as follows: Plasma, Blood Center and Hospital. The Company’s reporting units are as follows: Plasma, Blood Center, Interventional Technologies and Blood Management Technologies. When the Company completes business combinations, the Company assigns goodwill to the reporting units that it expects to benefit from the respective business combination at the time of acquisition.

Under ASC Update No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment entities perform their goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount by either performing a qualitative or quantitative assessment. The Company may elect to perform only a qualitative assessment for its annual impairment test when certain qualitative criteria are met that indicate that it is more likely than not the fair values of each reporting unit exceed their carrying values.

If the Company elects to perform a quantitative test, it determines carrying values of each reporting unit by allocating assets and liabilities, including corporate assets, which relate to a reporting unit’s operations and would be considered in determining its fair value, to the individual reporting units. The Company allocates assets and liabilities not directly related to a specific reporting unit, but from which the reporting unit benefits, based primarily on the respective revenue contribution of each reporting unit.

In addition, when performing a quantitative test, the Company primarily uses the income approach, specifically the discounted cash flow method, to derive the fair value of each of its reporting units in preparing its goodwill impairment assessments. This approach calculates fair value by estimating the after-tax cash flows attributable to a reporting unit and then discounting these after-tax cash flows to a present value using a risk-adjusted discount rate. The Company selected this method as being the most meaningful in preparing its goodwill assessments because the use of the income approach typically generates a more precise measurement of fair value than the market approach. In applying the income approach to its accounting for goodwill, the Company makes assumptions about the amount and timing of future expected cash flows, terminal value growth rates and appropriate discount rates. The amount and timing of future cash flows within the Company’s discounted cash flow analysis is based on its most recent operational budgets, long range strategic plans and other estimates. The terminal value growth rate is used to calculate the value of cash flows beyond the last projected period in the Company’s discounted cash flow analysis and reflects the Company’s best estimates for stable, perpetual growth of its reporting units. The Company uses estimates of market-participant risk adjusted weighted average cost of capital as a basis for determining the discount rates to apply to its reporting units’ future expected cash flows. The Company corroborates the valuations that arose from the discounted cash flow approach by performing both a market multiple valuation and by reconciling the aggregate fair value of its reporting units to its market capitalization at the time of the test. An impairment charge, if any, would then be recognized for the amount by which the carrying value exceeds the reporting unit’s fair value.

Annual Goodwill Impairment Test

In fiscal 2026 the Company elected to perform the annual goodwill impairment test using qualitative assessments for three reporting units and a quantitative assessment for one reporting unit for its annual goodwill impairment test. In fiscal 2025, the Company elected to perform quantitative assessments for its annual goodwill impairment test. In fiscal 2024, the Company performed a qualitative assessment. In fiscal 2026, 2025 and 2024, the results of the annual goodwill impairment test performed indicated that the estimated fair value of all of its reporting units exceeded their respective carrying values, however, in fiscal 2026 the fair value of the Interventional Technologies reporting unit, which is within the Hospital reportable segment, was $867.8 million, which only exceeded its carrying value of $821.6 million by 6%. The fair value of the Interventional Technologies reporting unit was primarily determined using a discounted cash flow approach utilizing a discount rate of 10.5%, which reflects a market-participant weighted average cost of capital based on the risk profile, size, and capital structure of the reporting unit.

The estimation of fair value requires significant judgment and is based primarily on a discounted cash flow approach, supplemented by market-based methods where appropriate. Key assumptions include projected revenue growth rates, operating margins, and the discount rate. These inputs are based on management’s expectations of future performance and market conditions and are inherently uncertain.

The Interventional Technologies reporting unit remains sensitive to changes in key assumptions. A decline in projected revenue growth rates, or an increase in the discount rate, could result in the carrying value exceeding fair value.

The Company monitors for goodwill impairment indicators throughout the year, including changes in macroeconomic conditions, industry trends, and business performance. No interim goodwill impairment indicators for the Interventional Technologies reporting unit were identified during fiscal 2026 that required an additional goodwill impairment test.

Although no goodwill impairment was recorded for the Interventional Technologies reporting unit during fiscal 2026, it remains at risk of future impairment if actual results differ from current estimates or if market conditions deteriorate.

Ongoing Monitoring of Long-Lived Intangible Asset Impairment

The Company also evaluates long-lived intangible assets subject to amortization for intangible impairment quarterly to determine if any adverse conditions exist that would indicate that the carrying value of an asset or asset group may not be recoverable, or that a change in the remaining useful life is required. Conditions indicating that an intangible impairment exists include but are not limited to a change in the competitive landscape, internal decisions to pursue new or different technology strategies, a loss of a significant customer or a significant change in the marketplace including prices paid for the Company’s products or the size of the market for the Company’s products. Recoverability is assessed by comparing the carrying value of the asset group to the undiscounted cash flows expected to result from its use and eventual disposition. If the carrying value exceeds those undiscounted cash flows, an intangible impairment loss is measured as the excess of carrying value over fair value.

When an intangible impairment indicator exists, the Company tests the intangible asset for recoverability. For purposes of the recoverability test, the Company groups its amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset (asset group) exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset (asset group), the Company will write the carrying value down to the fair value in the period identified.

The Company generally calculates the fair value of its intangible assets as the present value of estimated future cash flows it expects to generate from the asset using a risk-adjusted discount rate. In determining its estimated future cash flows associated with its intangible assets, the Company uses estimates and assumptions regarding future revenues, operating margins, customer attrition, economic conditions and remaining useful lives of the asset (asset group).

If the Company determines the estimate of an intangible asset’s remaining useful life should be reduced based on its expected use of the asset, the remaining carrying amount of the asset is amortized prospectively over the revised estimated useful life.

In the fourth quarter of fiscal 2026, the Company identified intangible impairment indicators related to the Advanced Cooling Therapy, Inc., d/b/a Attune Medical (“Attune Medical”) asset group within the Interventional Technologies reporting unit, which is within the Hospital reportable segment, including lower revenue projections, changes in market conditions and declines in operating performance. As a result, a recoverability test was performed as of the first day of the fourth quarter in fiscal 2026 for the Attune Medical asset group and it was determined that the carrying value of the asset group exceeded the estimated undiscounted cash flows, indicating that the asset group was not recoverable. As a result, an additional fair value measurement was performed for the Attune Medical asset group.

The fair value of the Attune Medical asset group was measured using a discounted cash flow approach. As of the first day of the fourth quarter in fiscal 2026, the estimated fair value of the asset group was approximately $12.3 million, compared to a carrying value of $89.5 million, resulting in the recognition of an intangible impairment charge of $77.2 million in the fourth quarter of fiscal 2026.

Significant unobservable inputs used in the fair value measurement included projected revenues, operating margins, and a discount rate reflecting the estimated weighted average cost of capital of a market participant. The revenue and margin assumptions were based on internal forecasts, which incorporate assumptions about future market conditions, product adoption rates, pricing, and competitive dynamics. The discount rate utilized in the valuation of the Attune Medical asset group was 19.8%, which reflects the higher risk profile, earlier stage of commercialization, and greater uncertainty in projected cash flows relative to the broader Interventional Technologies reporting unit. The discount rate was developed using market-based inputs, including a risk-free rate, equity risk premium, and company-specific risk adjustments.

Cloud computing implementation costs

ASC Topic 350-40, Goodwill and Other, Internal-Use Software, specifies that certain costs incurred in the application development stage to implement cloud computing arrangements hosted by a third-party vendor are required to be capitalized. The Company includes these costs in other long-term assets. The costs are amortized using the straight-line method over the expected contract term, including extension periods and is included in selling, general and administrative expense in the consolidated statements of income.

Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed

ASC Topic 985-20, Software - Costs of Software to be Sold, Leased or Marketed, specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers, at which point capitalized costs are amortized over their estimated useful life of 5 to 10 years. Technological feasibility is established when it has a detailed design of the software and when research and development activities on the underlying device, if applicable, are completed. The Company capitalizes costs associated with both software that it sells as a separate product and software that is embedded in a device.

The Company reviews the net realizable value of capitalized assets periodically to assess the recoverability of amounts capitalized. There were no impairment charges recorded during fiscal 2026, 2025 and 2024. In the future, the net realizable value may be adversely affected by the loss of a significant customer or a significant change in the marketplace, which could result in an impairment being recorded. Refer to Note 10, Goodwill & Intangible Assets for more information regarding capitalized software.

Other Long-Term Liabilities

Other long-term liabilities represent items that are not payable or expected to settle within the next twelve months.

Research and Development Expenses

All research and development costs are expensed as incurred.

Advertising Costs

All advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statements of income.

Shipping and Handling Costs

Shipping and handling costs are included in selling, general and administrative expenses.

Income Taxes

The income tax provision is calculated for all jurisdictions in which the Company operates. The income tax provision process involves calculating current taxes due and assessing temporary differences arising from items that are taxable or deductible in different periods for tax and accounting purposes and are recorded as deferred tax assets and liabilities. Deferred tax assets are evaluated for realizability and a valuation allowance is maintained for the portion of the Company’s deferred tax assets that are not more-likely-than-not realizable. All available evidence, both positive and negative, has been considered to determine whether, based on the weight of that evidence, a valuation allowance is needed against the deferred tax assets. Refer to Note 6, Income Taxes, for further information and discussion of the Company’s income tax provision and balances.

The Company files income tax returns in all jurisdictions in which it operates. The Company records a liability for uncertain tax positions taken or expected to be taken in income tax returns. The Company’s consolidated financial statements reflect expected future tax consequences of such positions presuming the taxing authorities’ full knowledge of the position and all relevant facts. The Company records a liability for the portion of unrecognized tax benefits claimed that it has determined are not more-likely-than-not realizable. These tax reserves have been established based on management’s assessment as to the potential exposure attributable to the Company’s uncertain tax positions as well as interest and penalties attributable to these uncertain tax positions. All tax reserves are analyzed quarterly and adjustments are made as events occur that result in changes in judgment.

The Company evaluates at the end of each reporting period whether some or all of the undistributed earnings of its foreign subsidiaries are permanently reinvested. The Company recognizes deferred income tax liabilities to the extent that management asserts that undistributed earnings of its foreign subsidiaries are not permanently reinvested or will not be permanently reinvested in the future. The Company’s position is based upon several factors including management’s evaluation of Haemonetics’ and its subsidiaries’ financial requirements, the short-term and long-term operational and fiscal objectives of the Company and the tax consequences associated with the repatriation of earnings.

Convertible Senior Notes

The Company accounts for convertible senior notes as a single liability measured at its amortized cost. At issuance, the carrying amount is calculated as the proceeds, net of initial debt issuance costs. The difference between the principal amount and carrying value is amortized to interest expense over the term of the convertible senior notes using the effective interest rate method.

A detailed analysis of the terms of the convertible senior notes transactions is required to determine the existence of any derivatives that may require separate mark-to-market accounting under applicable accounting guidance. Refer to Note 13, Financial Instruments and Fair Value Measurements for further details.

Derivative Instruments

The Company accounts for its derivative financial instruments in accordance with ASC Topic 815, Derivatives and Hedging and ASC Topic 820, Fair Value Measurements and Disclosures. In accordance with ASC Topic 815, the Company records all derivatives on the consolidated balance sheets at fair value. The accounting for the change in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative as a hedging instrument for accounting purposes and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. In addition, ASC Topic 815 provides that, for derivative instruments that qualify for hedge accounting, changes in the fair value are either (a) offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings or (b) recognized in equity until the hedged item is recognized in earnings, depending on whether the derivative is being used to hedge changes in fair value or cash flows. The ineffective portion of a derivative’s change in fair value is immediately recognized in earnings. The Company does not use derivative financial instruments for trading or speculation purposes.

When the underlying hedged transaction affects earnings, the gains or losses on the forward foreign exchange rate contracts designated as hedges are recorded in net revenues, cost of goods sold, operating expenses and other expense, net in the Company’s consolidated statements of income, depending on the nature of the underlying hedged transactions. The cash flows related to the gains and losses are classified in the consolidated statements of cash flows as part of cash flows from operating activities. For those derivative instruments that are not designated as part of a hedging relationship the Company records the gains or losses in earnings currently. These gains and losses are intended to offset the gains and losses recorded on net monetary assets or liabilities that are denominated in foreign currencies. The Company recorded foreign currency losses of $3.2 million in fiscal 2026, foreign currency gains of $0.9 million in fiscal 2025, and foreign currency losses of $4.0 million in fiscal 2024.

On a quarterly basis, the Company assesses whether the cash flow hedges are highly effective in offsetting changes in the cash flow of the hedged item. The Company manages the credit risk of its counterparties by dealing only with institutions that it considers financially sound and considers the risk of non-performance to be remote. Additionally, the Company’s interest rate risk management strategy includes the use of interest rate swaps to mitigate its exposure to changes in variable interest rates. The Company’s objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations.

The Company’s derivative instruments do not subject its earnings or cash flows to material risk, as gains and losses on these derivatives are intended to offset losses and gains on the item being hedged. The Company does not enter into derivative transactions for speculative purposes and it does not have any non-derivative instruments that are designated as hedging instruments pursuant to ASC Topic 815. Refer to Note 13, Financial Instruments and Fair Value Measurements.

Share-Based Compensation

The Company expenses the fair value of share-based awards granted to employees, board members and others, net of estimated forfeitures. To calculate the grant-date fair value of its stock options the Company uses the Black-Scholes option-pricing model, for performance share units based on relative total shareholder return (“rTSR”) the Company uses Monte Carlo simulation models, and for performance share units based on the average annual organic revenue growth rate (“AAGR”) the Company recognizes expense based on the number of awards expected to vest, which requires management to assess the probability of achieving the performance conditions. This assessment is based on internal revenue forecasts, historical performance and current market conditions, and is reassessed at each reporting date.

Costs Associated with Exit Activities

The Company records employee termination costs in accordance with ASC Topic 712, Compensation - Nonretirement and Postemployment Benefits, if it pays the benefits as part of an on-going benefit arrangement, which includes benefits provided as part of its established severance policies or that it provides in accordance with international statutory requirements. The Company accrues employee termination costs associated with an on-going benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and the liability can be reasonably estimated. The Company accounts for employee termination benefits that represent a one-time benefit in accordance with ASC Topic 420, Exit or Disposal Cost Obligations. It records such costs into expense over the employee’s future service period, if any.

Other costs associated with exit activities may include contract termination costs, including costs related to leased facilities to be abandoned or subleased, consultant fees and impairments of long-lived assets. The costs are expensed in accordance with ASC Topic 420 and ASC Topic 360, Property, Plant and Equipment and are included in costs of goods sold and selling, general and administrative costs in its consolidated statements of income. Additionally, costs directly related to the Company’s active restructuring initiatives, including program management costs, accelerated depreciation and costs to transfer product lines among facilities are included within costs of goods sold and selling, general and administrative costs in its consolidated statements of income. Refer to Note 5, Restructuring, for further information and discussion of its restructuring plans.

Valuation of Acquisitions

The Company allocates the amounts it pays for each acquisition to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition, including acquired identifiable intangible assets. The Company bases the estimated fair value of identifiable intangible assets on detailed valuations that use significant assumptions including forecasted cash flows, revenues attributable to existing technology and discount rates. When estimating the significant assumptions to be used in the valuation, the Company includes a consideration of current industry information, market and economic trends, historical results of the acquired business and other relevant factors. These significant assumptions are forward-looking and could be affected by future economic and market conditions. The Company allocates any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill.

Strategic Investments

The Company holds strategic investments in privately held entities. Certain of these investments are accounted for under the equity method to the extent the Company determines it has the ability to exercise significant influence over the operating and financial policies of the investees. For equity instruments that do not have readily determinable fair values and are not accounted for under the equity method, the Company applies the measurement alternative, recording them at cost less impairment. The carrying amount for these instruments would be subsequently adjusted for observable price changes, or prices in orderly transactions for an identical investment or similar investment of the same issuer. In addition, these investments are periodically evaluated for impairment, and the investments are classified as other long-term assets on the Company’s consolidated balance sheets.

In cases where the Company acquires a company in which it previously held an equity stake, the Company attributes a portion of the purchase price to the previously-held equity interest, which is implied based on the total purchase consideration allocable to each of the shareholders, including Haemonetics, according to priority of equity interests. The Company remeasures its previously held equity interest in the acquiree at its acquisition date fair value and records a gain or loss for the difference between the fair value and carrying value in interest and other expense, net in the consolidated statements of income. Refer to Note 3, Acquisitions, Divestitures and Strategic Investments, for further information and discussion regarding the acquisition.

Concentration of Credit Risk and Significant Customers

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable. In fiscal 2026, 2025 and 2024, the Company’s ten largest customers accounted for approximately 44%, 42% and 48% of net revenues, respectively. In fiscal 2026, one Plasma customer accounted for approximately 13% of total net revenues.

Certain markets and industries can expose the Company to concentrations of credit risk. For example, in the Plasma business unit, sales are concentrated with several large customers. As a result, accounts receivable extended to any one of these biopharmaceutical customers can be significant at any point in time. Also, a portion of the Company’s trade accounts receivable outside the U.S. include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries’ national economies. The Company has not incurred significant losses on government receivables. The Company continually evaluates all government receivables for potential collection risks associated with the availability of government funding and reimbursement practices. If the financial condition of customers or the countries’ healthcare systems deteriorate such that their ability to make payments is uncertain, allowances may be required in future periods.

Recent Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In December 2023, the FASB issued ASC Update No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASC Update No. 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASC Update No. 2023-09 is effective for the Company’s first fiscal year beginning after December 15, 2024 and early adoption is permitted. ASC Update No. 2023-09 became applicable to Haemonetics beginning with the fiscal 2026 Annual Report on Form 10-K. The Company adopted the new guidance effective December 28, 2025 on a prospective basis. Refer to Note 6, Income Taxes for further presentation on this.

In September 2025, the FASB issued ASC Update No. 2025-07, Derivatives and Hedging and Revenue from Contracts with Customers. ASC Update No. 2025-07 reduces cost, complexity and diversity in practice of evaluating whether contracts with features based on the operations or activities of one of the parties to the contract are derivatives. The updated guidance is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. The Company elected to early adopt ASU Update No. 2025-07 on a prospective basis effective the beginning of the fourth quarter of fiscal 2026. The adoption did not have a material impact on the financial statements, including prior interim periods.

Recently Issued Accounting Pronouncements Not Yet Adopted

In November 2024, the FASB issued ASC Update No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures. ASC Update No. 2024-03 requires detailed cost and expense information disaggregated in the financial statements notes. The updated guidance is effective for fiscal years beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. ASC Update No. 2024-03 is applicable to Haemonetics beginning with the fiscal 2028 Annual Report on Form 10-K and the Company is currently evaluating the impact to its interim and annual report disclosures.

In July 2025, the FASB issued ASC Update No. 2025-05, Financial Instruments - Credit Losses (Topic 326). ASC Update No. 2025-05 introduces a practical expedient related to the estimation of expected credit losses for current accounts receivable and current contract assets that arise from transactions accounted for under FASB Accounting Standards Codification 606. Under ASC Update No. 2025-05, an entity is required to disclose whether it has elected to use the practical expedient. An entity that makes the accounting policy election is required to disclose the date through which subsequent cash collections are evaluated. The updated guidance is effective for fiscal years beginning December 15, 2025, with early adoption permitted. ASC Update No. 2025-05 is applicable to Haemonetics beginning with the fiscal 2027 Annual Report on Form 10-K and the Company is currently evaluating the impact to its interim and annual report disclosures. The guidance can be applied on a prospective basis with the option to apply the standard retrospectively.

In September 2025, the FASB issued ASC Update No. 2025-06, Intangibles - Goodwill and Other - Internal-Use Software. ASC Update No. 2025-06 eliminates references to development stages in the capitalization guidance and requires costs to be capitalized once management authorizes funding and will be completed and used as intended. The updated guidance is effective for fiscal years beginning after December 15, 2027, with early adoption permitted. ASC Update No. 2025-06 is applicable to Haemonetics beginning with the fiscal 2029 Annual Report on Form 10-K and the Company is currently evaluating the impact to its interim and annual report disclosures. The guidance can be applied on a prospective basis with the option to apply the standard retrospectively.

In November 2025, the FASB issued ASC Update No. 2025-09, Derivatives and Hedging. ASC Update No. 2025-09 enables groups of forecasted transactions to now share similar risk exposure with ongoing assessments of risk similarity to better reflect economic hedging strategies. The updated guidance is effective for fiscal years beginning after December 15, 2028, with early adoption permitted. ASC Update No. 2025-09 is applicable to Haemonetics beginning with the fiscal 2030 Annual Report on Form 10-K and the Company is currently evaluating the impact to its interim and annual report disclosures. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively.

In December 2025, the FASB issued ASC Update No. 2025-11, Interim Reporting. ASC Update No. 2025-11 improves navigability and consistency in interim reporting by providing a comprehensive list of interim disclosures that are required from U.S. GAAP as well as a disclosure principle for additional transparency. The updated guidance is effective for fiscal years beginning after December 15, 2027, with early adoption permitted. ASC Update No. 2025-11 is applicable to Haemonetics beginning with the fiscal 2029 Annual Report on Form 10-K and the Company is currently evaluating the impact to its interim and annual report disclosures.

In December 2025, the FASB issued ASC Update No. 2025-12, Codification Improvements. ASC Update No. 2025-12 makes a broad set of technical corrections, clarifications and targeted improvements to the FASB Accounting Standards Codification to address unintended application issues and improve the operability of U.S. GAAP across a range of topics. The updated guidance is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. ASC Update No. 2025-12 is applicable to Haemonetics beginning with the fiscal 2028 Annual Report on Form 10-K and the Company is currently evaluating the impact to its interim and annual report disclosures.

CAPITAL STOCK (Tables)

12 Months Ended

Mar. 28, 2026

Share-Based Payment Arrangement [Abstract]

Schedule of Stock-Based Compensation Cost

Compensation cost related to share-based transactions is recognized in the consolidated financial statements based on fair value. The total amount of share-based compensation expense, which is recorded on a straight-line basis, is as follows:


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Selling, general and administrative expenses	$	29,511	$	25,971	$	23,662
Research and development	2,945		1,847		3,106
Cost of goods sold	1,371		1,818		1,564
Total share-based compensation	$	33,827	$	29,636	$	28,332

Schedule of Summary of Stock Option Activity

A summary of stock option activity for the fiscal year ended March 28, 2026 is as follows:


	Options Outstanding	Weighted Average Exercise Price per Share		Weighted Average Remaining Life (years)	Aggregate Intrinsic Value
	(Dollars in Thousands, Except Share and Per Share Data)
Outstanding as of March 29, 2025	993,587	$	81.75	3.5	$	2,249
Granted	227,425	70.05
Exercised	(36,267)	57.90
Forfeited/Canceled	(166,850)	89.42
Outstanding as of March 28, 2026	1,017,895	$	78.74	3.5	$	45
Exercisable as of March 28, 2026	599,839	$	79.67	2.2	$	33
Vested or expected to vest as of March 28, 2026	945,805	$	78.87	3.0	$	45

Schedule of Assumptions Utilized for Estimating Fair Value of Option Grants

The assumptions utilized for option grants during the periods presented are as follows:


	Year Ended
	2026			2025			2024
Volatility	44.2		%	43.9		%	45.3		%
Expected life (years)	5.4			5.2			5.1
Risk-free interest rate	4.1		%	4.4		%	3.5		%
Dividend yield	0.0		%	0.0		%	0.0		%
Grant-date fair value per option	$	32.35		$	43.56		$	39.46

Schedule of Summary of Restricted Stock Units Activity

A summary of RSU activity for the fiscal year ended March 28, 2026 is as follows:


	Shares	Weighted Average Grant Date Fair Value
Unvested as of March 29, 2025	303,003	$	81.27
Granted	225,738	$	70.52
Vested	(157,290)	$	78.36
Forfeited	(41,633)	$	78.15
Unvested as of March 28, 2026	329,818	$	75.69

The weighted-average grant-date fair value of RSUs granted and total fair value of RSUs vested are as follows:


	Year Ended
	2026		2025		2024
Grant-date fair value per RSU	$	70.52	$	95.09	$	89.21
Fair value of RSUs vested	$	78.36	$	75.04	$	67.14

Schedule of Performance Share Unit awards

A summary of PSU activity for the fiscal year ended March 28, 2026 is as follows:


	Shares	Weighted Average Grant Date Fair Value
Unvested as of March 29, 2025	335,843	$	112.10
Granted(1)	220,349	$	87.66
Vested(2)	(162,066)	$	84.96
Forfeited	(36,495)	$	114.24
Unvested as of March 28, 2026	357,631	$	108.86

__________

(1) Includes 35,443 shares issued for awards vested during fiscal 2026 based on achievement of performance metrics.

(2) Includes the vesting of 162,066 shares that were earned for TSR-based PSU awards granted in fiscal 2023 for performance periods ending during fiscal 2026, representing 128% of the target award.

Schedule of Share-based Payment Award, Equity Other Than Options, Valuation Assumptions

The assumptions used in the Monte Carlo model for PSUs granted during each fiscal year were as follows:


	Year Ended
	2026		2025		2024
Expected stock price volatility	31.81	%	35.35	%	48.20	%
Peer group stock price volatility	46.62	%	35.95	%	40.29	%
Correlation of returns	27.81	%	58.08	%	59.93	%

The weighted-average grant-date fair value of PSUs granted is as follows:


	Year Ended
	2026		2025		2024
Grant-date fair value per PSU	$	87.66	$	128.25	$	128.83
Fair value of PSUs vested	$	84.96	$	72.35	$	—

Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions

The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:


	Year Ended
	2026		2025		2024
Volatility	47.6	%	29.3	%	28.6	%
Expected life (months)	6		6		6
Risk-free interest rate	4.1	%	4.9	%	5.4	%
Dividend Yield	0.0	%	0.0	%	0.0	%

EARNINGS PER SHARE (Tables)

12 Months Ended

Mar. 28, 2026

Earnings Per Share [Abstract]

Schedule of Earnings Per Share Reconciliation

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.


	Year Ended
	2026		2025		2024
	(Dollars and Shares in Thousands, Except Per Share Data)
Net income	$	97,308	$	167,679	$	117,558

Basic weighted average shares outstanding	47,179		50,330		50,706
Dilutive net effect of common stock equivalents	175		400		691
Diluted weighted average shares	47,354		50,730		51,397

Net income per share
Basic	$	2.06	$	3.33	$	2.32
Diluted	$	2.05	$	3.31	$	2.29

Anti-dilutive shares excluded from the calculation	936		768		606

NOTES PAYABLE AND LONG-TERM DEBT (Tables)

12 Months Ended

Mar. 28, 2026

Debt Disclosure [Abstract]

Schedule of Notes Payable and Long-Term Debt

Notes payable and long-term debt consisted of the following:


	March 28, 2026		March 29, 2025
	(Dollars in Thousands)
Convertible notes	$	688,775	$	983,951
Term loan, net of financing fees	235,131		240,028
Revolving credit facility	300,000		—
Other borrowings	674		809
Total Debt	1,224,580		1,224,788
Less: current portion	(5,015)		(303,558)
Long-term debt	$	1,219,565	$	921,230

Schedule of Notes Payable and Long-Term Debt Maturities

The future aggregate amount of debt maturities are as follows:


	Debt Maturities
	(Dollars in Thousands)
Fiscal 2027	$	7,874
Fiscal 2028	12,564
Fiscal 2029	18,818
Fiscal 2030	1,200,073
Fiscal 2031	77
Thereafter	401
Total debt maturities	$	1,239,807

PROPERTY, PLANT AND EQUIPMENT (Tables)

12 Months Ended

Mar. 28, 2026

Property, Plant, and Equipment [Abstract]

Schedule of Property, Plant and Equipment

Property, plant and equipment consisted of the following:


	March 28, 2026		March 29, 2025
	(Dollars in Thousands)
Land	$	2,251	$	1,985
Building and building improvements	109,793		105,079
Plant equipment and machinery	197,552		181,825
Office equipment and information technology	131,085		130,924
Haemonetics equipment	371,205		395,152
Construction in progress	29,943		22,229
Property, plant and equipment, at cost	841,829		837,194
Less: accumulated depreciation	(536,068)		(553,142)
Property, plant and equipment, net	$	305,761	$	284,052

INVENTORIES (Tables)

12 Months Ended

Mar. 28, 2026

Inventory Disclosure [Abstract]

Schedule of Inventories


	March 28, 2026		March 29, 2025
	(Dollars in Thousands)
Raw materials	$	114,873	$	128,574
Work-in-process	11,974		14,956
Finished goods	179,523		221,611
Total	$	306,370	$	365,141

NOTES PAYABLE AND LONG-TERM DEBT - Narrative (Details) $ / shares in Units, shares in Thousands						1 Months Ended	12 Months Ended
	Mar. 28, 2026 USD ($)	Mar. 02, 2026 USD ($)	May 28, 2024 USD ($) $ / shares	Apr. 30, 2024 USD ($)	Jul. 26, 2022	Mar. 31, 2021 unit day $ / shares shares	Mar. 28, 2026 USD ($)	Mar. 29, 2025 USD ($)	Mar. 30, 2024 USD ($)	Mar. 05, 2021 USD ($)	Jun. 15, 2018 USD ($)
Debt Instrument [Line Items]
Gain (loss) on repurchase of debt instrument							$ 0	$ 12,600,000	$ 0
Interest expense							19,300,000	35,900,000	19,500,000
Repayments of convertible debt							300,000,000	185,500,000	0
Proceeds from issuance of convertible notes							0	700,000,000	0
Long-term debt	$ 1,239,807,000						1,239,807,000
Payments for purchase of capped call related to convertible notes							0	$ 88,200,000	$ 0
Debt instrument, percent of principal amount due in years 1 through 3				2.50%
Debt instrument, percent of principal amount due in year 4				5.00%
Debt instrument, percent of principal amount due in year 5				7.50%
Revolving credit facility
Debt Instrument [Line Items]
Proceeds from lines of credit	300,000,000.0
2026 Notes Capped Calls
Debt Instrument [Line Items]
Debt instrument, convertible, capped call transaction, initial strike price \| $ / shares						$ 175.34
Debt instrument, convertible, capped call transaction, initial cap price \| $ / shares						250.48
2029 Notes Capped Calls
Debt Instrument [Line Items]
Debt instrument, convertible, capped call transaction, initial strike price \| $ / shares						117.12
Debt instrument, convertible, capped call transaction, initial cap price \| $ / shares						$ 180.18
Debt instrument, convertible, capped call transaction, anti-dilution adjustment, shares \| shares						5,980
Convertible notes
Debt Instrument [Line Items]
Face amount of debt	700,000,000.0						700,000,000.0			$ 500,000,000.0
Debt instrument, interest rate, stated percentage										0.00%
Debt instrument, redemption price, percentage						130.00%
Debt instrument, convertible, threshold trading days \| unit						20
Debt instrument, convertible, threshold consecutive trading days \| unit						30
Debt instrument, redemption price, percentage of principal amount redeemed						98.00%
Debt instrument, redemption, maximum period to purchase shares at discount						60 days
Debt instrument, redemption, threshold consecutive trading days \| day						10
Debt instrument, redemption price, percentage of previous closing price						10.00%
Amortization of debt discount (premium)							11,200,000
Convertible notes \| Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage						130.00%
Debt instrument, convertible, threshold trading days \| day						20
Debt instrument, convertible, threshold consecutive trading days \| day						30
Convertible notes \| Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage						100.00%
Convertible notes \| Convertible Senior Notes Due 2026
Debt Instrument [Line Items]
Debt instrument, repurchased face amount			$ 200,000,000.0
Debt instrument, repurchase amount			185,500,000
Gain (loss) on extinguishment of debt, before debt issuance cost writeoff			14,500,000
Deferred debt issuance cost, writeoff			1,900,000
Gain (loss) on repurchase of debt instrument			12,600,000
Interest expense							1,500,000
Repayments of convertible debt		$ 300,000,000.0
Convertible notes \| Convertible Senior Notes Due 2029
Debt Instrument [Line Items]
Face amount of debt			$ 700,000,000.0
Debt instrument, interest rate, stated percentage			2.50%
Interest expense							20,800,000
Proceeds from issuance of convertible notes			$ 682,800,000
Debt conversion, converted instrument, rate			0.85385%
Debt instrument, convertible, conversion price (in dollars per share) \| $ / shares			$ 117.12
Debt issuance costs, gross			$ 17,200,000
Effective interest rate			3.00%
Long-term debt	$ 688,800,000						$ 688,800,000
Term Loan
Debt Instrument [Line Items]
Face amount of debt											$ 750,000,000.0
Term Loan \| 2024 Revised Credit Agreement
Debt Instrument [Line Items]
Face amount of debt				$ 250,000,000.0
Repayments of Long-term Debt				$ 12,500,000
Term Loan \| 2024 Revised Credit Agreement \| Minimum
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage				1.125%
Term Loan \| 2024 Revised Credit Agreement \| Maximum
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage				1.75%
Revolving credit facility
Debt Instrument [Line Items]
Maximum borrowing capacity											$ 420,000,000.0
Commitment fee							0.20%
Revolving credit facility \| Minimum
Debt Instrument [Line Items]
Commitment fee							0.125%
Revolving credit facility \| Maximum
Debt Instrument [Line Items]
Commitment fee							0.25%
Revolving credit facility \| 2024 Revised Credit Agreement
Debt Instrument [Line Items]
Consolidated total leverage ratio	4.0						4.0
Consolidated interest coverage ratio	4.5						4.5
Unsecured Debt \| Revised Credit Agreement
Debt Instrument [Line Items]
Interest costs capitalized							$ 5,900,000
Unsecured Debt \| Revised Credit Agreement \| Minimum
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage					1.125%
Debt Instrument, Interest Rate, Floor					0.00%
Unsecured Debt \| Revised Credit Agreement \| Maximum
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage					1.75%
Line of Credit
Debt Instrument [Line Items]
Long-term debt	$ 0						0
Maximum borrowing capacity	$ 17,700,000						17,700,000
Line of Credit \| Revised Credit Agreement \| Revolving credit facility
Debt Instrument [Line Items]
Interest costs capitalized							$ 17,600,000
Line of Credit \| Revised Credit Agreement \| Minimum \| Revolving credit facility
Debt Instrument [Line Items]
Commitment fee					0.125%
Line of Credit \| Revised Credit Agreement \| Maximum \| Revolving credit facility
Debt Instrument [Line Items]
Commitment fee					0.25%
Term Loan
Debt Instrument [Line Items]
Effective interest rate	5.60%						5.60%
Amortization of debt discount (premium)							$ 3,900,000
Long-term debt	$ 239,100,000						$ 239,100,000

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Mar. 29, 2025

Accounting Standards Update and Change in Accounting Principle [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Fiscal Year

Haemonetics’ fiscal year ends on the Saturday closest to the last day of March. Fiscal years 2026, 2025 and 2024 include 52 weeks with each quarter having 13 weeks.

Principles of Consolidation

Use of Estimates

Contingencies

Revenue Recognition

Product Revenues

Software and Other Revenues

Significant Judgments

Contract Balances

Practical Expedients

Translation of Foreign Currencies

Cash and Cash Equivalents

Allowance for Credit Losses

Inventories

Property, Plant and Equipment


Asset Classification						Estimated Useful Lives
Building						30 – 40 Years
Building improvements						5 – 20 Years
Plant equipment and machinery						3 – 15 Years
Office equipment and information technology						3 – 10 Years
Haemonetics equipment						3 – 7 Years

Goodwill and Intangible Assets

Annual Goodwill Impairment Test

Ongoing Monitoring of Long-Lived Intangible Asset Impairment

Cloud computing implementation costs

Other long-term assets as of March 28, 2026 included approximately $62.4 million of capitalized implementation costs related to a new global enterprise resource planning system. There were $44.0 million of implementation costs capitalized as of March 29, 2025. Amortization expense was $1.4 million, $1.4 million and $0.9 million in fiscal 2026, 2025 and 2024, respectively.

Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed

Other Current Liabilities

Other current liabilities represent items payable or expected to settle within the next twelve months. The items included in the fiscal year end balances were:


	March 28, 2026		March 29, 2025
	(Dollars in Thousands)
Contract liabilities	$	42,310	$	43,348
Contingent consideration	17,597		2,278
Other	98,430		102,507
Total	$	158,337	$	148,133

Other Long-Term Liabilities

Other long-term liabilities represent items that are not payable or expected to settle within the next twelve months.

Research and Development Expenses

All research and development costs are expensed as incurred.

Advertising Costs

All advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statements of income. Advertising expenses were $7.4 million, $7.7 million and $7.1 million in fiscal 2026, 2025 and 2024, respectively.

Shipping and Handling Costs

Shipping and handling costs are included in selling, general and administrative expenses.

Income Taxes

Convertible Senior Notes

Derivative Instruments

Share-Based Compensation

Costs Associated with Exit Activities

Valuation of Acquisitions

Strategic Investments

Concentration of Credit Risk and Significant Customers

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements Not Yet Adopted

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS (Tables)

12 Months Ended

Mar. 28, 2026

Business Combination [Abstract]

Business Combination, Recognized Asset Acquired and Liability Assumed

The total purchase price of $164.4 million consists of the amounts presented below, which represent the initial determination of the fair value of the identifiable assets acquired and liabilities assumed:


	January 9, 2026
	(Dollars in Thousands)
Cash and cash equivalents	$	449
Accounts receivable	21
Inventories	1,056
Prepaid expenses and other current assets	1,736
Property, plant and equipment	575
Intangible assets	117,100
Goodwill	50,478
Other long-term assets	1,972
Total assets acquired	$	173,387
Accounts payable	$	1,186
Accrued payroll and related costs	2,889
Other current liabilities	4,741

Other long-term liabilities	199
Total liabilities assumed	9,015
Net assets acquired	$	164,372

The purchase price of $176.2 million consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:


	April 1, 2024
	(Dollars in Thousands)
Accounts receivable	$	3,784
Inventories	26,300
Prepaid expenses and other current assets	906
Property, plant and equipment	200
Intangible assets	105,800
Goodwill	70,256

Total assets acquired	$	207,246
Accounts payable	$	2,260
Accrued payroll and related costs	2,129
Other liabilities	496
Deferred tax liability	26,155

Total liabilities assumed	31,040
Net assets acquired	$	176,206

Business Combination, Intangible Asset, Acquired, Finite-Lived

Intangible assets acquired consist of the following:


	Amount		Weighted-Average Amortization Period	Risk-Adjusted Discount Rates used in Purchase Price Allocation
	(Dollars in Thousands)
Developed technology	$	117,100	16 years	16.5	%
Total	$	117,100

Intangible assets acquired consist of the following:


	Amount		Weighted-Average Amortization Period	Risk-Adjusted Discount Rates used in Purchase Price Allocation
	(Dollars in Thousands)
Developed technology	$	96,100	10 years	22.0	%
Customer contracts and related relationships	7,800		10 years	21.5	%
Trade names	1,900		10 years	21.5	%
Total	$	105,800

Business Combination

The purchase price of $243.9 million consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:


	December 12, 2023
	(Dollars in Thousands)
Accounts receivable	$	5,960
Inventories	12,075
Prepaid expenses and other current assets	2,062
Property, plant and equipment	3,028
Intangible assets	172,000
Goodwill	79,400
Other long-term assets	4,705
Total assets acquired	$	279,230
Accounts payable	$	3,251
Accrued payroll and related costs	1,723
Other liabilities	9,746
Deferred tax liability	14,805
Other long-term liabilities	5,853
Total liabilities assumed	35,378
Net assets acquired	$	243,852

Intangible assets acquired consist of the following:


	Amount		Weighted-Average Amortization Period	Risk-Adjusted Discount Rates used in Purchase Price Allocation
	(Dollars in Thousands)
Developed technology	$	114,900	15 years	20.5	%
Customer contracts and related relationships	52,300		15 years	18.9	%
Trade names	4,800		15 years	20.5	%
Total	$	172,000

- Definition

Tabular disclosure of business combination. Includes, but is not limited to, recognized asset and liability.

+ References + Details

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Mar. 28, 2026

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Interest Rate Derivatives

The Company held the following interest rate swaps as of March 28, 2026:


Hedged Item	Original Notional Amount		Notional Amount as of March 28, 2026		Designation Date	Effective Date	Termination Date	Fixed Interest Rate	Estimated Fair Value Assets
	(Dollars in Thousands)
1-month USD Term SOFR	$	109,900	$	100,321	9/27/2024	9/30/2024	4/30/2029	3.3%	$	859
1-month USD Term SOFR	109,900		98,966		9/27/2024	9/30/2024	4/30/2029	3.3%	912
Total	$	219,800	$	199,287					$	1,771

Accounts Receivable, Allowance for Credit Loss

The following is a roll forward of the allowance for credit losses:


	Allowance for Credit Losses (Recoveries)
	(Dollars in Thousands)
Balance as of April 1, 2023	$	4,932
Credit loss	840
Recoveries	(77)
Balance as of March 30, 2024	$	5,695
Credit loss	725
Recoveries	(120)
Balance as of March 29, 2025	$	6,300
Credit loss	615
Write-offs	(3,129)
Recoveries	(93)
Balance as of March 28, 2026	$	3,693

Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments

The following table presents the effect of the Company’s derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC Topic 815 in its consolidated statements of income and consolidated statements of comprehensive income for the fiscal year ended March 28, 2026.


Derivative Instruments	Amount of Gain (Loss) Recognized in AOCL		Amount of Gain (Loss) Reclassified from AOCL into Earnings		Classification in Earnings	Amount of Gain (Loss) Excluded from Effectiveness Testing		Classification in Earnings
	(Dollars in Thousands)
Designated foreign currency hedge contracts, net of tax	$	2,540	$	1,145	Net revenues, COGS and SG&A	$	2,637	Interest and other expense, net
Non-designated foreign currency hedge contracts	$	—	$	—		$	(5,111)	Interest and other expense, net
Designated interest rate swaps, net of tax	$	(443)	$	(5)	Interest and other expense, net	$	—

Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets

The following tables present the fair value of the Company’s derivative instruments as they appear in its consolidated balance sheets as of March 28, 2026 and March 29, 2025:


	Classification	March 28, 2026		March 29, 2025
		(Dollars in Thousands)
Derivative Assets:
Designated foreign currency hedge contracts	Prepaid expenses and other current assets	$	1,245	$	193
Non-designated foreign currency hedge contracts	Prepaid expenses and other current assets	330		85
Designated interest rate swaps	Prepaid expenses and other current assets	823		1,305
Designated interest rate swaps	Other long-term assets	947		1,020
Total		$	3,345	$	2,603

Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	50	$	471
Non-designated foreign currency hedge contracts	Other current liabilities	63		25


Total		$	113	$	496

Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of March 28, 2026 and March 29, 2025.


	As of March 28, 2026
	Level 1		Level 2		Level 3		Total
	(Dollars in Thousands)
Assets
Money market funds	$	90,716	$	—	$	—	$	90,716
Designated foreign currency hedge contracts	—		1,245		—		1,245
Non-designated foreign currency hedge contracts	—		330		—		330
Designated interest rate swaps	—		1,770		—		1,770

Total	$	90,716	$	3,345	$	—	$	94,061

Liabilities
Designated foreign currency hedge contracts	$	—	$	50	$	—	$	50
Non-designated foreign currency hedge contracts	—		63		—		63

Contingent consideration	—		—		21,063		21,063
Total	$	—	$	113	$	21,063	$	21,176


	As of March 29, 2025
	Level 1		Level 2		Level 3		Total
	(Dollars in Thousands)
Assets
Money market funds	$	158,916	$	—	$	—	$	158,916
Designated foreign currency hedge contracts	—		193		—		193
Non-designated foreign currency hedge contracts	—		85		—		85
Designated interest rate swaps	—		2,325		—		2,325
Total	$	158,916	$	2,603	$	—	$	161,519

Liabilities
Designated foreign currency hedge contracts	$	—	$	471	$	—	$	471
Non-designated foreign currency hedge contracts	—		25		—		25

Contingent consideration	—		—		2,278		2,278
Total	$	—	$	496	$	2,278	$	2,774

The level 3 fair value measurements of contingent consideration liabilities include the following significant unobservable inputs:


	Fair Value as of
	March 28, 2026		Valuation Technique	Unobservable Input	Range
	(Dollars in Thousands)
Revenue-based payments	$	3,076	Monte Carlo Simulation Model	Discount rate	3.4%
				Projected fiscal year of payments	2028 - 2030



Event-based payments	$	390	Monte Carlo Simulation Model	Discount rate	5.8%
				Projected fiscal year of payment	2027 - 2028
	$	17,597		Discount Rate	3.0%
				Projected fiscal year of payment	2027

Fair Value as of

March 29, 2025

Valuation Technique

Unobservable Input

Range

(Dollars in Thousands)

Revenue-based payments

1,214

Monte Carlo Simulation Model

Discount rate

6.3%

Projected fiscal year of payments

2026 - 2028

Event-based payment

1,064

Monte Carlo Simulation Model

Discount rate

5.8%

Projected fiscal year of payment

2026 - 2028

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

A reconciliation of the change in the fair value of contingent consideration is included in the following table:


	Contingent Consideration
	(Dollars in Thousands)
Balance as of March 30, 2024	$	—
Acquisition date fair value of contingent consideration	25,000
Purchase accounting adjustments	300

Change in fair value	(23,022)

Balance as of March 29, 2025	$	2,278
Acquisition date fair value of contingent consideration	20,673

Payment of contingent consideration	(9)
Change in fair value	(1,879)

Balance as of March 28, 2026	$	21,063

DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION (Details)	12 Months Ended
	Mar. 28, 2026 unit
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of business units	3

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
Cybersecurity Risk Management and Strategy Disclosure	Mar. 28, 2026
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	We assess, identify and manage risks from cybersecurity threats through our global cybersecurity program. The program is managed by a full-time Chief Information Security Officer (“CISO”) whose organization manages our cybersecurity strategy, architecture, policies, standards and processes for the security of Haemonetics’ enterprise network and information assets. The CISO reports to our Chief Information Officer (“CIO”) and is supported by a dedicated security operations team. Our current CISO has over 20 years of information technology experience, including positions of increasing responsibility with respect to security architecture, software engineering, security operations and incident response. The CISO’s organization monitors, manages and works to identify and assess, cybersecurity risks through various technologies, resources, processes and policies that are regularly updated to align with the changing threat landscape, our evolving business needs as well as global regulatory requirements. Our global cybersecurity program is aligned to the National Institute of Standards and Technology (“NIST”) Cybersecurity Framework and is certified to the ISO 27001 global standard on Information Security Management. Our cybersecurity program is closely integrated with our QMS under the ISO 13485 standard. Our program utilizes layered defenses to help protect against cybersecurity threats and to work to secure our assets, reduce detection time and improve recoverability. Among other things, this includes ongoing systems monitoring with support from a managed detection and response service provider and other third-party vendors to augment our monitoring and response capabilities, as well as a standardized incident response program with incident response team members participating in regularly scheduled management reviews and tabletop exercises. Our CISO and CIO conduct regular cross-functional management reviews of our programs, including with members of senior leadership. All employees and those contractors of the Company with access to our information systems receive annual cybersecurity awareness training, and we have integrated cybersecurity and data protection topics into our Code of Conduct. All critical information systems have a written business continuity plan that is exercised at least annually. The entire program is audited annually by both internal and third-party auditors.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	We evaluate cybersecurity risk as part of our broader enterprise risk framework. Our Board of Directors oversees Haemonetics’ enterprise-wide approach to risk management while our management team is responsible for managing risk on a day-to-day basis and for bringing to the Board’s attention material risks facing the Company, including with respect to cybersecurity threats.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	Our Board of Directors oversees Haemonetics’ enterprise-wide approach to risk management while our management team is responsible for managing risk on a day-to-day basis and for bringing to the Board’s attention material risks facing the Company, including with respect to cybersecurity threats. The Board focuses on the quality and scope of the Company’s risk management strategies and considers the most significant areas of risk inherent in the Company’s business strategies and operations as well as the steps that management is taking to mitigate those risks.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	Additionally, certain Board committees consider discrete categories of cybersecurity risk relating to their respective areas of responsibility. Our CISO reports at least annually on Haemonetics’ threat landscape and security programs to our Governance and Compliance Committee, which oversees Haemonetics’ compliance programs and policies regarding data privacy and cybersecurity risks associated with our information technology systems. Management also reports on these programs to the Audit Committee as needed and periodically reviews with our Technology Committee certain aspects of new and existing products as they relate to quality, safety and cybersecurity.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	ur CISO reports at least annually on Haemonetics’ threat landscape and security programs to our Governance and Compliance Committee, which oversees Haemonetics’ compliance programs and policies regarding data privacy and cybersecurity risks associated with our information technology systems. Management also reports on these programs to the Audit Committee as needed and periodically reviews with our Technology Committee certain aspects of new and existing products as they relate to quality, safety and cybersecurity.
Cybersecurity Risk Role of Management [Text Block]	Our Board of Directors oversees Haemonetics’ enterprise-wide approach to risk management while our management team is responsible for managing risk on a day-to-day basis and for bringing to the Board’s attention material risks facing the Company, including with respect to cybersecurity threats. The Board focuses on the quality and scope of the Company’s risk management strategies and considers the most significant areas of risk inherent in the Company’s business strategies and operations as well as the steps that management is taking to mitigate those risks. We conduct an annual enterprise risk assessment – including consideration of cybersecurity risks – that is reviewed with the Board and Audit Committee and informs strategic priorities throughout the Company. Additionally, certain Board committees consider discrete categories of cybersecurity risk relating to their respective areas of responsibility. Our CISO reports at least annually on Haemonetics’ threat landscape and security programs to our Governance and Compliance Committee, which oversees Haemonetics’ compliance programs and policies regarding data privacy and cybersecurity risks associated with our information technology systems. Management also reports on these programs to the Audit Committee as needed and periodically reviews with our Technology Committee certain aspects of new and existing products as they relate to quality, safety and cybersecurity.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	The program is managed by a full-time Chief Information Security Officer (“CISO”) whose organization manages our cybersecurity strategy, architecture, policies, standards and processes for the security of Haemonetics’ enterprise network and information assets. The CISO reports to our Chief Information Officer (“CIO”) and is supported by a dedicated security operations team.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	Our current CISO has over 20 years of information technology experience, including positions of increasing responsibility with respect to security architecture, software engineering, security operations and incident response.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	Our CISO reports at least annually on Haemonetics’ threat landscape and security programs to our Governance and Compliance Committee, which oversees Haemonetics’ compliance programs and policies regarding data privacy and cybersecurity risks associated with our information technology systems. Management also reports on these programs to the Audit Committee as needed and periodically reviews with our Technology Committee certain aspects of new and existing products as they relate to quality, safety and cybersecurity.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

RETIREMENT PLANS (Schedule of Components of Net Periodic Benefit Costs of Defined Benefit Pension Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Retirement Benefits [Abstract]
Service cost	$ 1,804	$ 1,630	$ 1,316
Interest cost on benefit obligation	649	630	684
Expected return on plan assets	(273)	(314)	(264)
Actuarial loss (gain)	(19)	17	(180)
Amortization of unrecognized prior service cost	(236)	(219)	(215)
Plan settlements	15	(104)	0
Total	$ 1,940	$ 1,640	$ 1,341
DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag	Interest cost on benefit obligation
DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag	Expected return on plan assets
DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag	Actuarial loss (gain)
DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfPriorServiceCostCreditStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag	Amortization of unrecognized prior service cost
DefinedBenefitPlanNetPeriodicBenefitCostCreditSettlementGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag	Plan settlements

INCOME TAXES (Schedule of Income Taxes Paid) (Details) $ in Thousands	12 Months Ended
	Mar. 28, 2026 USD ($)
Income Tax Disclosure [Abstract]
Federal	$ 41,750
State	10,082
Foreign	8,833
Total	$ 60,665

INVENTORIES - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
INVENTORIES - Narrative (Details) - USD ($) $ in Thousands	Mar. 29, 2025	Mar. 28, 2026
Inventory [Line Items]
Inventories, net	$ 365,141	$ 306,370
Inventory recall expense	$ 4,400
Revision of Prior Period, Reclassification, Adjustment
Inventory [Line Items]
Inventories, net		$ (26,400)

CAPITAL STOCK

12 Months Ended

Mar. 28, 2026

Share-Based Payment Arrangement [Abstract]

CAPITAL STOCK

Stock Plans

The Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan (the “2019 Equity Plan”) was approved and became effective on July 25, 2019 (the “Effective Date”). The 2019 Equity Plan permits the award of incentive stock options, non-qualified stock options, stock appreciation rights (“SARs”), restricted stock, restricted stock units (including performance-based restricted stock units) and other awards to the Company’s key employees, non-employee directors and certain consultants and advisors of the Company and its subsidiaries. The 2019 Equity Plan is administered by the Compensation Committee of the Board of Directors (the “Committee”), which consists of four independent members of the Company’s Board of Directors, and is the successor to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan, as amended (the “2005 Equity Plan”). Upon the Effective Date, no further awards were granted under the 2005 Equity Plan; however, each outstanding award under the 2005 Equity Plan will remain outstanding under that plan and continue to be governed under its terms and any applicable award agreement.

The 2019 Equity Plan initially had a share reserve of 2,700,000 new shares of common stock, plus the number of shares of common stock reserved for issuance under the 2005 Plan that remained available for grant under the 2005 Plan as of July 25, 2019, an aggregate of 5,759,433 shares as of the Effective Date.

On August 4, 2023, the 2019 Equity Plan was amended and restated to increase the number of shares available for issuance under the Plan by 2,966,231 additional shares, from 1,975,970 shares to 4,942,201 shares of common stock, subject to adjustment as provided by the terms of the 2019 Equity Plan, as amended and restated.

Under the 2019 Equity Plan, as amended and restated, any shares that are subject to the award of stock options or SARs will be counted against the authorized share reserve as one share for every one share issued and any shares that are subject to awards other than stock options, SARs or cash awards will be counted against the authorized share reserve as 2.76 shares for every one share granted. Shares of common stock subject to outstanding grants under the 2005 Equity Plan as of the Effective Date that terminate, expire, or are otherwise canceled without having been exercised will be added to the share reserve at the applicable 2019 Equity Plan ratios. The total shares available for future grant under the 2019 Equity Plan, as amended and restated and giving effect to the applicable adjustment provisions, were 3,108,477 as of March 28, 2026.

Share-Based Compensation


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Selling, general and administrative expenses	$	29,511	$	25,971	$	23,662
Research and development	2,945		1,847		3,106
Cost of goods sold	1,371		1,818		1,564
Total share-based compensation	$	33,827	$	29,636	$	28,332

Stock Options

Options are granted to purchase common stock at prices as determined by the Committee, but in no event shall such exercise price be less than the fair market value of the common stock at the time of the grant. Options generally vest in equal installments over a four-year period for employees and one year from grant for non-employee directors. Options expire not more than seven years from the date of the grant. The grant-date fair value of options, adjusted for estimated forfeitures, is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. Forfeitures are estimated based on historical experience.

A summary of stock option activity for the fiscal year ended March 28, 2026 is as follows:


	Options Outstanding	Weighted Average Exercise Price per Share		Weighted Average Remaining Life (years)	Aggregate Intrinsic Value
	(Dollars in Thousands, Except Share and Per Share Data)
Outstanding as of March 29, 2025	993,587	$	81.75	3.5	$	2,249
Granted	227,425	70.05
Exercised	(36,267)	57.90
Forfeited/Canceled	(166,850)	89.42
Outstanding as of March 28, 2026	1,017,895	$	78.74	3.5	$	45
Exercisable as of March 28, 2026	599,839	$	79.67	2.2	$	33
Vested or expected to vest as of March 28, 2026	945,805	$	78.87	3.0	$	45

The total intrinsic value of options exercised was $0.6 million, $6.4 million and $12.4 million during fiscal 2026, 2025 and 2024, respectively.

As of March 28, 2026, there was $10.1 million of total unrecognized compensation cost related to non-vested stock options. This cost is expected to be recognized over a weighted average period of 2.5 years.

The fair value was estimated using the Black-Scholes option-pricing model based on the closing stock price at the grant date and the weighted average assumptions specific to the underlying options. Expected volatility assumptions are based on the historical volatility of the Company’s common stock over the expected term of the option. The risk-free interest rate was selected based upon yields of U.S. Treasury issues with a term equal to the expected life of the option being valued. The expected life of the option was estimated with reference to historical exercise patterns, the contractual term of the option and the vesting period.

The assumptions utilized for option grants during the periods presented are as follows:


	Year Ended
	2026			2025			2024
Volatility	44.2		%	43.9		%	45.3		%
Expected life (years)	5.4			5.2			5.1
Risk-free interest rate	4.1		%	4.4		%	3.5		%
Dividend yield	0.0		%	0.0		%	0.0		%
Grant-date fair value per option	$	32.35		$	43.56		$	39.46

Restricted Stock Units

Restricted Stock Units (“RSUs”) generally vest in equal installments over a three or four-year period for employees and one year from grant for non-employee directors. The grant-date fair value of RSUs, adjusted for estimated forfeitures, is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The fair market value of RSUs is determined based on the market value of the Company’s shares on the date of grant.

A summary of RSU activity for the fiscal year ended March 28, 2026 is as follows:


	Shares	Weighted Average Grant Date Fair Value
Unvested as of March 29, 2025	303,003	$	81.27
Granted	225,738	$	70.52
Vested	(157,290)	$	78.36
Forfeited	(41,633)	$	78.15
Unvested as of March 28, 2026	329,818	$	75.69

The weighted-average grant-date fair value of RSUs granted and total fair value of RSUs vested are as follows:


	Year Ended
	2026		2025		2024
Grant-date fair value per RSU	$	70.52	$	95.09	$	89.21
Fair value of RSUs vested	$	78.36	$	75.04	$	67.14

As of March 28, 2026, there was $13.8 million of total unrecognized compensation cost related to non-vested restricted stock units. This cost is expected to be recognized over a weighted average period of 1.7 years.

Performance Share Units

The grant date fair value of Performance Share Units (“PSUs”), adjusted for estimated forfeitures, is recognized as expense on a straight-line basis from the grant date through the end of the performance period. The value of these PSUs is generally based on (i) rTSR, which equals the total shareholder return for the Company as compared with the total shareholder return of a PSU comparison group and; (ii) the AAGR of the Company, both of which are measured over a three-year performance period. For outstanding rTSR-based PSUs, the comparison group for awards granted prior to fiscal 2026 consists of the components of the Standard and Poor’s (“S&P”) MidCap 400 Index and for awards granted in fiscal 2026 consists of the components of the S&P Health Care Equipment Select Industry Index. For outstanding AAGR-based PSUs, the Company recognizes expense based on the number of awards expected to vest, which requires management to assess the probability of achieving the performance conditions. This assessment is based on internal revenue forecasts, historical performance, and current market conditions, and is reassessed at each reporting date. Depending on the Company’s performance under the above-mentioned PSU awards during the performance period, a recipient of the award is entitled to receive a number of ordinary shares equal to a percentage, ranging from 0% to 200% of the award granted. If the Company’s total shareholder return for the performance period is negative, then any share payout for rTSR-based PSU awards will be capped at 100% of the target award, regardless of the Company’s performance relative to the comparison group. As a result, the Company may issue up to 715,262 shares related to outstanding performance-based awards.

A summary of PSU activity for the fiscal year ended March 28, 2026 is as follows:


	Shares	Weighted Average Grant Date Fair Value
Unvested as of March 29, 2025	335,843	$	112.10
Granted(1)	220,349	$	87.66
Vested(2)	(162,066)	$	84.96
Forfeited	(36,495)	$	114.24
Unvested as of March 28, 2026	357,631	$	108.86

__________

(1) Includes 35,443 shares issued for awards vested during fiscal 2026 based on achievement of performance metrics.

(2) Includes the vesting of 162,066 shares that were earned for TSR-based PSU awards granted in fiscal 2023 for performance periods ending during fiscal 2026, representing 128% of the target award.

The Company uses the Monte Carlo model to estimate the probability of satisfying the performance criteria and the resulting fair value of PSU awards with market conditions. The assumptions used in the Monte Carlo model for PSUs granted during each fiscal year were as follows:


	Year Ended
	2026		2025		2024
Expected stock price volatility	31.81	%	35.35	%	48.20	%
Peer group stock price volatility	46.62	%	35.95	%	40.29	%
Correlation of returns	27.81	%	58.08	%	59.93	%

The weighted-average grant-date fair value of PSUs granted is as follows:


	Year Ended
	2026		2025		2024
Grant-date fair value per PSU	$	87.66	$	128.25	$	128.83
Fair value of PSUs vested	$	84.96	$	72.35	$	—

As of March 28, 2026, there was $18.7 million of total unrecognized compensation cost related to non-vested performance share units. This cost is expected to be recognized over a weighted average period of 1.8 years.

Employee Stock Purchase Plan

The Company has an Employee Stock Purchase Plan (the “Purchase Plan”) under which a maximum of 3,200,000 shares (subject to adjustment for stock splits and similar changes) of common stock may be purchased by eligible employees. Substantially all of its full-time employees are eligible to participate in the Purchase Plan.

The Purchase Plan provides for two “purchase periods” within each of its fiscal years, the first commencing on November 1 of each year and continuing through April 30 of the next calendar year, and the second commencing on May 1 of each year and continuing through October 31 of such year. Shares are purchased through an accumulation of payroll deductions (of not less than 2% or more than 15% of compensation, as defined) for the number of whole shares determined by dividing the balance in the employee’s account on the last day of the purchase period by the purchase price per share for the stock determined under the Purchase Plan. The purchase price for shares is the lower of 85% of the fair market value of the common stock at the beginning of the purchase period, or 85% of such value at the end of the purchase period.

The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:


	Year Ended
	2026		2025		2024
Volatility	47.6	%	29.3	%	28.6	%
Expected life (months)	6		6		6
Risk-free interest rate	4.1	%	4.9	%	5.4	%
Dividend Yield	0.0	%	0.0	%	0.0	%

The weighted average grant date fair value of the six-month option inherent in the Purchase Plan was approximately $15.98, $19.13 and $20.27 during fiscal 2026, 2025 and 2024, respectively.

RETIREMENT PLANS (Schedule of Estimated Future Benefit Payments) (Details) $ in Thousands	Mar. 28, 2026 USD ($)
Expected Benefit Payments
Fiscal 2027	$ 1,701
Fiscal 2028	1,681
Fiscal 2029	1,916
Fiscal 2030	2,320
Fiscal 2031	1,861
Fiscal 2032-2036	$ 11,783

LEASES (Tables)

12 Months Ended

Mar. 28, 2026

Leases [Abstract]

Assets and Liabilities Lessee [Table Text Block]

The following table presents supplemental consolidated balance sheets information related to the Company’s operating leases:


	Classification	March 28, 2026		March 29, 2025
		(Dollars in Thousands)
Assets
Operating lease right-of-use assets	Other long-term assets	$	39,619	$	47,492
Liabilities
Operating lease liabilities	Other current liabilities	$	9,243	$	8,107
Operating lease liabilities	Other long-term liabilities	$	40,898	$	50,454

Lessee, Operating Leases, Other Information [Table Text Block]

The following table presents the weighted average remaining lease term and discount rate information related to the Company’s operating leases:


	March 28, 2026		March 29, 2025
Weighted average remaining lease term (years)	6.7		7.5
Weighted average discount rate	4.6	%	5.0	%

Lease, Cost [Table Text Block]

The following table presents supplemental cash flow information related to the Company’s operating leases:


	March 28, 2026		March 29, 2025		March 30, 2024
	(Dollars in Thousands)
Cash paid for amounts included in the measurement of operating lease liabilities
Operating cash flows used for operating leases	$	11,803	$	11,201	$	10,636
Right-of-use assets obtained in exchange for new operating lease liabilities	$	997	$	399	$	2,450

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

The following table presents the maturities of the Company’s operating lease liabilities as of March 28, 2026:


	Operating Leases
	(Dollars in Thousands)
Fiscal 2027	$	11,631
Fiscal 2028	9,567
Fiscal 2029	7,621
Fiscal 2030	7,261
Fiscal 2031	7,029
Thereafter	16,895
Total future minimum operating lease payments	60,004
Less: imputed interest	(9,863)
Present value of operating lease liabilities	$	50,141

EARNINGS PER SHARE (Share Repurchase Plan) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended					3 Months Ended
	Mar. 28, 2026	Sep. 30, 2025	Apr. 30, 2025	Oct. 31, 2024	Aug. 31, 2022	Mar. 28, 2026
2022 Share Repurchase Program
Accelerated Share Repurchases [Line Items]
Share repurchase program, period in force					3 years
Share repurchase program, authorized, amount					$ 300,000
Accelerated share repurchases, settlement (payment) or receipt					$ 75,000
Shares repurchased (in shares)					1,000,000.0
Repurchase price (in dollars per share)					$ 75.20
2024 Accelerated Share Repurchase Program
Accelerated Share Repurchases [Line Items]
Accelerated share repurchases, settlement (payment) or receipt				$ 75,000
Shares repurchased (in shares)				1,000,000.0
Repurchase price (in dollars per share)				$ 74.36
2025 Accelerated Share Repurchase Program
Accelerated Share Repurchases [Line Items]
Share repurchase program, authorized, amount			$ 500,000
Accelerated share repurchases, settlement (payment) or receipt	$ 75,000	$ 75,000	$ 150,000			$ 75,000
Shares repurchased (in shares)	1,218,798	1,430,579	2,386,131
Repurchase price (in dollars per share)	$ 61.54	$ 52.43	$ 62.86
Share repurchase program, remaining authorized, amount	$ 325,000					325,000
Rule 10b5-1 Trading Plan
Accelerated Share Repurchases [Line Items]
Accelerated share repurchases, settlement (payment) or receipt	$ 25,000					$ 25,000
Shares repurchased (in shares)						360,457
Repurchase price (in dollars per share)						$ 69.36

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Additional Information (Details) - USD ($) $ in Thousands					3 Months Ended		12 Months Ended
	Jan. 09, 2026	Jan. 13, 2025	Apr. 01, 2024	Dec. 12, 2023	Jun. 28, 2025	Mar. 29, 2025	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024	Jan. 08, 2026
Business Combination [Line Items]
Acquisitions							$ 60,180	$ 150,906	$ 243,852
Goodwill						$ 604,269	656,368	604,269	565,082
Proceeds from divestiture and sale of assets							0	43,291	1,500
Inventories, net						(365,141)	(306,370)	(365,141)
Property, plant and equipment, net						284,052	305,761	284,052
Divestitures								6,381
Investments						61,600	19,200	61,600
Revision of Prior Period, Reclassification, Adjustment
Business Combination [Line Items]
Inventories, net							26,400
Property, plant and equipment, net							7,800
Divestitures						6,400
Accrued liabilities							(100)
Disposal Group, Not Discontinued Operations \| Whole Blood
Business Combination [Line Items]
Proceeds from divestiture and sale of assets		$ 43,300
Business combination, contingent consideration, asset		$ 22,500
Disposal Group, Not Discontinued Operations \| Whole Blood \| Transition Services Agreement
Business Combination [Line Items]
Disposal group, support services upon completion of disposal, maximum term		36 months
Payments for (proceeds from) removal costs							(400)
Disposal Group, Not Discontinued Operations \| Whole Blood \| Contract Manufacturing Agreement
Business Combination [Line Items]
Disposal group, support services upon completion of disposal, maximum term		18 months
Payments for (proceeds from) removal costs							(1,700)
Vivasure Medical LTD
Business Combination [Line Items]
Business combination, consideration transferred	$ 164,400
Acquisitions	60,200
Cash acquired from acquisition	400
Business combination, contingent consideration, liability	$ 20,700
Business combination, contingent consideration performance period	3 years
Business combination, achieved in stages, preacquisition equity interest in acquiree, remeasurement, gain							$ 4,900
Business Combination, Achieved in Stages, Preacquisition Equity Interest in Acquiree, Remeasurement, Gain, Statement of Income or Comprehensive Income [Extensible Enumeration]							Remeasurement of contingent consideration
Business combination, achieved in stages, preacquisition and acquired equity interests in acquiree, percentage										30.00%
Business combination, achieved in stages, preacquisition equity interest in acquiree, fair value							$ 47,300
Goodwill	$ 50,478
Business combination, acquisition-related cost, expense							$ 1,100
Cash and cash equivalents	$ 449
Investments						$ 48,700		$ 48,700
Attune Medical
Business Combination [Line Items]
Payments to acquire businesses, gross			$ 162,000
Acquisitions			150,500
Business combination, contingent consideration, liability			$ 25,300
Business combination, contingent consideration performance period			3 years
Goodwill			$ 70,256
Business combination, working capital adjustment			400
Business combination, recognized asset acquired to liability assumed, excess (less)			176,206
Cash and cash equivalents			11,500
Deferred tax liability			$ 26,155
Attune Medical \| Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense
Business Combination [Line Items]
Business combination, acquisition-related cost, expense					$ 9,800
OpSens, Inc.
Business Combination [Line Items]
Business combination, consideration transferred				$ 243,900
Payments to acquire businesses, gross				254,500
Acquisitions				10,600
Goodwill				79,400
Business combination, acquisition-related cost, expense									$ 6,600
Deferred tax liability				$ 14,805

PROPERTY, PLANT AND EQUIPMENT

12 Months Ended

Mar. 28, 2026

Property, Plant, and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consisted of the following:


	March 28, 2026		March 29, 2025
	(Dollars in Thousands)
Land	$	2,251	$	1,985
Building and building improvements	109,793		105,079
Plant equipment and machinery	197,552		181,825
Office equipment and information technology	131,085		130,924
Haemonetics equipment	371,205		395,152
Construction in progress	29,943		22,229
Property, plant and equipment, at cost	841,829		837,194
Less: accumulated depreciation	(536,068)		(553,142)
Property, plant and equipment, net	$	305,761	$	284,052

Depreciation expense was $61.2 million, $60.0 million and $55.8 million in fiscal 2026, 2025 and 2024, respectively.

In the fourth quarter of fiscal 2025, the Company completed the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were sold. The property, plant and equipment related to the divestiture had a gross value of $40.8 million and a net carrying value of $7.8 million and has been removed from the consolidated balance sheets.

In the first quarter of fiscal 2025, the Company received $19.9 million of cash upon the sale of a manufacturing facility and related assets that previously met held for sale criteria, which resulted in a gain of $14.1 million that was recorded in selling, general and administrative expenses on the consolidated statements of income.

- Definition

The entire disclosure for property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/360/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482130/360-10-45-13

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.CC)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-SubTopic 360
-Topic 958
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477798/958-360-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-SubTopic 360
-Topic 958
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477798/958-360-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-SubTopic 360
-Topic 958
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477798/958-360-50-7

+ Details

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)

12 Months Ended

Mar. 28, 2026

Stockholders' Equity Note [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

The following is a roll-forward of the components of AOCL, net of tax, for the years ended March 28, 2026 and March 29, 2025:


	Foreign currency		Defined benefit plans		Net Unrealized Gain (Loss) on Derivatives		Total
	(Dollars in Thousands)
Balance, March 30, 2024	$	(38,274)	$	1,748	$	894	$	(35,632)
Other comprehensive loss before reclassifications	(17,974)		(599)		(935)		(19,508)
Amounts reclassified from AOCL(1)	—		—		56		56
Balance, March 29, 2025	$	(56,248)	$	1,149	$	15	$	(55,084)
Other comprehensive income before reclassifications	16,916		(403)		2,097		18,610
Amounts reclassified from AOCL(1)	—		—		(1,140)		(1,140)
Balance, March 28, 2026	$	(39,332)	$	746	$	972	$	(37,614)

__________

(1) Presented net of income taxes, the amounts of which are insignificant.

INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Tax at federal statutory rate	$ 26,886	$ 44,535	$ 31,892
State income taxes net of federal benefit	4,610	7,505	7,037
Statutory tax rate difference		(732)	(3,631)
Effect of cross-border tax laws	(770)
Other nontaxable or nondeductible items	1,496	2,845	2,355
Limitation on executive compensation	3,434
Federal research credits	(3,089)	(2,411)	(1,378)
Other tax credits	(852)
Changes in valuation allowances	37	1,744	(393)
Changes in unrecognized tax benefits	54
Income tax provision	$ 30,722	$ 44,392	$ 34,307
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Tax at federal statutory rate	21.00%	21.00%	21.00%
State income taxes net of federal benefit	3.60%	3.50%	4.60%
Statutory tax rate difference		(0.30%)	(2.40%)
Other items		(0.20%)	0.30%
Effect of cross-border tax laws	(0.60%)
Other nontaxable or nondeductible items	1.20%	1.30%	1.60%
Limitation on executive compensation	2.70%
Federal research credits	(2.40%)	(1.10%)	(0.90%)
Other tax credits	(0.70%)
Changes in valuation allowances	0.00%	0.90%	(0.20%)
Changes in unrecognized tax benefits	0.00%
Income tax provision	24.00%	20.90%	22.60%
Switzerland
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
State income taxes net of federal benefit	$ 2,246
Statutory tax rate difference	(5,051)
Other items	$ 21
Effective Income Tax Rate Reconciliation, Percent [Abstract]
State income taxes net of federal benefit	1.80%
Statutory tax rate difference	(3.90%)
Other items	0.00%
Canada
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
State income taxes net of federal benefit	$ (1,838)
Other items	$ (1,071)
Effective Income Tax Rate Reconciliation, Percent [Abstract]
State income taxes net of federal benefit	(1.50%)
Other items	(0.80%)
Ireland
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory tax rate difference	$ 1,341
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory tax rate difference	1.00%
Other foreign jurisdictions
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory tax rate difference	$ 3,267
Federal research credits	$ (2,000)
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory tax rate difference	2.60%
Income Tax Jurisdiction, Domestic Federal
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Federal research credits	$ (600)
United States
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Other items	$ 1
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Other items	0.00%

RESTRUCTURING (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Restructuring Cost and Reserve [Line Items]
Total restructuring and restructuring related costs	$ 3,219	$ 21,158	$ 23,588
Restructuring liability	1,307	3,025	11,794	$ 2,150
Restructuring related costs	105	7,245	9,499
2020 Program
Restructuring Cost and Reserve [Line Items]
Total restructuring and restructuring related costs		7,700	9,800
Restructuring and related cost, cost incurred to date	84,700
Restructuring liability	23	290	485	1,810
Portfolio Rationalization Initiatives
Restructuring Cost and Reserve [Line Items]
Total restructuring and restructuring related costs	(1,900)	13,000	14,000
Restructuring and related cost, cost incurred to date	25,100
Restructuring liability	716	2,735	11,309	0
Market and Regional Alignment Initiatives
Restructuring Cost and Reserve [Line Items]
Total restructuring and restructuring related costs	5,100	600
Restructuring and related cost, cost incurred to date	5,600
Restructuring liability	$ 568	$ 0	$ 0	$ 0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

SEGMENT AND ENTERPRISE-WIDE INFORMATION - Segment Reporting Information by Segment (Details) $ in Thousands	12 Months Ended
	Mar. 28, 2026 USD ($) unit	Mar. 29, 2025 USD ($)	Mar. 30, 2024 USD ($)
Segment Reporting [Line Items]
Number of reportable segments \| unit	3
Net revenues	$ 1,334,027	$ 1,360,824	$ 1,309,055
Significant segment expenses and operating performance:
Cost of goods sold	546,441	611,866	617,507
Selling, general and administrative	442,421	436,789	429,780
Research and development	59,766	62,722	54,435
Operating income	156,734	221,817	164,883
Amortization of acquired intangible assets	43,998	48,261	32,031
Impairment of intangible assets	86,546	2,391	10,419
Interest and other expense, net	(28,704)	(9,746)	(13,018)
Income before provision for income taxes	128,030	212,071	151,865
Total net revenues	1,334,027	1,360,824	1,309,055
Depreciation and amortization	111,717	115,586	97,215
Total long-lived assets	305,761	284,052
Blood Center
Significant segment expenses and operating performance:
Total net revenues	221,267	261,124	283,231
Hospital
Significant segment expenses and operating performance:
Total net revenues	588,304	564,269	456,289
Plasma
Segment Reporting [Line Items]
Net revenues	524,456	535,431	569,535
Significant segment expenses and operating performance:
Depreciation and amortization	47,368	48,264	45,712
Total long-lived assets	206,365	189,833
Plasma \| Plasma
Significant segment expenses and operating performance:
Total net revenues	524,456	535,431	569,535
Blood Center
Segment Reporting [Line Items]
Net revenues	221,267	261,124	283,231
Significant segment expenses and operating performance:
Depreciation and amortization	7,160	10,077	13,391
Total long-lived assets	39,677	40,337
Hospital
Segment Reporting [Line Items]
Net revenues	588,304	564,269	456,289
Significant segment expenses and operating performance:
Depreciation and amortization	57,189	57,245	38,112
Total long-lived assets	59,719	53,882
Apheresis \| Blood Center
Significant segment expenses and operating performance:
Total net revenues	220,861	213,134	211,173
Whole Blood \| Blood Center
Significant segment expenses and operating performance:
Total net revenues	406	47,990	72,058
Interventional Technologies \| Hospital
Significant segment expenses and operating performance:
Total net revenues	234,007	255,019	174,285
Blood Management Technologies \| Hospital
Significant segment expenses and operating performance:
Total net revenues	354,297	309,250	282,004
Operating Segments [Member] \| Plasma
Significant segment expenses and operating performance:
Cost of goods sold	214,135	237,050	264,042
Selling, general and administrative	105,323	98,418	109,729
Research and development	20,203	15,453	13,797
Operating income	184,795	184,510	181,967
Operating Segments [Member] \| Blood Center
Significant segment expenses and operating performance:
Cost of goods sold	112,666	142,512	165,564
Selling, general and administrative	54,133	60,023	67,339
Research and development	4,492	5,770	7,956
Operating income	49,976	52,819	42,372
Operating Segments [Member] \| Hospital
Significant segment expenses and operating performance:
Cost of goods sold	203,227	199,499	167,172
Selling, general and administrative	247,251	241,760	209,680
Research and development	34,091	34,035	27,239
Operating income	103,735	88,975	52,198
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]
Significant segment expenses and operating performance:
Operating income	156,734	221,817	164,883
Amortization of acquired intangible assets	49,812	63,217	35,378
Acquisition, integration and divestiture related costs	(14,155)	(22,904)	(11,249)
Restructuring and restructuring related costs	3,218	21,158	23,588
Digital transformation costs	21,526	20,273	15,667
Remeasurement of contingent consideration	1,879	23,022	0
Impairment of intangible assets	(86,546)	(2,391)	(10,419)
Other	$ (8,394)	$ 2,434	$ (15,353)

INCOME TAXES (Schedule of Income Tax Provision Components) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Current
Federal	$ 35,794	$ 29,818	$ 29,113
State	9,078	8,112	6,539
Foreign	12,251	12,085	9,532
Total current	57,123	50,015	45,184
Deferred
Federal	(17,960)	(6,555)	(6,165)
State	(3,175)	1,774	2,132
Foreign	(5,266)	(842)	(6,844)
Total deferred	(26,401)	(5,623)	(10,877)
Income tax provision	$ 30,722	$ 44,392	$ 34,307

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Acquired Intangible Assets (Details) - USD ($) $ in Thousands	Jan. 09, 2026	Apr. 01, 2024	Dec. 12, 2023	Mar. 28, 2026
Vivasure Medical LTD
Intangible Asset, Finite-Lived, Acquired [Line Items]
Intangible assets acquired	$ 117,100
Vivasure Medical LTD \| Developed technology
Intangible Asset, Finite-Lived, Acquired [Line Items]
Intangible assets acquired	$ 117,100
Weighted-Average Amortization Period	16 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation	16.50%
Attune Medical
Intangible Asset, Finite-Lived, Acquired [Line Items]
Intangible assets acquired				$ 105,800
Attune Medical \| Technology-Based Intangible Assets
Intangible Asset, Finite-Lived, Acquired [Line Items]
Intangible assets acquired				96,100
Weighted-Average Amortization Period		10 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation		22.00%
Attune Medical \| Customer Relationships
Intangible Asset, Finite-Lived, Acquired [Line Items]
Intangible assets acquired				7,800
Weighted-Average Amortization Period		10 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation		21.50%
Attune Medical \| Trade names
Intangible Asset, Finite-Lived, Acquired [Line Items]
Intangible assets acquired				$ 1,900
Weighted-Average Amortization Period		10 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation		21.50%
OpSens, Inc.
Intangible Asset, Finite-Lived, Acquired [Line Items]
Intangible assets acquired			$ 172,000
OpSens, Inc. \| Technology-Based Intangible Assets
Intangible Asset, Finite-Lived, Acquired [Line Items]
Intangible assets acquired			$ 114,900
Weighted-Average Amortization Period			15 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation			20.50%
OpSens, Inc. \| Customer Relationships
Intangible Asset, Finite-Lived, Acquired [Line Items]
Intangible assets acquired			$ 52,300
Weighted-Average Amortization Period			15 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation			18.90%
OpSens, Inc. \| Trademarks
Intangible Asset, Finite-Lived, Acquired [Line Items]
Intangible assets acquired			$ 4,800
Weighted-Average Amortization Period			15 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation			20.50%

INVENTORIES

12 Months Ended

Mar. 28, 2026

Inventory Disclosure [Abstract]

INVENTORIES

Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method.


	March 28, 2026		March 29, 2025
	(Dollars in Thousands)
Raw materials	$	114,873	$	128,574
Work-in-process	11,974		14,956
Finished goods	179,523		221,611
Total	$	306,370	$	365,141

In fiscal 2024, the Company issued a voluntary recall of certain products within the Whole Blood portion of the Company’s Blood Center business unit sold to customers in the U.S. and certain foreign jurisdictions. The Company has recorded charges of $4.4 million related to inventory.

RETIREMENT PLANS (Schedule of Activity Under Defined Benefit Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Change in Benefit Obligation:
Benefit Obligation, beginning of year	$ (30,956)	$ (32,323)
Service cost	(1,804)	(1,630)	$ (1,316)
Interest cost	(649)	(630)	(684)
Defined Benefit Plan, Benefit Obligation, Benefits Paid	1,470	851
Actuarial loss	(345)	(336)
Employee and plan participants contribution	(2,114)	(3,568)
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement	2,971	6,419
Foreign currency changes	(3,064)	261
Benefit obligation, end of year	(34,491)	(30,956)	(32,323)
Change in Plan Assets:
Fair value of plan assets, beginning of year	20,838	21,851
Defined Benefit Plan, Plan Assets, Contributions by Employer	1,497	1,627
Defined Benefit Plan, Plan Assets, Benefits Paid	568	663
Gain on plan assets	444	482
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	2,124	3,600
Plan settlements	(2,984)	(6,451)
Foreign currency changes	1,959	392
Fair value of plan assets, end of year	23,310	20,838	$ 21,851
Funded Status	(11,181)	(10,118)
Unrecognized net actuarial gain	(982)	(1,056)
Unrecognized prior service cost	(545)	(705)
Net amount recognized	$ (12,708)	$ (11,879)

DOCUMENT AND ENTITY INFORMATION - USD ($)	12 Months Ended
DOCUMENT AND ENTITY INFORMATION - USD ($)	Mar. 28, 2026	May 15, 2026	Sep. 27, 2025
Document And Entity Information [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Mar. 28, 2026
Current Fiscal Year End Date	--03-28
Document Transition Report	false
Entity File Number	001-14041
Entity Registrant Name	HAEMONETICS CORPORATION
Entity Incorporation, State or Country Code	MA
Entity Tax Identification Number	04-2882273
Entity Address, Address Line One	125 Summer Street,
Entity Address, City or Town	Boston,
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02110
City Area Code	(781)
Local Phone Number	848-7100
Title of 12(b) Security	Common stock, $0.01 par value per share
Trading Symbol	HAE
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Public Float			$ 2,226,588,933
Entity Common Stock, Shares Outstanding		45,445,983
Documents Incorporated by Reference	Portions of the definitive proxy statement for our Annual Meeting of Shareholders to be filed with the Securities and Exchange Commission within 120 days after the close of our fiscal year are incorporated by reference in Part III of this report.
Entity Central Index Key	0000313143
Document Fiscal Year Focus	2026
Document Fiscal Period Focus	FY
Amendment Flag	false

CAPITAL STOCK (Schedule of Summary of Equity Awards other than Options Activity) (Details) - $ / shares	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Shares, Beginning Balance (in shares)	303,003
Shares, Granted (in shares)	225,738
Shares, Vested (in shares)	(157,290)
Shares, Forfeited (in shares)	(41,633)
Shares, Ending Balance (in shares)	329,818	303,003
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Grant Date Fair Value (in dollars per share), Beginning Balance	$ 81.27
Weighted Average Grant Date Fair Value (in dollars per share), Granted	70.52	$ 95.09	$ 89.21
Weighted Average Grant Date Fair Value (in dollars per share), Vested	78.36	75.04	67.14
Weighted Average Grant Date Fair Value (in dollars per share), Forfeited	78.15
Weighted Average Grant Date Fair Value (in dollars per share), Ending Balance	$ 75.69	$ 81.27
Restricted Stock Units (RSUs) \| Minimum \| Employees
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Award vesting period	3 years
Performance Share Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Shares, Beginning Balance (in shares)	335,843
Shares, Granted (in shares)	220,349			35,443
Performance shares target, percentage	100.00%
Shares, Vested (in shares)	(162,066)
Shares, Forfeited (in shares)	(36,495)
Shares, Ending Balance (in shares)	357,631	335,843
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Grant Date Fair Value (in dollars per share), Beginning Balance	$ 112.10
Weighted Average Grant Date Fair Value (in dollars per share), Granted	87.66	$ 128.25	128.83
Weighted Average Grant Date Fair Value (in dollars per share), Vested	84.96	72.35	$ 0
Weighted Average Grant Date Fair Value (in dollars per share), Forfeited	114.24
Weighted Average Grant Date Fair Value (in dollars per share), Ending Balance	$ 108.86	$ 112.10
Performance Share Units (PSUs) \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Performance shares target, percentage	0.00%
Performance Period One \| Performance Share Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Performance shares target, percentage	128.00%
Shares, Vested (in shares)	(162,066)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 28, 2026	Mar. 29, 2025
Accounting Standards Update and Change in Accounting Principle [Abstract]
Contract liabilities	$ 42,310	$ 43,348
Contingent consideration	17,597	2,278
Other	98,430	102,507
Other current liabilities	$ 158,337	$ 148,133

LEASES

12 Months Ended

Mar. 28, 2026

Leases [Abstract]

Leases

LEASES

Lessee Activity

The Company has operating leases for office space, land, warehouse and manufacturing space, R&D laboratories, vehicles and certain equipment. Leases with an initial term of 12 months or less are not recognized on the consolidated balance sheets and expense for these leases is recognized on a straight-line basis over the lease term. The Company accounts for the lease components and the non-lease components as a single lease component. The Company’s leases have remaining lease terms of 1 year to approximately 30 years, some of which may include options to extend the leases for up to 10 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees.

The Company determines whether an arrangement is, or contains, a lease based on the unique facts and circumstances present at the inception of an arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.

The following table presents supplemental consolidated balance sheets information related to the Company’s operating leases:


	Classification	March 28, 2026		March 29, 2025
		(Dollars in Thousands)
Assets
Operating lease right-of-use assets	Other long-term assets	$	39,619	$	47,492
Liabilities
Operating lease liabilities	Other current liabilities	$	9,243	$	8,107
Operating lease liabilities	Other long-term liabilities	$	40,898	$	50,454

The following table presents the weighted average remaining lease term and discount rate information related to the Company’s operating leases:


	March 28, 2026		March 29, 2025
Weighted average remaining lease term (years)	6.7		7.5
Weighted average discount rate	4.6	%	5.0	%

The Company’s operating lease costs were $10.4 million, $12.1 million and $10.6 million during fiscal 2026, 2025 and 2024, respectively.

The following table presents supplemental cash flow information related to the Company’s operating leases:


	March 28, 2026		March 29, 2025		March 30, 2024
	(Dollars in Thousands)
Cash paid for amounts included in the measurement of operating lease liabilities
Operating cash flows used for operating leases	$	11,803	$	11,201	$	10,636
Right-of-use assets obtained in exchange for new operating lease liabilities	$	997	$	399	$	2,450

The following table presents the maturities of the Company’s operating lease liabilities as of March 28, 2026:


	Operating Leases
	(Dollars in Thousands)
Fiscal 2027	$	11,631
Fiscal 2028	9,567
Fiscal 2029	7,621
Fiscal 2030	7,261
Fiscal 2031	7,029
Thereafter	16,895
Total future minimum operating lease payments	60,004
Less: imputed interest	(9,863)
Present value of operating lease liabilities	$	50,141

Lessor Activity

Assets on the Company’s consolidated balance sheets classified as Haemonetics equipment primarily consists of medical devices installed at customer sites but owned by Haemonetics. These devices are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as the purchase and consumption of the Company’s disposable products. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where devices are provided under operating lease arrangements, a substantial majority of the entire lease revenue is variable and subject to subsequent non-lease component (disposable products) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Operating lease revenue represents approximately three percent of the Company’s total net sales.

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Interest Rate Swaps) (Details) $ in Thousands	Mar. 28, 2026 USD ($)	Sep. 27, 2024 USD ($) swap
Derivative [Line Items]
Number of interest rate swaps remaining \| swap		2,000
Interest Rate Swap, 4.08% Fixed Interest Rate
Derivative [Line Items]
Notional amount	$ 100,321	$ 109,900
Derivative fixed interest rate	3.30%
Derivative, Fair Value, Net	$ 859
Interest Rate Swap, 4.15% Fixed Interest Rate
Derivative [Line Items]
Notional amount	$ 98,966	109,900
Derivative fixed interest rate	3.30%
Derivative, Fair Value, Net	$ 912
Interest Rate Swap
Derivative [Line Items]
Notional amount	199,287	$ 219,800
Derivative, Fair Value, Net	$ 1,771

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Schedule of Net Assets and Liabilities Acquired (Details) - USD ($) $ in Thousands	Mar. 28, 2026	Jan. 09, 2026	Mar. 29, 2025	Apr. 01, 2024	Mar. 30, 2024	Dec. 12, 2023
Business Combination [Line Items]
Goodwill	$ 656,368		$ 604,269		$ 565,082
Vivasure Medical LTD
Business Combination [Line Items]
Cash and cash equivalents		$ 449
Accounts receivable		21
Inventories		1,056
Prepaid expenses and other current assets		1,736
Property, plant and equipment		575
Intangible assets		117,100
Goodwill		50,478
Other long-term assets		1,972
Total assets acquired		173,387
Accounts payable		1,186
Accrued payroll and related costs		2,889
Other liabilities		4,741
Other long-term liabilities		199
Total liabilities assumed		9,015
Net assets acquired		$ 164,372
Attune Medical
Business Combination [Line Items]
Cash and cash equivalents				$ 11,500
Accounts receivable				3,784
Inventories				26,300
Prepaid expenses and other current assets				906
Property, plant and equipment				200
Intangible assets				105,800
Goodwill				70,256
Total assets acquired				207,246
Accounts payable				2,260
Accrued payroll and related costs				2,129
Other liabilities				496
Deferred tax liability				26,155
Total liabilities assumed				31,040
Business combination, recognized asset acquired to liability assumed, excess (less)				$ 176,206
OpSens, Inc.
Business Combination [Line Items]
Accounts receivable						$ 5,960
Inventories						12,075
Prepaid expenses and other current assets						2,062
Property, plant and equipment						3,028
Intangible assets						172,000
Goodwill						79,400
Other long-term assets						4,705
Total assets acquired						279,230
Accounts payable						3,251
Accrued payroll and related costs						1,723
Other liabilities						9,746
Deferred tax liability						14,805
Other long-term liabilities						5,853
Total liabilities assumed						35,378
Net assets acquired						$ 243,852

COMMITMENTS AND CONTINGENCIES	12 Months Ended
COMMITMENTS AND CONTINGENCIES	Mar. 28, 2026
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. The Company believes that, except for those matters described below, there are no other proceedings or claims pending against it the ultimate resolution of which could have a material adverse effect on its financial condition or results of operations. At each reporting period, management evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies, for all matters. Legal costs are expensed as incurred. Plasma Biometric Information Privacy Act In the fourth quarter of fiscal 2021, a putative class action complaint was filed against the Company in the Circuit Court of Cook County, Illinois by Mary Crumpton, on behalf of herself and similarly situated individuals. The Company removed the case to the United States District Court for the Northern District Illinois. See Mary Crumpton v. Haemonetics Corporation, Case No. 1:21-cv-1402. In her complaint, the plaintiff asserted that between June 2017 and August 2018 she donated plasma at a center operated by one of the Company’s customers, that the center required her to scan her fingerprint on a finger scanner that stored her fingerprint to identify her prior to plasma donation, and that the Company’s eQue donor management software sent her biometric information to a Company-owned server to be collected and stored in a manner that violated her rights under the Illinois Biometric Information Privacy Act (“BIPA”). The plaintiff sought statutory damages, attorneys’ fees and injunctive and equitable relief. During the second quarter of fiscal 2024, the Company entered into a Memorandum of Understanding providing terms that would resolve the litigation and recorded an additional loss contingency related to this matter. In the third quarter of fiscal 2024, the parties requested preliminary court approval of a final settlement agreement, which was granted in February 2024, and the Company recorded an immaterial additional loss contingency related to settlement administration, resulting in an accrual of $8.7 million within other current liabilities in its consolidated balance sheets. In March 2024, administration of the settlement through the third-party administrator commenced and, in April 2025, the administrator notified the parties that distribution of the final settlement funds was underway and that administration would formally close 90 days thereafter. In the first quarter of fiscal 2025, the Company issued payment of the $8.7 million settlement amount following the court’s final approval of the settlement agreement and dismissal of the matter with prejudice. Sensor-Guided Technologies Patent Litigation During the fourth quarter of fiscal 2024, a complaint was filed in the U.S. District Court for the District of Delaware by Knoninklijke Philips N.V. and IP2IPO Innovations, Ltd. (together, the “Plaintiffs”) against OpSens, OpSens Medical, Inc., a wholly-owned subsidiary of Haemonetics, and Haemonetics (1:24-cv-00206-CFC). The complaint alleged, inter alia, that OpSens’ interventional cardiology systems, including its OptoWire and OptoMonitor® technology, infringed a single patent held by the Plaintiffs and sought both injunctive relief and damages. The Company recorded loss contingencies related to this matter in the first and fourth quarters of fiscal 2025 and in the first quarter of fiscal 2026, which did not have a material impact on its consolidated financial statements. In the second quarter of fiscal 2026, the parties entered into a final confidential settlement agreement to resolve the matter, which the court approved, and the Company recorded an immaterial additional loss contingency relating to final settlement of the matter. Plasma Patent Litigation During the first quarter of fiscal 2026, the Company filed a complaint against Terumo BCT in U.S. District Court for the District of Colorado (1:25-cv-01409). The complaint alleges that Terumo BCT infringes the Company’s intellectual property rights with respect to its donor-centric blood plasma collection patents, as embodied in the Company’s NexSys PCS® with YES® technology and NexSys PCS with Persona® technology. On June 26, 2025, Terumo filed a motion to dismiss. On July 17, 2025 and August 12, 2025, the Company filed amended complaints adding recently issued patents. On September 2, 2025, Terumo filed a partial motion to dismiss with prejudice claiming that the Company’s asserted patents were invalid under 35 U.S.C. section 101. Terumo has also filed inter partes and post-grant review petitions with the U.S. Patent and Trademark Office (PTO) seeking to invalidate the asserted patents. In October 2025, Terumo filed a motion to stay the district court proceedings pending resolution of the PTO petitions. The Company filed responses opposing Terumo’s motions in November 2025. Two of the nine PTO petitions have been instituted for further review, and seven of the PTO petitions were denied by the PTO. During the second quarter of fiscal 2026, the Company filed a complaint against Fresenius Kabi USA LLC in U.S. District Court for the Northern District of Illinois (1:25-cv-08680). The complaint alleges that Fresenius Kabi infringes the Company’s intellectual property rights with respect to its donor-centric blood plasma collection patents, as embodied in the Company’s NexSys PCS with YES technology and NexSys PCS with Persona technology. In October 2025, the Company filed an amended complaint to add Fenwal Inc. and Fresenius Kabi AG as parties to the matter. In December 2025, Fenwal filed its answer and counterclaims, alleging non-infringement and invalidity of the Company’s asserted patents and alleging infringement by the Company of certain of Fenwal’s U.S. patents. While the Company will incur costs in the course of pursuing these claims, and the outcome of litigation is inherently uncertain, the Company believes this is a necessary and appropriate action to safeguard its innovations, protect its intellectual property, and further the growth and development of its business.

RETIREMENT PLANS (Tables)

12 Months Ended

Mar. 28, 2026

Retirement Benefits [Abstract]

Schedule of Components of Net Periodic Benefit Costs of Defined Benefit Pension Plans

Some of the Company’s foreign subsidiaries have defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Net periodic benefit costs for the plans in the aggregate include the following components:


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Service cost	$	1,804	$	1,630	$	1,316
Interest cost on benefit obligation	649		630		684
Expected return on plan assets	(273)		(314)		(264)
Actuarial loss (gain)	(19)		17		(180)
Amortization of unrecognized prior service cost	(236)		(219)		(215)
Plan settlements	15		(104)		—
Total	$	1,940	$	1,640	$	1,341

Schedule of Activity Under Defined Benefit Plans

The activity under those defined benefit plans are as follows:


	March 28, 2026		March 29, 2025
	(Dollars in Thousands)
Change in Benefit Obligation:
Benefit Obligation, beginning of year	$	(30,956)	$	(32,323)
Service cost	(1,804)		(1,630)
Interest cost	(649)		(630)
Benefits paid	1,470		851
Actuarial loss	(345)		(336)
Employee and plan participants contribution	(2,114)		(3,568)
Plan settlements	2,971		6,419
Foreign currency changes	(3,064)		261
Benefit obligation, end of year	$	(34,491)	$	(30,956)
Change in Plan Assets:
Fair value of plan assets, beginning of year	$	20,838	$	21,851
Company contributions	1,497		1,627
Benefits paid	(568)		(663)
Gain on plan assets	444		482
Employee and plan participants contribution	2,124		3,600
Plan settlements	(2,984)		(6,451)
Foreign currency changes	1,959		392
Fair value of plan assets, end of year	$	23,310	$	20,838
Funded Status(1)	$	(11,181)	$	(10,118)
Unrecognized net actuarial gain	(982)		(1,056)
Unrecognized prior service cost	(545)		(705)
Net amount recognized	$	(12,708)	$	(11,879)

__________

(1) Substantially all of the unfunded status is non-current.

Schedule of Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax

The components of the change recorded in the Company’s accumulated other comprehensive loss related to its defined benefit plans, net of tax, are as follows:


	Accumulated Other Comprehensive Loss
	(Dollars in Thousands)
Balance as of April 1, 2023	$	4,075
Actuarial loss	(2,157)
Prior service credit	(170)

Balance as of March 30, 2024	$	1,748
Actuarial loss	(268)
Prior service credit	(242)
Plan settlements	(89)
Balance as of March 29, 2025	$	1,149
Actuarial loss	(169)
Prior service credit	(218)
Plan settlements	(16)
Balance as of March 28, 2026	$	746

Schedule of Weighted Average Rates Used to Determine Net Periodic Benefit Costs

The weighted average rates used to determine the net periodic benefit costs and projected benefit obligations were as follows:


	Year Ended
	2026		2025		2024
Discount rate	1.78	%	1.87	%	2.05	%
Rate of increased salary levels	2.72	%	2.71	%	1.86	%
Expected long-term rate of return on assets	0.96	%	0.88	%	0.94	%

Schedule of Estimated Future Benefit Payments

Estimated future benefit payments are as follows:


	Estimated Future Benefit Payments
	(Dollars in Thousands)
Fiscal 2027	$	1,701
Fiscal 2028	$	1,681
Fiscal 2029	$	1,916
Fiscal 2030	$	2,320
Fiscal 2031	$	1,861
Fiscal 2032-2036	$	11,783

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)

12 Months Ended

Mar. 28, 2026

Segment Reporting [Abstract]

Segment Reporting

Selected information by reportable segment is presented below:


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Net revenues:
Plasma	$	524,456	$	535,431	$	569,535
Blood Center	221,267		261,124		283,231
Hospital	588,304		564,269		456,289
Total net revenues	$	1,334,027	$	1,360,824	$	1,309,055

Significant segment expenses and operating performance:
Plasma
Cost of goods sold	$	214,135	$	237,050	$	264,042
Selling, general and administrative	105,323		98,418		109,729
Research and development	20,203		15,453		13,797
Plasma operating income	$	184,795	$	184,510	$	181,967
Blood Center
Cost of goods sold	$	112,666	$	142,512	$	165,564
Selling, general and administrative	54,133		60,023		67,339
Research and development	4,492		5,770		7,956
Blood Center operating income	$	49,976	$	52,819	$	42,372
Hospital
Cost of goods sold	$	203,227	$	199,499	$	167,172
Selling, general and administrative	247,251		241,760		209,680
Research and development	34,091		34,035		27,239
Hospital operating income	$	103,735	$	88,975	$	52,198
Corporate and unallocated expenses
Amortization of acquired assets	$	(49,812)	$	(63,217)	$	(35,378)
Acquisition, integration and divestiture related costs	(14,155)		(22,904)		(11,249)
Restructuring and restructuring related costs	(3,218)		(21,158)		(23,588)
Digital transformation costs	(21,526)		(20,273)		(15,667)
Remeasurement of contingent consideration	1,879		23,022		—
Impairment of intangible assets	(86,546)		(2,391)		(10,419)
Other(1)	(8,394)		2,434		(15,353)
Operating income	156,734		221,817		164,883
Interest and other expense, net	(28,704)		(9,746)		(13,018)
Income before provision for income taxes	$	128,030	$	212,071	$	151,865

__________

(1) Comprised of write downs of certain assets, EU MDR and EU IVDR costs, Litigation-related charges, gain on repurchase of convertible notes, gain on sale of property, plant and equipment, PCS2® related charges, gain on divestiture, and a provision for pre-acquisition inventory and inventory purchase commitments transferred from the Attune Medical acquisition that was deemed not recoverable.

Net revenues by business unit are as follows:


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Plasma
Plasma net revenues	$	524,456	$	535,431	$	569,535

Blood Center
Apheresis	$	220,861	$	213,134	$	211,173
Whole Blood	406		47,990		72,058
Blood Center net revenues	$	221,267	$	261,124	$	283,231

Hospital
Interventional Technologies	$	234,007	$	255,019	$	174,285
Blood Management Technologies	354,297		309,250		282,004
Hospital net revenues	$	588,304	$	564,269	$	456,289

Total net revenues	$	1,334,027	$	1,360,824	$	1,309,055

Depreciation and amortization, excluding impairment charges, by business unit are as follows:


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Plasma	$	47,368	$	48,264	$	45,712
Blood Center	7,160		10,077		13,391
Hospital	57,189		57,245		38,112
Total depreciation and amortization (excluding impairment charges)	$	111,717	$	115,586	$	97,215

Long-lived assets, comprised of property, plant and equipment, by business unit are as follows:


	March 28, 2026		March 29, 2025
	(Dollars in Thousands)
Plasma	$	206,365	$	189,833
Blood Center	39,677		40,337
Hospital	59,719		53,882
Total long-lived assets	$	305,761	$	284,052

Segment Information by Geographic Area

Long-lived assets, comprised of property, plant and equipment, by operating regions are as follows:


	March 28, 2026		March 29, 2025
	(Dollars in Thousands)
United States	$	224,699	$	217,212
Japan	916		1,250
Europe	32,080		20,024
Rest of Asia	30,833		28,705
Other	17,233		16,861
Total long-lived assets	$	305,761	$	284,052

Net revenues by operating regions are as follows:


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
United States	$	982,176	$	1,010,918	$	970,007
Japan	68,200		62,408		58,087
Europe	185,019		175,655		160,142
Rest of Asia	87,212		92,305		107,536
Other	11,420		19,538		13,283
Total net revenues	$	1,334,027	$	1,360,824	$	1,309,055

- Definition

Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

+ Details

RETIREMENT PLANS (Schedule of Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax [Roll Forward]
Beginning balance	$ 1,149	$ 1,748	$ 4,075
Actuarial loss	(169)	(268)	(2,157)
Prior service credit	(218)	(242)	(170)
Plan settlements	(16)	(89)
Ending balance	$ 746	$ 1,149	$ 1,748

NOTES PAYABLE AND LONG-TERM DEBT

12 Months Ended

Mar. 28, 2026

Debt Disclosure [Abstract]

NOTES PAYABLE AND LONG-TERM DEBT

Notes payable and long-term debt consisted of the following:


	March 28, 2026		March 29, 2025
	(Dollars in Thousands)
Convertible notes	$	688,775	$	983,951
Term loan, net of financing fees	235,131		240,028
Revolving credit facility	300,000		—
Other borrowings	674		809
Total Debt	1,224,580		1,224,788
Less: current portion	(5,015)		(303,558)
Long-term debt	$	1,219,565	$	921,230

Convertible Senior Notes

2026 Notes

On March 5, 2021, the Company issued $500.0 million aggregate principal amount of 0.0% convertible senior notes due 2026 (the “2026 Notes”). The 2026 Notes are governed by the terms of an Indenture between the Company and U.S. Bank Trust Company, National Association, as trustee.

In the first quarter of fiscal 2025, the Company repurchased $200.0 million of the aggregate principal amount for $185.5 million, resulting in a gain of $14.5 million related to the discount on repurchase. As the repurchase of the 2026 Notes met the criteria for extinguishment accounting, $1.9 million of unamortized debt issuance costs were allocated to the repurchase, resulting in a net gain of $12.6 million, which was recorded in interest and other expense, net on the consolidated statements of income.

On or after September 1, 2025, until the close of business on the scheduled trading day immediately preceding the maturity date, holders had the right to convert all or a portion of their 2026 Notes. No holders exercised conversion rights with respect to the 2026 Notes prior to maturity.

Interest expense related to the 2026 Notes was $1.5 million for fiscal 2026, which is entirely attributable to the amortization of the debt issuance costs.

On March 2, 2026, the Company repaid in full at maturity its 2026 Notes for an aggregate amount of $300.0 million in cash, representing the outstanding principal amount of the 2026 Notes. The repayment was funded with cash on hand and borrowings under the Company’s revolving credit facility. The capped call transactions entered into in connection with the issuance of the 2026 Notes expired in accordance with their terms upon the maturity of the 2026 Notes.

2029 Notes

On May 28, 2024, the Company issued $700.0 million aggregate principal amount of 2.5% convertible senior notes due 2029 (the “2029 Notes”). The 2029 Notes are governed by the terms of an Indenture between the Company and U.S. Bank Trust Company, National Association, as trustee. The total net proceeds from the sale of the 2029 Notes, after deducting the initial purchasers’ discounts and debt issuance costs, were $682.8 million, with a portion of funds used to repay the entirety of the balance on the revolving credit facility under the Company’s second amended and restated credit agreement, to repurchase a portion of the Company’s 2026 Notes, to complete capped call transactions in connection with the issuance of the 2029 Notes, as described further below, with the remaining proceeds available for other working capital requirements. The 2029 Notes will mature on June 1, 2029, unless earlier converted, redeemed or repurchased.

Holders may convert their notes at their option at any time prior to the close of business on the business day immediately preceding December 1, 2028 only under the following circumstances:

•During any calendar quarter (and only during such calendar quarter) beginning after September 30, 2024, if, the last reported sale price per share of the Company’s common stock exceeds 130% of the applicable conversion price on each applicable trading day for at least 20 trading days (whether or not consecutive) in the period of the 30 consecutive trading day period ending on, and including, the last trading day of the immediately preceding calendar quarter;

•During the five business day period after any five consecutive trading day period in which, for each day of that period, the trading price per $1,000 principal amount of the 2029 Notes for such trading day was less than 98% of the product of the last reported sale price of the Company’s common stock and the applicable conversion rate on such trading day;

•The Company issues to common stockholders any rights, options, or warrants, entitling them, for a period of not more than 60 days, to purchase shares of common stock at a price per share less than the average closing sale price of 10 consecutive trading days, or the Company’s election to make a distribution to common stockholders exceeding 10% of the previous day’s closing sale price;

•Upon the occurrence of specified corporate events, as set forth in the indenture governing the 2029 Notes; or

•Prior to the related redemption date if the Company calls the 2029 Notes for redemption.

On or after December 1, 2028, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2029 Notes, in multiples of $1,000 principal amount, at any time, regardless of the foregoing circumstances. The conversion rate for the 2029 Notes is 8.5385 shares of common stock per $1,000 principal amount of notes (which is equal to an initial conversion price of approximately $117.12 per share of the Company’s common stock), subject to adjustment as set forth in the Indenture. Upon conversion, the Company will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, common stock or a combination of cash and common stock, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the notes being converted. If a make-whole adjustment event, as described in the Indenture, occurs and a holder elects to convert its 2029 Notes in connection with such make-whole adjustment event, such holder may be entitled to an increase in the conversion rate as described in the Indenture.

During fiscal 2026, the conditions allowing holders of the 2029 Notes to convert have not been met. The 2029 Notes were therefore not convertible as of March 28, 2026 and were classified as long-term debt on the Company’s consolidated balance sheets.

The 2029 Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after June 5, 2027 and on or before the 50th scheduled trading day immediately before the maturity date, if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which the Company provides notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately before the date the Company sends the related redemption notice at a redemption price equal to 100% of the principal amount of the 2029 Notes to be redeemed, plus accrued and unpaid interest to, but excluding the redemption date. Upon the occurrence of certain fundamental changes involving the Company, holders of the 2029 Notes may require the Company to repurchase for cash all or part of their 2029 Notes at a repurchase price equal to 100% of the principal amount of the 2029 Notes to be repurchased, plus accrued and unpaid interest.

As a result of the issuance of the 2029 Notes, the Company recorded debt issuance costs of $17.2 million, which will be amortized to interest expense over the contractual term of the 2029 Notes at an effective interest rate of 3.0%.

As of March 28, 2026, the $700.0 million principal balance was netted down by $11.2 million of remaining debt issuance costs, resulting in a net convertible note payable of $688.8 million. Interest expense related to the 2029 Notes was $20.8 million for the fiscal year ended March 28, 2026, which includes nominal interest expense and the amortization of the debt issuance costs.

Capped Calls

In connection with the issuance of the 2026 Notes and the 2029 Notes, the Company entered into capped call transactions with certain counterparties (“Capped Calls”). The 2026 Notes Capped Calls each had an initial strike price of approximately $175.34 per share, and the 2029 Notes Capped Calls each have an initial strike price of approximately $117.12 per share, both are subject to certain adjustments, which correspond to the initial conversion price of the convertible notes. The 2026 Notes Capped Calls had initial cap prices of $250.48 per share, and the 2029 Notes Capped Calls have initial cap prices of $180.18 per share, both subject to certain adjustments. The Capped Calls are expected to partially offset the potential dilution to the Company’s common stock upon any conversion of the 2029 Notes, with such offset subject to a cap based on the cap price. No holders exercised conversion rights with respect to the 2026 Notes prior to maturity, and, in accordance with their terms upon maturity of the 2026 Notes, the Capped Calls related to the 2026 Notes have expired. The 2029 Notes Capped Calls cover approximately 5.98 million shares of the Company’s common stock, and is subject to anti-dilution adjustments. For accounting purposes, the Capped Calls are separate transactions, and not part of the 2029 Notes. As these transactions meet certain accounting criteria, the Capped Calls are recorded in stockholders’ equity and are not accounted for as derivatives. The cost of $88.2 million incurred to purchase the 2029 Notes Capped Calls was recorded as a reduction to additional paid-in capital in fiscal 2025 and will not be remeasured.

Credit Facilities

On July 26, 2022, the Company entered into an amended and restated credit agreement to refinance its credit facilities initially entered into in 2018 and extended their maturity dates through June 2025. The amended and restated credit agreement provided for a $750.0 million senior unsecured term loan and a $420.0 million senior unsecured revolving credit facility (together the “2022 Revised Credit Facilities”) with applicable interest rates during the period established using an annual rate equal to the Adjusted Term SOFR Rate plus ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio, as specified in the agreement.

On April 30, 2024, the Company entered into a second amended and restated credit agreement with certain lenders to refinance the 2022 Revised Credit Facilities and extend their maturity date through April 2029. The second amended and restated credit agreement provides for a $250.0 million senior unsecured term loan, the proceeds of which, along with $12.5 million of cash on hand, were used to retire the balance of the term loan under the 2022 Revised Credit Facilities, and a $750.0 million senior unsecured revolving credit facility (together, the “2024 Revised Credit Facilities”). Loans under the 2024 Revised Credit Facilities bear interest at an annual rate equal to the Adjusted Term SOFR Rate (as specified in the second amended and restated credit agreement), which is subject to a floor of 0%, plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio (as specified in the second amended and restated credit agreement) at the applicable measurement date. The revolving credit facility carries an unused fee that ranges from 0.125% to 0.250% annually based on the Company’s consolidated net leverage ratio at the applicable measurement date. The 2024 Revised Credit Facilities mature on April 30, 2029. The principal amount of the term loan under the 2024 Revised Credit Facilities amortizes quarterly through the maturity date at a rate of 2.5% for the first three years following the closing date, 5.0% for the fourth year following the closing date and 7.5% for the fifth year following the closing date, with the unpaid balance due at maturity.

Under the 2024 Revised Credit Facilities, the Company is required to maintain a consolidated leverage ratio not to exceed 4.0:1.0 or, upon two occasions during the term of the facility, 4.5:1.0 for the four consecutive fiscal quarters ended immediately following acquisitions meeting certain criteria specified in the agreement.

The Company applied modification accounting for the credit facility refinancing, which resulted in the capitalization of an additional $5.9 million in lender fees and third-party costs. For fiscal 2026, the Company recognized $17.6 million of interest expense and amortization of debt issuance costs related to its credit facilities.

As of March 28, 2026, $239.1 million was outstanding under the term loan with an effective interest rate of 5.6%, which was netted down by the $3.9 million of remaining debt discount, resulting in a net note payable of $235.1 million. In connection with the settlement of the 2026 Notes, the Company borrowed $300.0 million under the revolving credit facility, which was outstanding as of March 28, 2026. The Company also had $17.7 million of uncommitted operating lines of credit to fund its global operations under which there were no outstanding borrowings as of March 28, 2026.

Under the 2024 Revised Credit Facilities, the Company is required to maintain certain leverage and interest coverage ratios specified in the second amended and restated credit agreement as well as other customary non-financial affirmative and negative covenants. The Company is required to satisfy these covenants, on a pro forma basis, in connection with any new borrowings (including any letter of credit issuances) on the revolving credit facility as of the time of such borrowings. The Consolidated Interest Coverage Ratio is calculated as the consolidated EBITDA divided by consolidated interest expense while the Consolidated Net Leverage ratio is calculated as consolidated total debt minus liquidity, divided by consolidated EBITDA. Consolidated EBITDA includes EBITDA adjusted by non-recurring and unusual transactions specifically as defined in the 2024 Revised Credit Facilities.

The 2024 Revised Credit Facilities also contain usual and customary non-financial affirmative and negative covenants that include certain restrictions with respect to subsequent indebtedness, liens, loans and investments (including acquisitions), financial reporting obligations, mergers, consolidations, dispositions, dissolutions or liquidation, asset sales, affiliate transactions, change of its business, capital expenditures, share repurchase and other restricted payments. These covenants are subject to exceptions and qualifications set forth in the second amended and restated credit agreement.

Any failure to comply with the financial and operating covenants of the 2024 Revised Credit Facilities would prevent the Company from being able to borrow additional funds and would constitute a default, which could result in, among other things, the amounts outstanding including all accrued interest and unpaid fees, becoming immediately due and payable. In addition, the 2024 Revised Credit Facilities include customary events of default, in certain cases subject to customary cure periods. The Company was in compliance with the consolidated net leverage and interest coverage ratios specified in the 2024 Revised Credit Facilities as well as all other bank covenants as of March 28, 2026.

Commitment Fee

Pursuant to the 2024 Revised Credit Facilities, the Company is required to pay, on the last day of each calendar quarter, a commitment fee on the unused portion of the revolving credit facility. The commitment fee is subject to a pricing grid based on the Company’s consolidated leverage ratio. The commitment fee ranges from 0.125% to 0.250%. The current commitment fee on the undrawn portion of the revolving credit facility is 0.200%.

Interest

Interest expense was $19.3 million, $35.9 million and $19.5 million for fiscal 2026, 2025 and 2024, respectively. Accrued interest associated with the outstanding debt is included as a component of other current liabilities in the accompanying consolidated balance sheets. As of both March 28, 2026 and March 29, 2025, the Company had an insignificant amount of accrued interest associated with the outstanding debt.

The future aggregate amount of debt maturities are as follows:


	Debt Maturities
	(Dollars in Thousands)
Fiscal 2027	$	7,874
Fiscal 2028	12,564
Fiscal 2029	18,818
Fiscal 2030	1,200,073
Fiscal 2031	77
Thereafter	401
Total debt maturities	$	1,239,807

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Mar. 28, 2026

Accounting Standards Update and Change in Accounting Principle [Abstract]

Schedule of Property, Plant and Equipment Estimated Useful Lives

The Company provides for depreciation and amortization by charges to operations using the straight-line method in amounts estimated to recover the cost of the building and improvements, equipment and furniture and fixtures over their estimated useful lives as follows:


Asset Classification						Estimated Useful Lives
Building						30 – 40 Years
Building improvements						5 – 20 Years
Plant equipment and machinery						3 – 15 Years
Office equipment and information technology						3 – 10 Years
Haemonetics equipment						3 – 7 Years

Schedule of Other Accrued Liabilities

Other current liabilities represent items payable or expected to settle within the next twelve months. The items included in the fiscal year end balances were:


	March 28, 2026		March 29, 2025
	(Dollars in Thousands)
Contract liabilities	$	42,310	$	43,348
Contingent consideration	17,597		2,278
Other	98,430		102,507
Total	$	158,337	$	148,133

CAPITAL STOCK (Narrative) (Details) $ / shares in Units, $ in Millions			12 Months Ended
	Aug. 04, 2023 shares	Jul. 25, 2019 shares	Mar. 28, 2026 USD ($) period $ / shares shares	Mar. 29, 2025 USD ($) $ / shares shares	Mar. 30, 2024 USD ($) $ / shares	Aug. 03, 2023 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for grant (in shares)			3,108,477
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)			3,200,000
Number of purchase periods (in purchase periods) \| period			2
Percentage of purchase price for shares of common stock at fair market value (as a percent)			85.00%
Weighted average grant date fair value of the six-month option inherent in the Purchase Plan (in dollars per share) \| $ / shares			$ 15.98	$ 19.13	$ 20.27
Expected term			6 months	6 months	6 months
Employee Stock Purchase Plan \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares purchased through payroll deductions (as a percent)			2.00%
Employee Stock Purchase Plan \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares purchased through payroll deductions (as a percent)			15.00%
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)			1,017,895	993,587
Award expiration period			7 years
Total intrinsic value of options exercised \| $			$ 0.6	$ 6.4	$ 12.4
Total unrecognized compensation cost related to non vested awards \| $			$ 10.1
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years)			2 years 6 months
Expected term			5 years 4 months 24 days	5 years 2 months 12 days	5 years 1 month 6 days
Stock Options \| Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			4 years
Stock Options \| Non-employee director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			1 year
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity instruments other than options outstanding (in shares)			329,818	303,003
Total unrecognized compensation cost related to non vested awards \| $			$ 13.8
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years)			1 year 8 months 12 days
Shares, Vested (in shares)			157,290
Weighted Average Grant Date Fair Value (in dollars per share), Granted \| $ / shares			$ 70.52	$ 95.09	$ 89.21
Restricted Stock Units (RSUs) \| Employees \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			3 years
Restricted Stock Units (RSUs) \| Employees \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			4 years
Restricted Stock Units (RSUs) \| Non-employee director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			1 year
Performance Share Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)			715,262
Equity instruments other than options outstanding (in shares)			357,631	335,843
Total unrecognized compensation cost related to non vested awards \| $			$ 18.7
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years)			1 year 9 months 18 days
Shares, Vested (in shares)			162,066
Award performance period			3 years
Performance shares target, percentage			100.00%
Weighted Average Grant Date Fair Value (in dollars per share), Granted \| $ / shares			$ 87.66	$ 128.25	$ 128.83
Performance Share Units (PSUs) \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance shares target, percentage			0.00%
Performance Share Units (PSUs) \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance shares target, percentage			200.00%
2019 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized		2,700,000
2019 Equity Plan [Member] \| Share-based Payment Arrangement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)		5,759,433
Incentive Compensation Plan 2005 \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options counted against maximum number of award shares for every share option issued (in shares)			2.76
Amended and Restated 2019 Equity Plan \| Share-based Payment Arrangement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)	4,942,201					1,975,970
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized	2,966,231

REVENUE	12 Months Ended
REVENUE	Mar. 28, 2026
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUE As of March 28, 2026, the Company had $35.9 million of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of one year or more. The Company expects to recognize approximately 72% of this amount as revenue within the next twelve months and the remaining balance thereafter. Contract Balances The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables and contract assets, as well as customer advances, customer deposits and deferred revenue (contract liabilities) on the consolidated balance sheets. The difference in timing between billing and revenue recognition primarily occurs in software licensing arrangements, resulting in contract assets and contract liabilities. As of March 28, 2026 and March 29, 2025, the Company had contract liabilities of $42.3 million and $43.3 million, respectively. During fiscal 2026, the Company recognized $5.4 million of revenue that was included in the above March 29, 2025 contract liability balance. Contract liabilities are classified as other current liabilities and other long-term liabilities on the consolidated balance sheets. As of March 28, 2026 and March 29, 2025, the Company’s contract assets were $5.5 million and $11.6 million, respectively.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

INVENTORIES (Schedule of Inventories) (Details) - USD ($) $ in Thousands	Mar. 28, 2026	Mar. 29, 2025
Inventory Disclosure [Abstract]
Raw materials	$ 114,873	$ 128,574
Work-in-process	11,974	14,956
Finished goods	179,523	221,611
Total	$ 306,370	$ 365,141

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Allowance for Credit Losses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 6,300	$ 5,695	$ 4,932
Inventory reserve adjustment	615	725	840
Recoveries	(93)	(120)	(77)
Write-offs	(3,129)
Ending balance	$ 3,693	$ 6,300	$ 5,695

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Fair Value of Contingent Consideration Liabilities (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Derivative [Line Items]
Liabilities fair value	$ 21,176	$ 2,774
Level 3
Derivative [Line Items]
Liabilities fair value	21,063	2,278
Contingent Consideration
Derivative [Line Items]
Liabilities fair value	21,063	2,278
Contingent Consideration \| Level 3
Derivative [Line Items]
Liabilities fair value	21,063	2,278	$ 0
Revenue-based payments \| Contingent Consideration \| Level 3
Derivative [Line Items]
Liabilities fair value	$ 3,076	$ 1,214
Range	3.40%	6.30%
Event based payments 2 \| Contingent Consideration \| Level 3
Derivative [Line Items]
Liabilities fair value	$ 17,597
Range	3.00%
Event-based payments \| Contingent Consideration \| Level 3
Derivative [Line Items]
Liabilities fair value	$ 390	$ 1,064
Range	5.80%	5.80%

REVENUE (Details) - USD ($) $ in Thousands	12 Months Ended
REVENUE (Details) - USD ($) $ in Thousands	Mar. 28, 2026	Mar. 29, 2025
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation amount	$ 35,900
Optional exemption term	1 year
Performance obligation percent	72.00%
Contract liabilities	$ 42,300	$ 43,300
Revenue recognized	5,400
Contract assets	$ 5,500	$ 11,600
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-03-29
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Timing of satisifaction	12 months

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 29, 2024	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, at cost		$ 841,829	$ 837,194
Less: accumulated depreciation		(536,068)	(553,142)
Property, plant and equipment, net		305,761	284,052
Depreciation expense		61,200	60,000	$ 55,800
Proceeds from sale of property, plant and equipment	$ 19,900	1,375	23,253	1,810
Gain (loss) on disposition of property plant equipment	$ 14,100	714	15,698	$ 1,013
Revision of Prior Period, Reclassification, Adjustment
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, at cost		40,800
Property, plant and equipment, net		7,800
Land
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, at cost		2,251	1,985
Building and building improvements
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, at cost		109,793	105,079
Plant equipment and machinery
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, at cost		197,552	181,825
Office equipment and information technology
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, at cost		131,085	130,924
Haemonetics equipment
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, at cost		371,205	395,152
Construction in progress
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, at cost		$ 29,943	$ 22,229

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 3,025	$ 11,794	$ 2,150
Costs incurred, net of reversals	3,114	13,913	14,089
Restructuring related costs	105	7,245	9,499
Payments	(4,832)	(14,066)	(4,445)
Non-cash adjustments		(8,616)
Ending Balance	1,307	3,025	11,794
Total restructuring and restructuring related costs	3,219	21,158	23,588
Plasma
Restructuring Reserve [Roll Forward]
Costs incurred, net of reversals	447	258	1,015
Restructuring related costs	9	281	1,050
Blood Center
Restructuring Reserve [Roll Forward]
Costs incurred, net of reversals	(558)	4,742	5,606
Restructuring related costs	(1)	154	286
Hospital
Restructuring Reserve [Roll Forward]
Costs incurred, net of reversals	1,326	1,664	3,863
Restructuring related costs	0	143	408
All Other
Restructuring Reserve [Roll Forward]
Costs incurred, net of reversals	1,899	7,249	3,605
Restructuring related costs	97	6,667	7,755
Prior Programs
Restructuring Reserve [Roll Forward]
Beginning Balance	0	0	340
Costs incurred, net of reversals	0	0	(276)
Payments	0	0	(64)
Non-cash adjustments		0
Ending Balance	0	0	0
2020 Program
Restructuring Reserve [Roll Forward]
Beginning Balance	290	485	1,810
Costs incurred, net of reversals	(62)	566	450
Payments	(205)	(761)	(1,775)
Non-cash adjustments		0
Ending Balance	23	290	485
Total restructuring and restructuring related costs		7,700	9,800
Portfolio Rationalization Initiatives
Restructuring Reserve [Roll Forward]
Beginning Balance	2,735	11,309	0
Costs incurred, net of reversals	(1,919)	12,797	13,915
Payments	(100)	(12,755)	(2,606)
Non-cash adjustments		(8,616)
Ending Balance	716	2,735	11,309
Total restructuring and restructuring related costs	(1,900)	13,000	14,000
Market and Regional Alignment Initiatives
Restructuring Reserve [Roll Forward]
Beginning Balance	0	0	0
Costs incurred, net of reversals	5,095	550	0
Payments	(4,527)	(550)	0
Non-cash adjustments		0
Ending Balance	568	0	0
Total restructuring and restructuring related costs	5,100	600
Location, Statement of Income, Balance [Axis]: us-gaap:CostOfGoodsAndServicesSold
Restructuring Reserve [Roll Forward]
Costs incurred, net of reversals	(496)	11,328	11,286
Restructuring related costs	$ (33)	$ 3,304	$ 5,734
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of goods sold	Cost of goods sold	Cost of goods sold
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense
Restructuring Reserve [Roll Forward]
Costs incurred, net of reversals	$ 960	$ (61)	$ 456
Restructuring related costs	$ 11	$ 1,649	$ 1,750
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Research and development	Research and development	Research and development
Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense
Restructuring Reserve [Roll Forward]
Costs incurred, net of reversals	$ 2,650	$ 2,646	$ 2,347
Restructuring related costs	$ 127	$ 2,292	$ 2,015
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, general and administrative	Selling, general and administrative	Selling, general and administrative

INCOME TAXES (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
INCOME TAXES (Narrative) (Details) - USD ($) $ in Thousands	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Income Taxes [Line Items]
Valuation allowance, deferred tax asset, increase, amount	$ 2,300
Loss from continuing operations before income taxes, foreign	(40,794)	$ (50,271)	$ (39,302)
Effective income tax rate reconciliation, tax credit, research, amount	3,089	2,411	1,378
Provision for income taxes	30,722	44,392	34,307
Unrecognized tax benefits	1,594	2,822	3,743	$ 3,941
Unrecognized tax benefits that will impact effective tax rate	700	1,800	3,100
Accrued interest and penalties	100
Income tax examination, penalties and interest included in income tax expense	100	$ 300	$ 100
Ireland
Income Taxes [Line Items]
Loss from continuing operations before income taxes, foreign	135,500
Operating loss carry-forwards	140,000
Canada Revenue Agency
Income Taxes [Line Items]
Operating loss carry-forwards	21,500
Foreign Tax Authority, Provincial
Income Taxes [Line Items]
Operating loss carry-forwards	18,200
Other foreign jurisdictions
Income Taxes [Line Items]
Operating loss carry-forwards	6,800
Effective income tax rate reconciliation, tax credit, research, amount	2,000
Income Tax Jurisdiction, Domestic Federal
Income Taxes [Line Items]
Operating loss carry-forwards	6,600
Effective income tax rate reconciliation, tax credit, research, amount	600
Income Tax Jurisdiction, Domestic State and Local
Income Taxes [Line Items]
Operating loss carry-forwards	51,500
Operating loss carry-forwards subject to expiration	51,000
Operating loss carry-forwards not subject to expiration	500
Effective income tax rate reconciliation, tax credit, research, amount	$ 6,600

AUDIT INFORMATION	12 Months Ended
AUDIT INFORMATION	Mar. 28, 2026
Audit Information [Abstract]
Auditor Name	Ernst & Young LLP
Auditor Location	Boston, Massachusetts
Auditor Firm ID	42

INCOME TAXES (Schedule of Net Deferred Tax Asset) (Details) - USD ($) $ in Thousands	Mar. 28, 2026	Mar. 29, 2025
Income Tax Disclosure [Abstract]
Depreciation	$ 304	$ 97
Amortization of intangibles	4,286	4,796
Inventory	5,357	2,846
Accruals, reserves and other deferred tax assets	14,941	14,801
Net operating loss carry-forward	29,453	8,842
Stock based compensation	5,116	4,897
Operating lease liabilities	12,614	14,906
Tax credit carry-forward, net	7,734	6,713
Deferred Tax Assets, Research Expenses Capitalized	39,958	39,219
Gross deferred tax assets	119,763	97,117
Less valuation allowance	(14,238)	(11,930)
Total deferred tax assets (after valuation allowance)	105,525	85,187
Depreciation	(37,368)	(35,006)
Amortization of goodwill and intangibles	(79,850)	(87,905)
Unremitted earnings	(2,726)	(1,497)
Operating lease assets	(9,823)	(12,033)
Other deferred tax liabilities	(4,285)	(3,518)
Total deferred tax liabilities	(134,052)	(139,959)
Net deferred tax liabilities	$ (28,527)	$ (54,772)

GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($)	3 Months Ended			6 Months Ended	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Sep. 30, 2023	Sep. 27, 2025	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Intangible Asset, Finite-Lived [Line Items]
Purchase accounting adjustments						$ (19,248,000)
Divestitures						6,381,000
Reporting unit, percentage of fair value in excess of carrying amount	6.00%				6.00%
Fair value measurement, input measurement, discount rate					10.50%
Intangible asset, including goodwill, impairment loss			$ 10,400,000
Impairment of intangible assets					$ 86,546,000	2,391,000	$ 10,419,000
Intangible asset, finite-lived, after accumulated amortization	$ 441,752,000	$ 446,553,000			441,752,000	446,553,000
Gross Carrying Amount	805,515,000	762,866,000			805,515,000	762,866,000
Amortization of acquired intangible assets					50,500,000	55,600,000	41,400,000
Software development costs capitalized					6,700,000	7,700,000
Software costs capitalized, net	101,800,000	94,700,000			101,800,000	94,700,000
Non-amortizable intangibles	5,903,000	9,190,000			5,903,000	9,190,000
Capitalized costs amortized (placed into service)					6,100,000	6,700,000	$ 8,600,000
Reporting unit, carrying value	821,600,000				821,600,000
In-process software development
Intangible Asset, Finite-Lived [Line Items]
Non-amortizable intangibles	$ 5,900,000	$ 9,200,000			$ 5,900,000	$ 9,200,000
Minimum
Intangible Asset, Finite-Lived [Line Items]
Weighted average useful life	5 years				5 years
Maximum
Intangible Asset, Finite-Lived [Line Items]
Weighted average useful life	15 years				15 years
Attune Medical
Intangible Asset, Finite-Lived [Line Items]
Fair value measurement, input measurement, discount rate					19.80%
Impairment of intangible assets	$ 77,200,000
Finite-lived intangible assets, fair value disclosure	11,300,000				$ 11,300,000
Intellectual Property
Intangible Asset, Finite-Lived [Line Items]
Impairment of intangible assets				$ 9,300,000
Finite-lived intangible assets, fair value disclosure	$ 800,000				$ 800,000
Weighted average useful life	5 years				5 years
Developed technology
Intangible Asset, Finite-Lived [Line Items]
Weighted average useful life	11 years 7 months 6 days	12 years 1 month 6 days			11 years 7 months 6 days	12 years 1 month 6 days
Intangible asset, finite-lived, after accumulated amortization	$ 363,517,000	$ 350,021,000			$ 363,517,000	$ 350,021,000
Gross Carrying Amount	556,631,000	506,144,000			556,631,000	506,144,000
Developed technology \| Vivasure Medical LTD
Intangible Asset, Finite-Lived [Line Items]
Intangible asset, finite-lived, after accumulated amortization	117,100,000				117,100,000
Revision of Prior Period, Reclassification, Adjustment
Intangible Asset, Finite-Lived [Line Items]
Divestitures		$ 6,400,000
Hospital
Intangible Asset, Finite-Lived [Line Items]
Purchase accounting adjustments						(19,248,000)
Divestitures						0
Reporting unit, fair value	867,800,000				867,800,000
Blood Center
Intangible Asset, Finite-Lived [Line Items]
Purchase accounting adjustments						0
Divestitures						$ 6,381,000
Intangible asset, finite-lived, after accumulated amortization	0				0
Gross Carrying Amount	$ 185,600,000				$ 185,600,000

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Statement of Comprehensive Income [Abstract]
Net income	$ 97,308	$ 167,679	$ 117,558
Other comprehensive (loss) income:
Impact of defined benefit plans, net of tax	(403)	(599)	(2,327)
Foreign currency translation adjustment, net of tax	16,916	(17,974)	(4,339)
Unrealized gain on cash flow hedges, net of tax	2,097	(935)	4,912
Reclassifications into earnings of cash flow hedge (gains) losses, net of tax	(1,140)	56	(3,497)
Other comprehensive income (loss)	17,470	(19,452)	(5,251)
Comprehensive income	$ 114,778	$ 148,227	$ 112,307

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 14A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-17

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-4

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-5

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482739/220-10-55-15

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

+ Details

EARNINGS PER SHARE

12 Months Ended

Mar. 28, 2026

Earnings Per Share [Abstract]

EARNINGS PER SHARE

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.


	Year Ended
	2026		2025		2024
	(Dollars and Shares in Thousands, Except Per Share Data)
Net income	$	97,308	$	167,679	$	117,558

Basic weighted average shares outstanding	47,179		50,330		50,706
Dilutive net effect of common stock equivalents	175		400		691
Diluted weighted average shares	47,354		50,730		51,397

Net income per share
Basic	$	2.06	$	3.33	$	2.32
Diluted	$	2.05	$	3.31	$	2.29

Anti-dilutive shares excluded from the calculation	936		768		606

Basic earnings per share is calculated using the Company’s weighted average outstanding common shares. Diluted earnings per share is calculated using its weighted-average outstanding common shares including the dilutive effect of stock awards as determined under the treasury stock method and the outstanding convertible senior notes as determined under the net share settlement method. From the time of the issuance of the convertible senior notes, the average market price of the Company’s common shares has been less than the applicable initial conversion price, and consequently no shares have been included in diluted earnings per share for the conversion values of both the convertible senior notes.

2022 Share Repurchase Program

In August 2022, the Company announced that its Board of Directors had approved a three-year share repurchase program authorizing the repurchase of up to $300.0 million of Haemonetics common stock, based on market conditions, through August 2025. Under the 2022 share repurchase program, the Company was authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions.

In fiscal 2023, the Company completed a $75.0 million repurchase of its common stock pursuant to an accelerated share repurchase agreement (“ASR”) entered into with Citibank N.A. (“Citibank”) in August 2022. The total number of shares repurchased under the ASR was 1.0 million at an average price per share upon final settlement of $75.20.

In October 2024, the Company completed a $75.0 million repurchase of its common stock pursuant to an ASR entered into with Citibank in August 2024. The total number of shares repurchased under the ASR was 1.0 million at an average price per share upon final settlement of $74.36.

In April 2025, the Company completed a $150.0 million repurchase of its common stock pursuant to an ASR entered into with Goldman Sachs & Co. (“Goldman Sachs”) in February 2025. The total number of shares repurchased under the ASR was 2,386,131 at an average price per share upon final settlement of $62.86. As of March 29, 2025, the Company had fully funded the $300.0 million authorization under the 2022 share repurchase program.

2025 Share Repurchase Program

In April 2025 the Company’s Board of Directors approved a new share repurchase authorization of up to $500 million of Haemonetics common stock, based on market conditions, through April 2028. Under the 2025 share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions. The actual timing, number and value of shares repurchased will be determined by the Company at its discretion and will depend on a number of factors, including market conditions, applicable legal requirements and compliance with the terms of loan covenants. The 2025 share repurchase program may be suspended, modified or discontinued at any time, and the Company has no obligation to repurchase any amount of its common stock under the program.

In September 2025, the Company completed a $75.0 million repurchase of its common stock pursuant to an ASR entered into with Citibank in August 2025. The total number of shares repurchased under the ASR was 1,430,579 at an average price per share upon final settlement of $52.43.

During the fourth quarter of fiscal 2026, the Company repurchased $25.0 million of its common stock pursuant to a previously executed Rule 10b5-1 trading plan. The total number of shares repurchased pursuant to the Rule 10b5-1 trading plan was 360,457 at an average price per share upon final settlement of $69.36.

In March 2026, the Company completed a $75.0 million repurchase of its common stock pursuant to an ASR entered into with Goldman Sachs in February 2026. The total number of shares repurchased under the ASR was 1,218,798 at an average price per share upon final settlement of $61.54. As of March 28, 2026, the total remaining authorization for repurchases of the Company’s common stock under the 2025 share repurchase program was $325.0 million.

LEASES - Schedule of Weighted Average Lease Term and Discount Rate (Details)	Mar. 28, 2026	Mar. 29, 2025
Leases [Abstract]
Weighted average remaining lease term (years)	6 years 8 months 12 days	7 years 6 months
Weighted average discount rate	4.60%	5.00%

NOTES PAYABLE AND LONG-TERM DEBT (Schedule of Notes Payable and Long-Term Debt Maturities) (Details) $ in Thousands	Mar. 28, 2026 USD ($)
Debt Disclosure [Abstract]
Fiscal 2027	$ 7,874
Fiscal 2028	12,564
Fiscal 2029	18,818
Fiscal 2030	1,200,073
Fiscal 2031	77
Thereafter	401
Total debt maturities	$ 1,239,807

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References

+ Details

RESTRUCTURING

12 Months Ended

Mar. 28, 2026

Restructuring and Related Activities [Abstract]

RESTRUCTURING

On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify opportunities for efficiencies, enhance commercial capabilities, align its resources and offer its customers better solutions. In order to realize these opportunities, the Company undertakes restructuring-type activities to transform its business.

Operational Excellence Program

In July 2019, the Board of Directors of the Company approved the Operational Excellence Program (the “2020 Program”) and delegated authority to the Company’s management to determine the detail of the initiatives that will comprise the program. During fiscal 2022, the Company revised the 2020 Program to improve product and service quality, reduce cost principally in its manufacturing and supply chain operations and ensure sustainability while helping to offset impacts from a previously announced customer loss, rising inflationary pressures and effects of the COVID-19 pandemic. The 2020 Program closed as of March 29, 2025. During fiscal 2025 and 2024, the Company incurred $7.7 million and $9.8 million of restructuring and restructuring related costs under this program, respectively. Total cumulative charges under the 2020 Program were $84.7 million through March 29, 2025.

Portfolio Rationalization Initiatives

In November 2023, the Company announced its plans to end of life the ClotPro analyzer system within the Hospital business unit and certain products within the Blood Center business unit, primarily in Whole Blood, including the associated manufacturing operations and closure of certain other facilities. These portfolio rationalization initiatives closed as of March 29, 2025. Under these initiatives, during fiscal 2026 the Company recognized reversals of previously incurred costs of $1.9 million, as compared with restructuring and restructuring related costs incurred of $13.0 million and $14.0 million, respectively, during fiscal 2025 and fiscal 2024. Total cumulative charges under these portfolio rationalization initiatives are $25.1 million as of March 28, 2026.

Market and Regional Alignment Initiative

In May 2025, the Board approved the currently ongoing market and regional alignment initiative and delegated authority to the Company’s management to determine the details of the specific actions that will comprise the initiative. This strategic initiative is designed to improve operational performance and reduce costs by directing the Company’s resources toward the markets and geographies that offer the greatest growth and portfolio advancement opportunities. Initial actions related to this initiative were approved by the Board in January 2025, resulting in restructuring related costs during the fourth quarter of fiscal 2025. Under this initiative, during fiscal 2026 and 2025, the Company incurred restructuring and restructuring related costs of $5.1 million and $0.6 million, respectively, under this initiative. Total cumulative charges under the market and regional alignment initiative are $5.6 million as of March 28, 2026.

The following table summarizes the activity for restructuring reserves related to prior programs, the 2020 Program, portfolio rationalization initiatives, and market and regional alignment initiatives for the fiscal years 2026, 2025 and 2024, substantially all of which relates to employee severance, other employee costs, inventory reserves and lease termination fees:


	Prior Programs		2020 Program		Portfolio Rationalization Initiatives		Market and Regional Alignment Initiatives		Total
	(Dollars in Thousands)
Balance as of April 1, 2023	$	340	$	1,810	$	—	$	—	$	2,150
Costs incurred, net of reversals	(276)		450		13,915		—		14,089
Payments	(64)		(1,775)		(2,606)		—		(4,445)

Balance as of March 30, 2024	$	—	$	485	$	11,309	$	—	$	11,794
Costs incurred, net of reversals	—		566		12,797		550		13,913
Payments	—		(761)		(12,755)		(550)		(14,066)
Non-cash adjustments	—		—		(8,616)		—		(8,616)
Balance as of March 29, 2025	$	—	$	290	$	2,735	$	—	$	3,025
Costs incurred, net of reversals	—		(62)		(1,919)		5,095		3,114
Payments	—		(205)		(100)		(4,527)		(4,832)

Balance as of March 28, 2026	$	—	$	23	$	716	$	568	$	1,307

The following presents the restructuring costs by line item during fiscal 2026, 2025 and 2024 within the Company’s accompanying consolidated statements of income and consolidated statements of comprehensive income:


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Cost of goods sold	$	(496)	$	11,328	$	11,286
Research and development	960		(61)		456
Selling, general and administrative expenses	2,650		2,646		2,347
Total	$	3,114	$	13,913	$	14,089

As of March 28, 2026, the Company had a restructuring liability of $1.3 million, all of which is payable within the next twelve months.

In addition to the restructuring expenses included in the table above, the Company also incurred costs of $0.1 million, $7.2 million and $9.5 million in fiscal 2026, 2025 and 2024, respectively, that do not constitute restructuring costs under ASC 420, Exit and Disposal Cost Obligations, and which the Company instead refers to as restructuring related costs. These costs consist primarily of expenditures directly related to the restructuring actions.

The following presents the restructuring related costs by line item during fiscal 2026, 2025 and 2024 within the Company’s accompanying consolidated statements of income and consolidated statements of comprehensive income:


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Cost of goods sold	$	(33)	$	3,304	$	5,734
Research and development	11		1,649		1,750
Selling, general and administrative expenses	127		2,292		2,015
Total	$	105	$	7,245	$	9,499

The tables below present restructuring and restructuring related costs by reportable segment:


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Restructuring costs
Plasma	$	447	$	258	$	1,015
Blood Center	(558)		4,742		5,606
Hospital	1,326		1,664		3,863
Corporate	1,899		7,249		3,605
Total	$	3,114	$	13,913	$	14,089

Restructuring related costs
Plasma	$	9	$	281	$	1,050
Blood Center	(1)		154		286
Hospital	—		143		408
Corporate	97		6,667		7,755
Total	$	105	$	7,245	$	9,499

Total restructuring and restructuring related costs	$	3,219	$	21,158	$	23,588

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Feb. 29, 2024	Jun. 28, 2025
Commitments and Contingencies Disclosure [Abstract]
Loss in period	$ 8,700
Payments for legal settlements		$ 8,700

RETIREMENT PLANS

12 Months Ended

Mar. 28, 2026

Retirement Benefits [Abstract]

RETIREMENT PLANS

Defined Contribution Plans

The Company has a Savings Plus Plan (the “401k Plan”) that allows its U.S. employees to accumulate savings on a pre-tax basis. In addition, matching contributions are made to the 401k Plan based upon pre-established rates. The Company’s matching contributions amounted to approximately $8.9 million, $8.2 million and $8.1 million in fiscal 2026, 2025 and 2024, respectively. Upon the Company’s Board of Directors’ approval, additional discretionary contributions can also be made. No discretionary contributions were made for the 401k Plan in fiscal 2026, 2025, or 2024.

Some of the Company’s subsidiaries also have defined contribution plans, to which both the employee and the employer make contributions. The employer contributions to these plans totaled $1.1 million, $1.0 million and $0.7 million in fiscal 2026, 2025 and 2024, respectively.

Defined Benefit Plans

ASC Topic 715, Compensation — Retirement Benefits, requires an employer to: (a) recognize in its statement of financial position an asset for a plan’s over-funded status or a liability for a plan’s under-funded status; (b) measure a plan’s assets and its obligations that determine its funded status as of the end of the employer’s fiscal year (with limited exceptions); and (c) recognize changes in the funded status of a defined benefit post-retirement plan in the year in which the changes occur. Accordingly, the Company is required to report changes in its funded status in comprehensive loss on its consolidated statement of stockholders’ equity and consolidated statements of comprehensive income.

Benefits under these plans are generally based on either career average or final average salaries and creditable years of service as defined in the plans. The annual cost for these plans is determined using the projected unit credit actuarial cost method that includes actuarial assumptions and estimates that are subject to change.


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Service cost	$	1,804	$	1,630	$	1,316
Interest cost on benefit obligation	649		630		684
Expected return on plan assets	(273)		(314)		(264)
Actuarial loss (gain)	(19)		17		(180)
Amortization of unrecognized prior service cost	(236)		(219)		(215)
Plan settlements	15		(104)		—
Total	$	1,940	$	1,640	$	1,341

The activity under those defined benefit plans are as follows:


	March 28, 2026		March 29, 2025
	(Dollars in Thousands)
Change in Benefit Obligation:
Benefit Obligation, beginning of year	$	(30,956)	$	(32,323)
Service cost	(1,804)		(1,630)
Interest cost	(649)		(630)
Benefits paid	1,470		851
Actuarial loss	(345)		(336)
Employee and plan participants contribution	(2,114)		(3,568)
Plan settlements	2,971		6,419
Foreign currency changes	(3,064)		261
Benefit obligation, end of year	$	(34,491)	$	(30,956)
Change in Plan Assets:
Fair value of plan assets, beginning of year	$	20,838	$	21,851
Company contributions	1,497		1,627
Benefits paid	(568)		(663)
Gain on plan assets	444		482
Employee and plan participants contribution	2,124		3,600
Plan settlements	(2,984)		(6,451)
Foreign currency changes	1,959		392
Fair value of plan assets, end of year	$	23,310	$	20,838
Funded Status(1)	$	(11,181)	$	(10,118)
Unrecognized net actuarial gain	(982)		(1,056)
Unrecognized prior service cost	(545)		(705)
Net amount recognized	$	(12,708)	$	(11,879)

__________

(1) Substantially all of the unfunded status is non-current.

One of the benefit plans is funded by benefit payments made by the Company through the purchase of reinsurance contracts that do not qualify as plan assets under ASC Topic 715. Accordingly, that plan has no assets included in the information presented above. The total asset value associated with the reinsurance contracts was $7.3 million and $7.0 million as of March 28, 2026 and March 29, 2025, respectively. The total liability for this plan, which is included in the table above, was $7.1 million and $7.4 million as of March 28, 2026 and March 29, 2025, respectively.

The accumulated benefit obligation for all plans was $32.0 million and $29.1 million for fiscal 2026 and 2025, respectively. There were no plans where the plan assets were greater than the accumulated benefit obligation as of March 28, 2026 and March 29, 2025.

The components of the change recorded in the Company’s accumulated other comprehensive loss related to its defined benefit plans, net of tax, are as follows:


	Accumulated Other Comprehensive Loss
	(Dollars in Thousands)
Balance as of April 1, 2023	$	4,075
Actuarial loss	(2,157)
Prior service credit	(170)

Balance as of March 30, 2024	$	1,748
Actuarial loss	(268)
Prior service credit	(242)
Plan settlements	(89)
Balance as of March 29, 2025	$	1,149
Actuarial loss	(169)
Prior service credit	(218)
Plan settlements	(16)
Balance as of March 28, 2026	$	746

The Company expects to amortize $0.3 million from AOCL to net periodic benefit cost during fiscal 2027.

The weighted average rates used to determine the net periodic benefit costs and projected benefit obligations were as follows:


	Year Ended
	2026		2025		2024
Discount rate	1.78	%	1.87	%	2.05	%
Rate of increased salary levels	2.72	%	2.71	%	1.86	%
Expected long-term rate of return on assets	0.96	%	0.88	%	0.94	%

Assumptions for expected long-term rate of return on plan assets are based upon actual historical returns, future expectations of returns for each asset class and the effect of periodic target asset allocation rebalancing. The results are adjusted for the payment of reasonable expenses of the plan from plan assets.

The Company has no other material obligation for post-retirement or post-employment benefits.

The Company’s investment policy for pension plans is to balance risk and return through a diversified portfolio to reduce interest rate and market risk. Maturities are managed so that sufficient liquidity exists to meet immediate and future benefit payment requirements.

ASC Topic 820, Fair Value Measurements and Disclosures, provides guidance for reporting and measuring the plan assets of the Company’s defined benefit pension plan at fair value as of March 28, 2026. Using the same three-level valuation hierarchy for disclosure of fair value measurements as described in Note 13, Financial Instruments and Fair Value Measurements, all of the assets of the Company’s plan are classified within Level 2 of the fair value hierarchy because the plan assets are primarily insurance contracts.

Expected benefit payments for both plans are estimated using the same assumptions used in determining the Company’s benefit obligation as of March 28, 2026. Benefit payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments.

Estimated future benefit payments are as follows:


	Estimated Future Benefit Payments
	(Dollars in Thousands)
Fiscal 2027	$	1,701
Fiscal 2028	$	1,681
Fiscal 2029	$	1,916
Fiscal 2030	$	2,320
Fiscal 2031	$	1,861
Fiscal 2032-2036	$	11,783

The Company’s contributions for fiscal 2027 are expected to be consistent with fiscal 2026.

INCOME TAXES (Summary of Gross Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Unrecognized Tax Benefits [Roll Forward]
Beginning Balance	$ 2,822	$ 3,743	$ 3,941
Additions for tax positions of fiscal 2026	140	315	234
Additions for tax positions of a prior fiscal year	9	1,242	0
Additions for tax positions related to acquired businesses	0	91	0
Reductions of tax positions	(111)	(64)	(198)
Settlements of tax positions	(1,242)	0	0
Expiration of statute of limitations	(24)	(2,505)	(234)
Ending Balance	$ 1,594	$ 2,822	$ 3,743

GOODWILL AND INTANGIBLE ASSETS (Tables)

12 Months Ended

Mar. 28, 2026

Intangible Asset, Goodwill and Other [Abstract]

Goodwill

The changes in the carrying amount of goodwill by operating segment for fiscal 2026 and 2025 are as follows:


	Plasma		Blood Center		Hospital		Total
	(Dollars in Thousands)
Carrying amount as of March 30, 2024	$	29,043	$	33,484	$	502,555	$	565,082

Divestitures	—		(6,381)		—		(6,381)
Acquisitions	—		—		69,542		69,542
Purchase accounting adjustments	—		—		(19,248)		(19,248)
Currency translation	—		(136)		(4,590)		(4,726)
Carrying amount as of March 29, 2025	29,043		26,967		548,259		604,269



Acquisitions	—		—		50,478		50,478

Currency translation	—		(79)		1,700		1,621
Carrying amount as of March 28, 2026	$	29,043	$	26,888	$	600,437	$	656,368

Schedule of Amoritized Intangibles

The gross carrying amount of intangible assets and the related accumulated amortization as of March 28, 2026 and March 29, 2025 is as follows:


	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted Average Remaining Life (Years)
March 28, 2026	(Dollars in Thousands)
Amortizable:
Developed technology	$	556,631	$	193,114	$	363,517	11.6
Customer contracts and related relationships	130,862		76,489		54,373		11.3
Capitalized software	95,880		82,284		13,596		2.9
Patents and other	7,422		4,613		2,809		5.5
Trade names	14,720		7,263		7,457		10.4
Total	$	805,515	$	363,763	$	441,752

Non-amortizable:

In-process software development	5,903

Total	$	5,903


	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted Average Remaining Life (Years)
March 29, 2025	(Dollars in Thousands)
Amortizable:
Developed technology	$	506,144	$	156,123	$	350,021	12.1
Customer contracts and related relationships	135,561		70,842		64,719		12.6
Capitalized software	85,528		76,185		9,343		6.9
Patents and other	19,678		6,796		12,882		8.5
Trade names	15,955		6,367		9,588		12.3
Total	$	762,866	$	316,313	$	446,553

Non-amortizable:

In-process software development	9,190

Total	$	9,190

Schedule of Future Amortization Expense

Amortization expense on intangible assets for the next five years is estimated to be as follows:


	Amortization Expense
	(Dollars in Thousands)
Fiscal 2027	$	46,864
Fiscal 2028	$	44,781
Fiscal 2029	$	43,105
Fiscal 2030	$	41,836
Fiscal 2031	$	40,359

- Definition

Tabular disclosure of goodwill.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

+ Details

INCOME TAXES (Tables)

12 Months Ended

Mar. 28, 2026

Income Tax Disclosure [Abstract]

Schedule Domestic and Foreign Income Before Provision for Income Tax

Domestic and foreign income before provision for income tax is as follows:


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Domestic	$	87,236	$	161,800	$	112,563
Foreign	40,794		50,271		39,302
Total	$	128,030	$	212,071	$	151,865

Schedule of Income Tax Provision Components

The income tax provision (benefit) from continuing operations contains the following components:


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Current
Federal	$	35,794	$	29,818	$	29,113
State	9,078		8,112		6,539
Foreign	12,251		12,085		9,532
Total current	$	57,123	$	50,015	$	45,184
Deferred
Federal	(17,960)		(6,555)		(6,165)
State	(3,175)		1,774		2,132
Foreign	(5,266)		(842)		(6,844)
Total deferred	$	(26,401)	$	(5,623)	$	(10,877)
Total	$	30,722	$	44,392	$	34,307

Schedule of Net Deferred Tax Asset

Tax effected, significant temporary differences comprising the net deferred tax liability are as follows:


	March 28, 2026		March 29, 2025
	(Dollars in Thousands)
Deferred tax assets:
Depreciation	$	304	$	97
Amortization of intangibles	4,286		4,796
Inventory	5,357		2,846

Accruals, reserves and other deferred tax assets	14,941		14,801
Net operating loss carry-forward	29,453		8,842
Stock based compensation	5,116		4,897
Operating lease liabilities	12,614		14,906
Tax credit carry-forward, net	7,734		6,713
Capitalized research expenses	39,958		39,219
Gross deferred tax assets	119,763		97,117
Less valuation allowance	(14,238)		(11,930)
Total deferred tax assets (after valuation allowance)	105,525		85,187
Deferred tax liabilities:
Depreciation	(37,368)		(35,006)
Amortization of goodwill and intangibles	(79,850)		(87,905)
Unremitted earnings	(2,726)		(1,497)
Operating lease assets	(9,823)		(12,033)

Other deferred tax liabilities	(4,285)		(3,518)
Total deferred tax liabilities	(134,052)		(139,959)
Net deferred tax liabilities	$	(28,527)	$	(54,772)

Schedule of Effective Income Tax Rate Reconciliation

In accordance with the adoption of ASC Update No. 2023-09, income tax provision differs from the tax provision computed at the U.S. federal statutory income tax rate due to the following:


	Year Ended March 28, 2026
	(Dollars in Thousands)
Tax at federal statutory rate	$	26,886	21.0	%
State income taxes net of federal benefit(1)	4,610		3.6	%
Foreign tax effects
Switzerland
Statutory tax rate difference	(5,051)		(3.9)	%
Local income tax	2,246		1.8	%
Other items	21		—	%
Canada
Local income tax	(1,838)		(1.5)	%
Other items	(1,071)		(0.8)	%
Ireland	1,341		1.0	%
Other foreign jurisdictions	3,267		2.6	%
Effect of cross-border tax laws	(770)		(0.6)	%
Nontaxable or nondeductible items
Other nontaxable or nondeductible items	1,496		1.2	%
Limitation on executive compensation	3,434		2.7	%
Tax credits
Federal research credits	(3,089)		(2.4)	%
Other tax credits	(852)		(0.7)	%
Changes in valuation allowances	37		—	%
Changes in unrecognized tax benefits	54		—	%
Other, net	1		—	%
Income tax provision	$	30,722	24.0	%

_________

(1) The jurisdictions which account for the majority of the tax effect in this category include California, Texas, Florida, New York, Pennsylvania, Illinois and Georgia.

Prior to the adoption of ASC Update No. 2023-09, income tax provision differed from the tax provision computed at the U.S. federal statutory income tax rate due to the following:


		Year Ended
	2025			2024
		(Dollars in Thousands)
Tax at federal statutory rate		$	44,535	21.0	%	$	31,892	21.0	%

Impact of foreign operations		(732)		(0.3)	%	(3,631)		(2.4)	%
State income taxes net of federal benefit		7,505		3.5	%	7,037		4.6	%
Change in uncertain tax positions		(1,227)		(0.6)	%	(107)		(0.1)	%

Global intangible low taxed income		(1,380)		(0.7)	%	(555)		(0.4)	%
Unremitted earnings		163		0.1	%	171		0.1	%
Deferred statutory rate changes		543		0.3	%	(159)		(0.1)	%

Non-deductible executive compensation		5,130		2.4	%	3,256		2.1	%
Non-deductible expenses		2,845		1.3	%	2,355		1.6	%
Stock compensation benefits		(4,469)		(2.1)	%	(1,841)		(1.2)	%
Research credits		(2,411)		(1.1)	%	(1,378)		(0.9)	%
Contingent consideration		(4,774)		(2.3)	%	—		—	%
Impact of foreign tax law changes		(2,707)		(1.3)	%	(2,739)		(1.8)	%


Valuation allowance		1,744		0.9	%	(393)		(0.2)	%
Other, net		(373)		(0.2)	%	399		0.3	%
Income tax provision		$	44,392	20.9	%	$	34,307	22.6	%

Schedule of Unrecognized Tax Benefits Roll Forward

The following table summarizes the activity related to its gross unrecognized tax benefits for the fiscal years ended March 28, 2026, March 29, 2025 and March 30, 2024:


	March 28, 2026		March 29, 2025		March 30, 2024
	(Dollars in Thousands)
Beginning Balance	$	2,822	$	3,743	$	3,941
Additions for tax positions of fiscal 2026	140		315		234
Additions for tax positions of a prior fiscal year	9		1,242		—
Additions for tax positions related to acquired businesses	—		91		—
Reductions of tax positions	(111)		(64)		(198)
Settlements of tax positions	(1,242)		—		—
Expiration of statute of limitations	(24)		(2,505)		(234)
Ending Balance	$	1,594	$	2,822	$	3,743

Schedule of Cash Flow, Supplemental Disclosures

The following is a summary of cash income taxes paid, net of refunds:


	Year Ended
	2026
	(Dollars in Thousands)
Federal	$	41,750
State	10,082
Foreign	8,833
Total	$	60,665

LEASES - Cash Flow Information From Operating Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Leases [Abstract]
Operating cash flows used for operating leases	$ 11,803	$ 11,201	$ 10,636
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 997	$ 399	$ 2,450

INCOME TAXES (Schedule of Effective Income Tax Rate Reconciliation Prior to ASU Adoption) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Income Tax Disclosure [Abstract]
Tax at federal statutory rate	$ 26,886	$ 44,535	$ 31,892
Tax at federal statutory rate	21.00%	21.00%	21.00%
Statutory tax rate difference		$ (732)	$ (3,631)
Statutory tax rate difference		(0.30%)	(2.40%)
State income taxes net of federal benefit	$ 4,610	$ 7,505	$ 7,037
State income taxes net of federal benefit	3.60%	3.50%	4.60%
Change in uncertain tax positions		$ (1,227)	$ (107)
Change in uncertain tax positions		(0.60%)	(0.10%)
Global intangible low taxed income		$ (1,380)	$ (555)
Global intangible low taxed income		(0.70%)	(0.40%)
Unremitted earnings		$ 163	$ 171
Unremitted earnings		0.10%	0.10%
Deferred statutory rate changes		$ 543	$ (159)
Deferred statutory rate changes		0.30%	(0.10%)
Non-deductible executive compensation		$ 5,130	$ 3,256
Non-deductible executive compensation		(2.40%)	(2.10%)
Other nontaxable or nondeductible items	$ 1,496	$ 2,845	$ 2,355
Other nontaxable or nondeductible items	1.20%	1.30%	1.60%
Stock compensation benefits		$ (4,469)	$ (1,841)
Stock compensation benefits		(2.10%)	(1.20%)
Federal research credits	$ (3,089)	$ (2,411)	$ (1,378)
Federal research credits	(2.40%)	(1.10%)	(0.90%)
Contingent consideration		$ (4,774)	$ 0
Contingent consideration		(2.30%)	0.00%
Effective Income Tax Rate Reconciliation, Cantonal step-up attribute carryforward, Amount		$ (2,707)	$ (2,739)
Effective Income Tax Rate Reconciliation, Cantonal step-up attribute carryforward, Percent		(1.30%)	1.80%
Valuation allowance	$ 37	$ 1,744	$ (393)
Changes in valuation allowances	0.00%	0.90%	(0.20%)
Other, net		$ (373)	$ 399
Other items		(0.20%)	0.30%
Income tax provision	$ 30,722	$ 44,392	$ 34,307
Income tax provision	24.00%	20.90%	22.60%

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details) $ in Thousands		12 Months Ended
	Sep. 27, 2024 swap	Mar. 28, 2026 USD ($)	Mar. 29, 2025 USD ($)	Mar. 30, 2024 USD ($)	Apr. 30, 2024
Derivative [Line Items]
Number of interest rate swaps remaining \| swap	2,000
Contingent consideration		$ 17,597	$ 2,278
Business combination, contingent consideration, liability, noncurrent		3,400	2,300
Fair Value, Measurements, Recurring
Derivative [Line Items]
Liabilities fair value		21,176	2,774
Level 3 \| Fair Value, Measurements, Recurring
Derivative [Line Items]
Liabilities fair value		21,063	2,278
Level 2 \| Fair Value, Measurements, Recurring
Derivative [Line Items]
Liabilities fair value		113	496
Convertible Senior Notes Due 2029 \| Level 2
Derivative [Line Items]
Convertible debt, fair value disclosures		662,400	$ 668,400
Minimum \| 2024 Revised Credit Agreement \| Term Loan
Derivative [Line Items]
Debt instrument, interest rate, stated percentage					1.125%
Maximum \| 2024 Revised Credit Agreement \| Term Loan
Derivative [Line Items]
Debt instrument, interest rate, stated percentage					1.75%
Designated as Hedging Instrument \| Cash Flow Hedging
Derivative [Line Items]
Loss on investment		(2,500)
Designated as Hedging Instrument \| Interest Rate Swap
Derivative [Line Items]
Loss on investment		$ 400
Foreign Exchange Contract
Derivative [Line Items]
Percentage of sales generated outside the US		26.40%	25.70%	25.90%
Maturity period for foreign currency contracts		1 year
Foreign Exchange Contract \| Designated as Hedging Instrument
Derivative [Line Items]
Designated foreign currency hedge contracts outstanding		$ 30,100	$ 23,600
Foreign Exchange Contract \| Not Designated as Hedging Instrument
Derivative [Line Items]
Non-designated foreign currency hedge contracts outstanding		75,300	89,600
Interest Rate Swap
Derivative [Line Items]
Derivative, blended fixed interest rate	3.31%
Derivative, percentage of notional value of debt	80.00%
Contingent Consideration \| Fair Value, Measurements, Recurring
Derivative [Line Items]
Liabilities fair value		21,063	2,278
Contingent Consideration \| Level 3 \| Fair Value, Measurements, Recurring
Derivative [Line Items]
Liabilities fair value		21,063	2,278	$ 0
Contingent Consideration \| Level 2 \| Fair Value, Measurements, Recurring
Derivative [Line Items]
Liabilities fair value		$ 0	$ 0

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS

12 Months Ended

Mar. 28, 2026

Business Combination [Abstract]

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS

Acquisitions

Vivasure Medical Limited

On January 9, 2026, the Company acquired all of the outstanding equity interests of Vivasure Medical Limited (“Vivasure”) for a net purchase price of $164.4 million. The net purchase price included $60.2 million paid in cash at closing, net of $0.4 million cash acquired and after giving effect to the value of certain prior investments and loans made by the Company to Vivasure, as well as other customary closing adjustments, and the fair value of contingent consideration of $20.7 million. The contingent consideration is based on sales growth over the three years following the completion of the acquisition and the achievement of certain other milestones, and is also subject to adjustments based on the value of certain prior investments and loans. The Company financed this transaction through available cash on hand. During fiscal 2026, the Company recorded a gain of $4.9 million within interest and other expense, net on the consolidated statements of income as a result of the remeasurement of the Company’s prior equity interest of approximately 30% in Vivasure, which had a fair value of $47.3 million.

Vivasure is a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure. Vivasure’s PerQseal® Elite system uses a proprietary bioabsorbable patch to seal large-bore (up to 26 F) arteriotomies and venotomies from inside the vessel, offering a sutureless, fully absorbable solution for structural heart and endovascular procedures. In 2025, Vivasure submitted a premarket approval application to the U.S. FDA for the PerQseal Elite arterial closure system and received CE Mark in Europe for both arterial and venous indications. The addition of Vivasure expands the Hospital business unit portfolio in the interventional cardiology market and will be included in the Hospital reportable segment.

Purchase Price Allocation

The Company accounted for the acquisition as a business combination, and in accordance with FASB ASC 805, Business Combinations (Topic 805), recorded the assets acquired and liabilities assumed at their fair values as of the acquisition date. The fair value of assets acquired and liabilities assumed have been recognized based on management’s estimates and assumptions using the information regarding facts and circumstances that existed at the closing date. The assessment of fair value is preliminary and is based on information that was available at the time the Company’s consolidated financial statements were prepared. Measurement period adjustments may arise upon the availability of further information regarding events or circumstances that existed at the acquisition date and will be recorded in the period in which they are determined, as if they had been completed at the acquisition date. The finalization of the Company’s purchase accounting assessment could result in changes in the valuation of assets acquired and liabilities assumed, which could be material. The final determination of the fair value of certain assets and liabilities will be completed within the measurement period as required by Topic 805.


	January 9, 2026
	(Dollars in Thousands)
Cash and cash equivalents	$	449
Accounts receivable	21
Inventories	1,056
Prepaid expenses and other current assets	1,736
Property, plant and equipment	575
Intangible assets	117,100
Goodwill	50,478
Other long-term assets	1,972
Total assets acquired	$	173,387
Accounts payable	$	1,186
Accrued payroll and related costs	2,889
Other current liabilities	4,741

Other long-term liabilities	199
Total liabilities assumed	9,015
Net assets acquired	$	164,372

The Company determined that the identifiable intangible asset was primarily developed technology. The fair value of the intangible asset was based on valuation techniques with estimates and assumptions developed by the Company. Developed technology was valued using the excess earnings method. In developing the discount rates applied to the cash flow projections, the discount rates were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital and then adjusted to reflect the relative risk of the asset.

The excess of the purchase price over the tangible assets, identifiable intangible asset and assumed liabilities was recorded as goodwill. As a result of the acquisition of Vivasure, the Company recognized goodwill of $50.5 million based on expected synergies from integration into the Company’s Hospital business unit. The goodwill is not deductible for tax purposes and relates entirely to the Hospital reportable segment.

Intangible assets acquired consist of the following:


	Amount		Weighted-Average Amortization Period	Risk-Adjusted Discount Rates used in Purchase Price Allocation
	(Dollars in Thousands)
Developed technology	$	117,100	16 years	16.5	%
Total	$	117,100

Acquisition-Related Costs

The Company incurred $1.1 million of acquisition-related costs during fiscal 2026 in connection with the Vivasure acquisition. These costs related to legal and other professional fees, which were recognized in selling, general and administrative on the consolidated statements of income.

The Company’s consolidated financial statements include the results of Vivasure from the date the acquisition was completed. Pro forma financial information has not been presented as the acquisition is not material to the Company’s overall financial results.

For information regarding the remeasurement of the contingent consideration liability refer to Note 13, Financial Instruments and Fair Value Measurements.

Attune Medical

On March 5, 2024, the Company entered into a definitive agreement to acquire Attune Medical, the manufacturer of the ensoETM® proactive esophageal cooling device, pursuant to which among other things, the Company agreed to acquire all of the issued and outstanding common shares of Attune Medical. On April 1, 2024, the Company completed its acquisition of Attune Medical for a net purchase price of $176.2 million, which included an upfront cash payment of $162.0 million, or $150.5 million net of $11.5 million cash acquired, the fair value of contingent consideration of $25.3 million, and $0.4 million of working capital adjustments. The contingent consideration is based on sales growth over the next three years, which is uncapped, and the achievement of certain other milestones. Refer to Note 13, Financial Instruments and Fair Value Measurements for further information regarding the contingent consideration liability. The Company financed the acquisition through a combination of cash on hand and borrowings under its senior unsecured revolving credit facility.

Attune Medical's ensoETM technology is designed for use across a range of medical conditions involving patient cooling or warming, including treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery, among others. The Company’s addition of the Esophageal Protection product line through its acquisition of Attune Medical expands the Hospital business unit’s presence in electrophysiology and complements its Vascular Closure product line within Interventional Technologies, which is included in the Hospital reportable segment.

Purchase Price Allocation

The Company accounted for the acquisition as a business combination, and in accordance with FASB ASC 805, Business Combinations, recorded the assets acquired and liabilities assumed at their fair values as of the acquisition date. The fair value of assets acquired and liabilities assumed have been recognized based on management’s estimates and assumptions using the information regarding facts and circumstances that existed at the closing date.

The purchase price of $176.2 million consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:


	April 1, 2024
	(Dollars in Thousands)
Accounts receivable	$	3,784
Inventories	26,300
Prepaid expenses and other current assets	906
Property, plant and equipment	200
Intangible assets	105,800
Goodwill	70,256

Total assets acquired	$	207,246
Accounts payable	$	2,260
Accrued payroll and related costs	2,129
Other liabilities	496
Deferred tax liability	26,155

Total liabilities assumed	31,040
Net assets acquired	$	176,206

The Company determined that the identifiable intangible assets were developed technology, customer contracts and related relationships and trade names. The fair values of intangible assets were based on valuation techniques with estimates and assumptions developed by the Company. Developed technology was valued using the excess earnings method. Customer contracts and related relationships were valued using the distributor method. The trademark was valued using the relief from royalty method. The cash flows used in the valuation of the intangible assets were based on estimates used to price the transaction. In developing the discount rates applied to the cash flow projections, the discount rates were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital and then adjusted to reflect the relative risk of the asset.

The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. As a result of the acquisition of Attune Medical, the Company recognized goodwill of $70.3 million based on expected synergies from integration into the Company’s Hospital business unit. The goodwill is not deductible for tax purposes and relates entirely to the Hospital reportable segment.

Intangible assets acquired consist of the following:


	Amount		Weighted-Average Amortization Period	Risk-Adjusted Discount Rates used in Purchase Price Allocation
	(Dollars in Thousands)
Developed technology	$	96,100	10 years	22.0	%
Customer contracts and related relationships	7,800		10 years	21.5	%
Trade names	1,900		10 years	21.5	%
Total	$	105,800

The Company recorded a long-term net deferred tax liability of $26.2 million primarily related to fair value adjustments recorded associated with definite-lived intangible assets and inventory in which there is no tax basis, partially offset by deferred tax assets primarily related to net operating losses acquired.

Acquisition-Related Costs

The Company incurred $9.8 million of acquisition-related costs during fiscal 2025 in connection with the Attune Medical acquisition. These costs related to legal and other professional fees, which were recognized in selling, general and administrative on the consolidated statements of income.

The Company’s consolidated financial statements include the results of Attune Medical from the date the acquisition was completed. Pro forma financial information has not been presented as the acquisition is not material to the Company’s overall financial results.

For information regarding the remeasurement of the contingent consideration liability refer to Note 13, Financial Instruments and Fair Value Measurements.

OpSens Inc.

On October 10, 2023, the Company entered into an Arrangement Agreement with OpSens Inc. (“OpSens”), a medical device cardiology-focused company delivering solutions based on its proprietary optical technology, pursuant to which, among other things, the Company agreed to acquire all of the issued and outstanding common shares of OpSens. On December 12, 2023, the Company completed its acquisition of OpSens for a net purchase price of $243.9 million, reflecting total consideration of $254.5 million, net of $10.6 million of cash acquired. The Company financed the acquisition through a combination of cash on hand and borrowings under its senior unsecured revolving credit facility.

OpSens offers commercially and clinically validated optical technology for use primarily in interventional cardiology. OpSens’ core products include the SavvyWire®, a sensor-guided 3-in-1 guidewire for transcatheter aortic valve replacement (“TAVR”) procedures, advancing the workflow of the procedure and enabling potentially shorter hospital stays for patients; and the OptoWire®, a pressure guidewire that aims to improve clinical outcomes by accurately and consistently measuring fractional flow reserve and diastolic pressure ratio to aid clinicians in the diagnosis and treatment of patients with coronary artery disease. OpSens also manufactures a range of fiber optic sensor solutions used in medical devices and other critical industrial applications. The addition of OpSens expands the Hospital business unit portfolio in the interventional cardiology market and is included in the Hospital reportable segment.

Purchase Price Allocation

The purchase price of $243.9 million consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:


	December 12, 2023
	(Dollars in Thousands)
Accounts receivable	$	5,960
Inventories	12,075
Prepaid expenses and other current assets	2,062
Property, plant and equipment	3,028
Intangible assets	172,000
Goodwill	79,400
Other long-term assets	4,705
Total assets acquired	$	279,230
Accounts payable	$	3,251
Accrued payroll and related costs	1,723
Other liabilities	9,746
Deferred tax liability	14,805
Other long-term liabilities	5,853
Total liabilities assumed	35,378
Net assets acquired	$	243,852

The Company determined that the identifiable intangible assets were developed technology, customer contracts and related relationships and trade names. The fair values of intangible assets were based on valuation techniques with estimates and assumptions developed by the Company. Developed technology and customer contracts and related relationships were valued using the excess earnings method. Trademarks were valued using the relief from royalty method. The cash flows used in the valuation of the intangible assets were based on estimates used to price the transaction. In developing the discount rates applied to the cash flow projections, the discount rates were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital and then adjusted to reflect the relative risk of the asset.

The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. As a result of the acquisition of OpSens, the Company recognized goodwill of $79.4 million based on expected synergies from integration into the Company’s Hospital business unit. The goodwill is not deductible for tax purposes and relates entirely to the Hospital reportable segment.

Intangible assets acquired consist of the following:


	Amount		Weighted-Average Amortization Period	Risk-Adjusted Discount Rates used in Purchase Price Allocation
	(Dollars in Thousands)
Developed technology	$	114,900	15 years	20.5	%
Customer contracts and related relationships	52,300		15 years	18.9	%
Trade names	4,800		15 years	20.5	%
Total	$	172,000

The Company recorded a net long-term deferred tax liability of $14.8 million, primarily as a result of fair value adjustments recorded associated with definite-lived intangible assets and inventory in which there is no tax basis.

Acquisition-Related Costs

The Company incurred $6.6 million of acquisition-related costs for fiscal 2024 in connection with the OpSens acquisition. These costs related to legal and other professional fees, which were recognized in selling, general and administrative on the consolidated statements of income.

The Company’s consolidated financial statements include the results of OpSens from the date the acquisition was completed. Pro forma financial information has not been presented as the acquisition is not material to the Company’s overall financial results.

Divestiture of the Whole Blood Product Line

On December 3, 2024, the Company announced that it had entered into a definitive agreement to sell its Whole Blood product line and related assets within its Blood Center reportable segment to GVS, S.p.A (“GVS”), a manufacturer of filter solutions for applications in the healthcare and life sciences sectors. The divested assets include the Company’s complete portfolio of proprietary whole blood collection, processing and filtration solutions, along with the Company’s manufacturing facility in Covina, California where certain of these products are produced, and related equipment and assets located at the Company’s manufacturing facility in Tijuana, Mexico.

On January 13, 2025, the Company completed the transaction with GVS in exchange for upfront cash consideration of $43.3 million, after customary post-closing adjustments, and up to $22.5 million in contingent consideration, based on sales growth over the next three years and the achievement of certain other milestones.

The assets that were derecognized in connection with the sale consisted of $26.4 million of inventory, $7.8 million of property, plant and equipment and $6.4 million of goodwill, which were previously classified as held for sale in prepaid expenses and other current assets in the consolidated balance sheets in the third quarter of fiscal 2025.

In connection with the sale, the Company recognized a gain from the sale of the business in interest and other expense, net in the consolidated statements of income for the year ended March 29, 2025. The gain was not material and included the cash receipts of $43.3 million less net assets transferred to GVS or otherwise derecognized and net of transaction costs of $0.1 million.

As part of the sale, the Company entered into a Transition Services Agreement (“TSA”) with GVS to ensure a smooth transition of business operations. Under the TSA, the Company will continue to provide certain regulatory, quality, logistical and operational support services to GVS for a maximum period of 36 months following the transaction closing to facilitate GVS's integration of the acquired business. Under the TSA, the Company is entitled to be reimbursed for the costs incurred plus a mark-up and has recorded net income and expenses related to the agreement in selling, general and administrative in the consolidated statements of income, which was approximately $0.4 million during fiscal 2026.

In addition to the TSA, Haemonetics and GVS entered into a Contract Manufacturing Agreement (“CMA”), under which Haemonetics will continue to manufacture certain whole blood filtration products for GVS for a maximum term of 18 months. The CMA allows GVS to gradually transition manufacturing operations while ensuring supply continuity for customers. Under the CMA, the Company is entitled to be reimbursed for the costs incurred plus a mark-up and has recorded net income and expenses related to the agreement in selling, general and administrative in the consolidated statements of income, which was approximately $1.7 million during fiscal 2026.

Strategic Investments

As part of the Company’s business development activities, it holds strategic investments in certain entities. The Company has strategic investments totaling $19.2 million as of March 28, 2026. As of March 29, 2025, the Company had strategic investments and loans of $61.6 million, including $48.7 million in strategic investments and loans to Vivasure. On January 9, 2026 the Company completed the acquisition of Vivasure. The Company’s strategic investments are classified as other long-term assets on the Company’s consolidated balance sheets, and the Company has not recorded any material adjustments to the carrying value of the Company’s strategic investments, other than those related to the Vivasure acquisition, in fiscal 2026, fiscal 2025 or fiscal 2024.

- Definition

The entire disclosure for business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-38

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 46
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-46

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 43
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-43

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 45
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-45

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-29

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-29

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-5

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-4

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 40
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479326/805-40-45-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-30/tableOfContent

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-20/tableOfContent

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-5

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-10/tableOfContent

+ Details

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss
Balance, shares (in shares) at Apr. 01, 2023		50,448,519
Beginning balance, value at Apr. 01, 2023	$ 817,997	$ 504	$ 594,706	$ 253,168	$ (30,381)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan (in shares)		79,168
Employee stock purchase plan	5,604	$ 1	5,603
Exercise of stock options (in shares)		163,064
Exercise of stock options	1,610	$ 2	6,816	(5,208)
Issuance of restricted stock, net of cancellations (in shares)		166,193
Issuance of restricted stock, net of cancellations	0	$ 2	(2)
Tax withholding on employee equity awards (in shares)		(68,944)
Tax withholding on employee equity awards	(5,891)	$ (1)	(828)	(5,062)
Share-based compensation expense	28,332		28,332
Net income	117,558			117,558
Other comprehensive income (loss)	(5,251)				(5,251)
Balance, shares (in shares) at Mar. 30, 2024		50,788,000
Ending balance, value at Mar. 30, 2024	959,959	$ 508	634,627	360,456	(35,632)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan (in shares)		97,092
Employee stock purchase plan	6,476	$ 0	6,476
Exercise of stock options (in shares)		91,735
Exercise of stock options	1,857	$ 1	6,637	(4,781)
Shares repurchased (in shares)		(3,030,887)
Shares repurchased	(226,848)	$ (30)	(64,533)	(162,285)
Issuance of restricted stock, net of cancellations (in shares)		305,806
Issuance of restricted stock, net of cancellations	0	$ 3	(3)
Tax withholding on employee equity awards (in shares)		(35,847)
Tax withholding on employee equity awards	(10,271)		(1,376)	(8,895)
Purchase of capped call related to convertible notes	(88,200)		(88,200)
Share-based compensation expense	29,636		29,636
Net income	167,679			167,679
Other comprehensive income (loss)	(19,452)				(19,452)
Balance, shares (in shares) at Mar. 29, 2025		48,215,899
Ending balance, value at Mar. 29, 2025	820,836	$ 482	523,264	352,174	(55,084)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan (in shares)		126,607
Employee stock purchase plan	6,099	$ 1	6,098
Exercise of stock options (in shares)		31,727
Exercise of stock options	1,794		2,061	(267)
Shares repurchased (in shares)		(3,373,720)
Shares repurchased	(176,331)	$ (33)	(10,320)	(165,978)
Issuance of restricted stock, net of cancellations (in shares)		270,400
Issuance of restricted stock, net of cancellations	0	$ 3	(3)
Tax withholding on employee equity awards (in shares)		(18,246)
Tax withholding on employee equity awards	(4,683)		(790)	(3,893)
Share-based compensation expense	33,827		33,827
Net income	97,308			97,308
Other comprehensive income (loss)	17,470				17,470
Balance, shares (in shares) at Mar. 28, 2026		45,252,667
Ending balance, value at Mar. 28, 2026	$ 796,320	$ 453	$ 554,137	$ 279,344	$ (37,614)

RETIREMENT PLANS (Schedule of Weighted Average Rates Used to Determine Net Periodic Benefit Costs) (Details)	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Retirement Benefits [Abstract]
Discount rate	1.78%	1.87%	2.05%
Rate of increased salary levels	2.72%	2.71%	1.86%
Expected long-term rate of return on assets	0.96%	0.88%	0.94%

CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($) $ in Thousands	Mar. 28, 2026	Mar. 29, 2025
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 3,693	$ 6,300
Intangible assets, accumulated amortization	$ 363,763	$ 316,313
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	45,252,667	48,215,899
Common stock, outstanding (in shares)	45,252,667	48,215,899

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

+ Details

LEASES - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
LEASES - Narrative (Details) - USD ($) $ in Millions	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Lessee, Lease, Description [Line Items]
Lessee, operating lease, renewal term	10 years
Operating lease, cost	$ 10.4	$ 12.1	$ 10.6
Operating lease revenue as a percentage of net sales (as a percent)	3.00%
Minimum
Lessee, Lease, Description [Line Items]
Lessee, operating lease, term of contract	1 year
Maximum
Lessee, Lease, Description [Line Items]
Lessee, operating lease, term of contract	30 years

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Income Statement [Abstract]
Net revenues	$ 1,334,027	$ 1,360,824	$ 1,309,055
Cost of goods sold	546,441	611,866	617,507
Gross profit	787,586	748,958	691,548
Operating expenses:
Research and development	59,766	62,722	54,435
Selling, general and administrative	442,421	436,789	429,780
Amortization of acquired intangible assets	43,998	48,261	32,031
Remeasurement of contingent consideration	(1,879)	(23,022)	0
Impairment of intangible assets	86,546	2,391	10,419
Total operating expenses	630,852	527,141	526,665
Operating income	156,734	221,817	164,883
Interest and other expense, net	(28,704)	(9,746)	(13,018)
Income before provision for income taxes	128,030	212,071	151,865
Provision for income taxes	30,722	44,392	34,307
Net income	$ 97,308	$ 167,679	$ 117,558
Net income per share:
Basic (in dollars per share)	$ 2.06	$ 3.33	$ 2.32
Diluted (in dollars per share)	$ 2.05	$ 3.31	$ 2.29
Weighted average shares outstanding
Basic (in shares)	47,179	50,330	50,706
Diluted (in shares)	47,354	50,730	51,397

Insider Trading Policies and Procedures	12 Months Ended
Insider Trading Policies and Procedures	Mar. 28, 2026
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

SEGMENT AND ENTERPRISE-WIDE INFORMATION

12 Months Ended

Mar. 28, 2026

Segment Reporting [Abstract]

SEGMENT AND ENTERPRISE-WIDE INFORMATION

The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company’s reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company’s chief operating decision maker (“CODM”), identified as the Company’s Chief Executive Officer.

The Company’s reportable and operating segments are as follows:

•Plasma

•Blood Center

•Hospital

The CODM measures and evaluates the operating segments based on operating income for purposes of assessing business performance and allocating resources. Certain corporate expenses and amounts considered to be non-recurring or non-operational are excluded from segment operating income. These items include acquisition, integration and divestiture related costs, amortization of acquired assets, restructuring costs, restructuring related costs, a provision for pre-acquisition inventory and inventory purchase commitments transferred from the Attune Medical acquisition that was deemed not recoverable, digital transformation costs related to the upgrade of the Company’s enterprise resource planning system, impairments and write downs, costs related to compliance with the European Union Medical Device Regulation (“EU MDR”) and In Vitro Diagnostic Regulation (“EU IVDR”), unusual or infrequent and material litigation-related charges and gains, losses on dispositions and sale of assets, remeasurement of the contingent consideration and unusual or infrequent gains such as on repurchases of convertible notes or divestitures. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. During the fourth quarter of fiscal 2025, the CODM began reviewing financial information including allocations of certain corporate costs including global functional support and overhead costs determined to benefit the segments. The prior period segment disclosures have been recast to reflect the new presentation.

The Company does not track its assets by segment, and as a result it is not practical to show assets or depreciation by segment. Consequently, the Company’s CODM does not review assets by segment when assessing business performance and allocating resources.

Selected information by reportable segment is presented below:


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Net revenues:
Plasma	$	524,456	$	535,431	$	569,535
Blood Center	221,267		261,124		283,231
Hospital	588,304		564,269		456,289
Total net revenues	$	1,334,027	$	1,360,824	$	1,309,055

Significant segment expenses and operating performance:
Plasma
Cost of goods sold	$	214,135	$	237,050	$	264,042
Selling, general and administrative	105,323		98,418		109,729
Research and development	20,203		15,453		13,797
Plasma operating income	$	184,795	$	184,510	$	181,967
Blood Center
Cost of goods sold	$	112,666	$	142,512	$	165,564
Selling, general and administrative	54,133		60,023		67,339
Research and development	4,492		5,770		7,956
Blood Center operating income	$	49,976	$	52,819	$	42,372
Hospital
Cost of goods sold	$	203,227	$	199,499	$	167,172
Selling, general and administrative	247,251		241,760		209,680
Research and development	34,091		34,035		27,239
Hospital operating income	$	103,735	$	88,975	$	52,198
Corporate and unallocated expenses
Amortization of acquired assets	$	(49,812)	$	(63,217)	$	(35,378)
Acquisition, integration and divestiture related costs	(14,155)		(22,904)		(11,249)
Restructuring and restructuring related costs	(3,218)		(21,158)		(23,588)
Digital transformation costs	(21,526)		(20,273)		(15,667)
Remeasurement of contingent consideration	1,879		23,022		—
Impairment of intangible assets	(86,546)		(2,391)		(10,419)
Other(1)	(8,394)		2,434		(15,353)
Operating income	156,734		221,817		164,883
Interest and other expense, net	(28,704)		(9,746)		(13,018)
Income before provision for income taxes	$	128,030	$	212,071	$	151,865

__________

Net revenues by business unit are as follows:


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Plasma
Plasma net revenues	$	524,456	$	535,431	$	569,535

Blood Center
Apheresis	$	220,861	$	213,134	$	211,173
Whole Blood	406		47,990		72,058
Blood Center net revenues	$	221,267	$	261,124	$	283,231

Hospital
Interventional Technologies	$	234,007	$	255,019	$	174,285
Blood Management Technologies	354,297		309,250		282,004
Hospital net revenues	$	588,304	$	564,269	$	456,289

Total net revenues	$	1,334,027	$	1,360,824	$	1,309,055

Depreciation and amortization, excluding impairment charges, by business unit are as follows:


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Plasma	$	47,368	$	48,264	$	45,712
Blood Center	7,160		10,077		13,391
Hospital	57,189		57,245		38,112
Total depreciation and amortization (excluding impairment charges)	$	111,717	$	115,586	$	97,215

Long-lived assets, comprised of property, plant and equipment, by business unit are as follows:


	March 28, 2026		March 29, 2025
	(Dollars in Thousands)
Plasma	$	206,365	$	189,833
Blood Center	39,677		40,337
Hospital	59,719		53,882
Total long-lived assets	$	305,761	$	284,052

Long-lived assets, comprised of property, plant and equipment, by operating regions are as follows:


	March 28, 2026		March 29, 2025
	(Dollars in Thousands)
United States	$	224,699	$	217,212
Japan	916		1,250
Europe	32,080		20,024
Rest of Asia	30,833		28,705
Other	17,233		16,861
Total long-lived assets	$	305,761	$	284,052

Net revenues by operating regions are as follows:


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
United States	$	982,176	$	1,010,918	$	970,007
Japan	68,200		62,408		58,087
Europe	185,019		175,655		160,142
Rest of Asia	87,212		92,305		107,536
Other	11,420		19,538		13,283
Total net revenues	$	1,334,027	$	1,360,824	$	1,309,055

- Definition

The entire disclosure for segment reporting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

+ Details

GOODWILL AND INTANGIBLE ASSETS

12 Months Ended

Mar. 28, 2026

Intangible Asset, Goodwill and Other [Abstract]

GOODWILL AND INTANGIBLE ASSETS

The changes in the carrying amount of goodwill by operating segment for fiscal 2026 and 2025 are as follows:


	Plasma		Blood Center		Hospital		Total
	(Dollars in Thousands)
Carrying amount as of March 30, 2024	$	29,043	$	33,484	$	502,555	$	565,082

Divestitures	—		(6,381)		—		(6,381)
Acquisitions	—		—		69,542		69,542
Purchase accounting adjustments	—		—		(19,248)		(19,248)
Currency translation	—		(136)		(4,590)		(4,726)
Carrying amount as of March 29, 2025	29,043		26,967		548,259		604,269



Acquisitions	—		—		50,478		50,478

Currency translation	—		(79)		1,700		1,621
Carrying amount as of March 28, 2026	$	29,043	$	26,888	$	600,437	$	656,368

The decrease in goodwill of $19.2 million for purchase accounting adjustments in fiscal 2025 was primarily related to the Company obtaining additional facts and information to finalize the pre-acquisition tax returns and associated analyses for OpSens. This resulted in the Company revising its estimate of the net deferred tax liability recorded as of the acquisition date. Refer to Note 3, Acquisitions, Divestitures and Strategic Investments, for additional information regarding the acquisitions of OpSens, Attune Medical and Vivasure.

In the fourth quarter of fiscal 2025, the Company completed the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were sold. The goodwill related to the divestiture of $6.4 million has been removed from the consolidated balance sheets. Refer to Note 3, Acquisitions, Divestitures and Strategic Investments, for additional information regarding the divestiture of its Whole Blood product line.

In fiscal 2026, 2025 and 2024, the results of the annual goodwill impairment test performed indicated that the estimated fair value of all of its reporting units exceeded their respective carrying values, however, in fiscal 2026 the fair value of the Interventional Technologies reporting unit, which is within the Hospital reportable segment, fair value was $867.8 million, which only exceeded its carrying value of $821.6 million by 6%. The fair value of the Interventional Technologies reporting unit was primarily determined using a discounted cash flow approach utilizing a discount rate of 10.5%, which reflects a market-participant weighted average cost of capital based on the risk profile, size, and capital structure of the reporting unit.

The estimation of fair value requires significant judgment and is based primarily on a discounted cash flow approach, supplemented by market-based methods where appropriate. Key assumptions include projected revenue growth rates, operating margins, terminal growth rates, and the discount rate. These inputs are based on management’s expectations of future performance and market conditions and are inherently uncertain.

The Company monitors for goodwill impairment indicators throughout the year, including changes in macroeconomic conditions, industry trends, and business performance. No interim goodwill impairment indicators were identified during fiscal 2026 that required an additional recoverability test.

Although no goodwill impairment was recorded during fiscal 2026, the Interventional Technologies reporting unit remains at risk of future impairment if actual results differ from current estimates or if market conditions deteriorate.

The gross carrying amount of intangible assets and the related accumulated amortization as of March 28, 2026 and March 29, 2025 is as follows:


	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted Average Remaining Life (Years)
March 28, 2026	(Dollars in Thousands)
Amortizable:
Developed technology	$	556,631	$	193,114	$	363,517	11.6
Customer contracts and related relationships	130,862		76,489		54,373		11.3
Capitalized software	95,880		82,284		13,596		2.9
Patents and other	7,422		4,613		2,809		5.5
Trade names	14,720		7,263		7,457		10.4
Total	$	805,515	$	363,763	$	441,752

Non-amortizable:

In-process software development	5,903

Total	$	5,903


	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted Average Remaining Life (Years)
March 29, 2025	(Dollars in Thousands)
Amortizable:
Developed technology	$	506,144	$	156,123	$	350,021	12.1
Customer contracts and related relationships	135,561		70,842		64,719		12.6
Capitalized software	85,528		76,185		9,343		6.9
Patents and other	19,678		6,796		12,882		8.5
Trade names	15,955		6,367		9,588		12.3
Total	$	762,866	$	316,313	$	446,553

Non-amortizable:

In-process software development	9,190

Total	$	9,190

In the second quarter of fiscal 2024, the Company recorded an intangible asset impairment charge of $10.4 million related to the intangibles acquired as part of the enicor GmbH acquisition completed in fiscal 2021 within the Hospital business unit.

During fiscal 2026, the Company recorded total intangible asset impairment charges of $86.5 million. This included a $9.3 million intangible impairment charge in the first half of fiscal 2026 related to the intellectual property associated with the HAS viscoelastic diagnostic devices, related assays and disposables within the Hospital business unit, as acquired from HemoAssay Science and Technology (Suzhou) Co. Ltd., a China-incorporated company, and its affiliates (collectively, “HemoAssay”) in fiscal 2021. The intangible impairment charge was the result of lower revenue projections of the HemoAssay devices and disposables. The fair value as of March 28, 2026 was $0.8 million with a remaining useful life of approximately five years. Additionally, in the fourth quarter of fiscal 2026, the Company recorded an intangible asset impairment charge of $77.2 million related to long-lived intangible assets associated with the acquisition of Attune Medical, which occurred in fiscal 2025 within the Interventional Technologies reporting unit, which is within the Hospital reportable segment. The intangible impairment charge was the result of lower revenue projections, changes in market conditions and declines in operating performance. The fair value as of March 28, 2026 was $11.3 million.

Significant unobservable inputs used in the Level 3 fair value measurement of the HemoAssay intangible assets included projected revenues, costs and the remaining useful lives of the assets. The Level 3 inputs for the Attune Medical included projected revenues, operating margins, and a discount rate reflecting the estimated weighted average cost of capital of a market participant. The revenue and margin assumptions were based on internal forecasts, which incorporate assumptions about future market conditions, product adoption rates, pricing, and competitive dynamics. The discount rate utilized in the valuation of the Attune Medical asset group was 19.8%, which reflects the higher risk profile, earlier stage of commercialization, and greater uncertainty in projected cash flows relative to the broader Interventional Technologies reporting unit. The discount rate was developed using market-based inputs, including a risk-free rate, equity risk premium, and company-specific risk adjustments.

The Company continues to monitor the HemoAssay and Attune Medical asset group for intangible impairment indicators, including macroeconomic conditions, industry trends, and changes in business performance. While the intangible impairment charge recognized reflects management’s best estimate of fair value as of the testing date, it is reasonably possible that changes in assumptions or future business conditions could result in additional impairment charges in future periods.

In the fourth quarter of fiscal 2026, the Company acquired Vivasure and recorded $117.1 million of developed technology based on the purchase accounting valuation. Refer to Note 3, Acquisitions, Divestitures and Strategic Investments, for additional information regarding the Vivasure acquisition.

In the fourth quarter of fiscal 2025, the Company completed the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were sold. The related intangible assets are fully amortized and have a net book value of zero. The gross intangible assets value was $185.6 million. Refer to Note 3, Acquisitions, Divestitures and Strategic Investments, for additional information regarding the divestiture.

Intangible assets include the value assigned to license rights and developed technology, patents, customer contracts and relationships and trade names. The estimated useful lives for all of these intangible assets are approximately 5 to 15 years.

Aggregate amortization expense for amortized intangible assets for fiscal 2026, 2025 and 2024 was $50.5 million, $55.6 million and $41.4 million, respectively.

Amortization expense on intangible assets for the next five years is estimated to be as follows:


	Amortization Expense
	(Dollars in Thousands)
Fiscal 2027	$	46,864
Fiscal 2028	$	44,781
Fiscal 2029	$	43,105
Fiscal 2030	$	41,836
Fiscal 2031	$	40,359

For costs incurred related to the development of software to be sold, leased, or otherwise marketed, the Company applies the provisions of ASC Topic 985-20, Software - Costs of Software to be Sold, Leased or Marketed, which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers. The costs capitalized for each project are included in intangible assets in the consolidated financial statements.

The Company capitalized $6.7 million and $7.7 million in software development costs for ongoing initiatives during fiscal 2026 and 2025, respectively. As of March 28, 2026 and March 29, 2025, the Company had a total of $101.8 million and $94.7 million, respectively, of software costs capitalized, of which $5.9 million and $9.2 million, respectively, are related to in process software development initiatives and the remaining balance represents in-service assets that are being amortized over their useful lives. Amortization expense for capitalized software was $6.1 million, $6.7 million and $8.6 million for fiscal 2026, 2025 and 2024, respectively.

Insider Trading Arrangements	12 Months Ended
Insider Trading Arrangements	Mar. 28, 2026
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

CAPITAL STOCK (Schedule of Share-Based Compensation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 33,827	$ 29,636	$ 28,332
Location, Statement of Income, Balance [Axis]: us-gaap:CostOfGoodsAndServicesSold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	1,371	1,818	1,564
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	2,945	1,847	3,106
Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 29,511	$ 25,971	$ 23,662

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 28, 2026	Mar. 29, 2025
Current assets:
Cash and cash equivalents	$ 245,440	$ 306,763
Accounts receivable, less allowance for credit losses of $3,693 as of March 28, 2026 and $6,300 as of March 29, 2025	216,855	202,657
Inventories, net	306,370	365,141
Prepaid expenses and other current assets	66,214	60,414
Total current assets	834,879	934,975
Property, plant and equipment, net	305,761	284,052
Intangible assets, less accumulated amortization of $363,763 as of March 28, 2026 and $316,313 as of March 29, 2025	447,655	455,743
Goodwill	656,368	604,269
Deferred tax asset	9,521	7,803
Other long-term assets	141,741	164,106
Total assets	2,395,925	2,450,948
Current liabilities:
Notes payable and current maturities of long-term debt	5,015	303,558
Accounts payable	51,056	66,999
Accrued payroll and related costs	68,191	59,423
Other current liabilities	158,337	148,133
Total current liabilities	282,599	578,113
Long-term debt, net of current maturities	1,219,565	921,230
Deferred tax liability	38,048	62,575
Other long-term liabilities	59,393	68,194
Stockholders’ equity:
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 45,252,667 shares as of March 28, 2026 and 48,215,899 shares as of March 29, 2025	453	482
Additional paid-in capital	554,137	523,264
Retained earnings	279,344	352,174
Accumulated other comprehensive loss	(37,614)	(55,084)
Total stockholders’ equity	796,320	820,836
Total liabilities and stockholders’ equity	$ 2,395,925	$ 2,450,948

NOTES PAYABLE AND LONG-TERM DEBT (Schedule of Notes Payable and Long-Term Debt) (Details) - USD ($) $ in Thousands	Mar. 28, 2026	Mar. 29, 2025
Debt Instrument [Line Items]
Long-term debt	$ 1,224,580	$ 1,224,788
Less: current portion	(5,015)	(303,558)
Long-term debt	1,219,565	921,230
Convertible notes
Debt Instrument [Line Items]
Long-term debt	688,775	983,951
Term loan, net of financing fees
Debt Instrument [Line Items]
Long-term debt	235,131	240,028
Revolving credit facility
Debt Instrument [Line Items]
Long-term debt	300,000	0
Other borrowings
Debt Instrument [Line Items]
Long-term debt	$ 674	$ 809

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.9-06)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 26: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 42: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

+ Details

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedules of Derivatives) (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Assets
Money market funds	$ 90,716	$ 158,916
Assets fair value	94,061	161,519
Liabilities
Liabilities fair value	21,176	2,774
Level 1
Assets
Money market funds	90,716	158,916
Assets fair value	90,716	158,916
Liabilities
Liabilities fair value	0	0
Level 2
Assets
Money market funds	0	0
Assets fair value	3,345	2,603
Liabilities
Liabilities fair value	113	496
Level 3
Assets
Money market funds	0	0
Assets fair value	0	0
Liabilities
Liabilities fair value	21,063	2,278
Designated as Hedging Instrument
Assets
Derivative Asset	3,345	2,603
Liabilities
Derivative Liability, Current	113	496
Foreign Exchange Contract \| Designated as Hedging Instrument
Assets
Derivative Asset, Current	1,245	193
Liabilities
Derivative Liability, Current	50	471
Derivative Assets		193
Derivative Liabilities		471
Foreign Exchange Contract \| Designated as Hedging Instrument \| Level 1
Assets
Derivative Asset, Current	0
Liabilities
Derivative Liability, Current	0
Derivative Assets		0
Derivative Liabilities		0
Foreign Exchange Contract \| Designated as Hedging Instrument \| Level 2
Assets
Derivative Asset, Current	1,245
Liabilities
Derivative Liability, Current	50
Derivative Assets		193
Derivative Liabilities		471
Foreign Exchange Contract \| Designated as Hedging Instrument \| Level 3
Assets
Derivative Asset, Current	0
Liabilities
Derivative Liability, Current	0
Derivative Assets		0
Derivative Liabilities		0
Foreign Exchange Contract \| Not Designated as Hedging Instrument
Assets
Derivative Asset, Current	330	85
Liabilities
Derivative Liability, Current	63	25
Derivative Assets		85
Derivative Liabilities		25
Foreign Exchange Contract \| Not Designated as Hedging Instrument \| Level 1
Assets
Derivative Asset, Current	0
Liabilities
Derivative Liability, Current	0
Derivative Assets		0
Derivative Liabilities		0
Foreign Exchange Contract \| Not Designated as Hedging Instrument \| Level 2
Assets
Derivative Asset, Current	330
Liabilities
Derivative Liability, Current	63
Derivative Assets		85
Derivative Liabilities		25
Foreign Exchange Contract \| Not Designated as Hedging Instrument \| Level 3
Assets
Derivative Asset, Current	0
Liabilities
Derivative Liability, Current	0
Derivative Assets		0
Derivative Liabilities		0
Interest Rate Swap \| Designated as Hedging Instrument
Assets
Derivative Asset, Current		1,305
Derivative Asset, Noncurrent		1,020
Liabilities
Derivative Assets		2,325
Interest Rate Swap \| Designated as Hedging Instrument \| Level 1
Liabilities
Derivative Assets		0
Interest Rate Swap \| Designated as Hedging Instrument \| Level 2
Assets
Derivative Asset, Current	823
Derivative Asset, Noncurrent	947
Liabilities
Derivative Assets		2,325
Interest Rate Swap \| Designated as Hedging Instrument \| Level 3
Liabilities
Derivative Assets		0
Interest Rate Swap \| Not Designated as Hedging Instrument
Assets
Derivative Asset	1,770
Interest Rate Swap \| Not Designated as Hedging Instrument \| Level 1
Assets
Derivative Asset	0
Interest Rate Swap \| Not Designated as Hedging Instrument \| Level 2
Assets
Derivative Asset	1,770
Interest Rate Swap \| Not Designated as Hedging Instrument \| Level 3
Assets
Derivative Asset	0
Contingent Consideration
Liabilities
Liabilities fair value	21,063	2,278
Contingent Consideration \| Level 1
Liabilities
Liabilities fair value	0	0
Contingent Consideration \| Level 2
Liabilities
Liabilities fair value	0	0
Contingent Consideration \| Level 3
Liabilities
Liabilities fair value	$ 21,063	$ 2,278	$ 0

RESTRUCTURING (Tables)

12 Months Ended

Mar. 28, 2026

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Transformation Costs by Type of Cost


	Prior Programs		2020 Program		Portfolio Rationalization Initiatives		Market and Regional Alignment Initiatives		Total
	(Dollars in Thousands)
Balance as of April 1, 2023	$	340	$	1,810	$	—	$	—	$	2,150
Costs incurred, net of reversals	(276)		450		13,915		—		14,089
Payments	(64)		(1,775)		(2,606)		—		(4,445)

Balance as of March 30, 2024	$	—	$	485	$	11,309	$	—	$	11,794
Costs incurred, net of reversals	—		566		12,797		550		13,913
Payments	—		(761)		(12,755)		(550)		(14,066)
Non-cash adjustments	—		—		(8,616)		—		(8,616)
Balance as of March 29, 2025	$	—	$	290	$	2,735	$	—	$	3,025
Costs incurred, net of reversals	—		(62)		(1,919)		5,095		3,114
Payments	—		(205)		(100)		(4,527)		(4,832)

Balance as of March 28, 2026	$	—	$	23	$	716	$	568	$	1,307


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Cost of goods sold	$	(496)	$	11,328	$	11,286
Research and development	960		(61)		456
Selling, general and administrative expenses	2,650		2,646		2,347
Total	$	3,114	$	13,913	$	14,089

Restructuring and Related Costs by Segment


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Cost of goods sold	$	(33)	$	3,304	$	5,734
Research and development	11		1,649		1,750
Selling, general and administrative expenses	127		2,292		2,015
Total	$	105	$	7,245	$	9,499

The tables below present restructuring and restructuring related costs by reportable segment:


	Year Ended
	2026		2025		2024
	(Dollars in Thousands)
Restructuring costs
Plasma	$	447	$	258	$	1,015
Blood Center	(558)		4,742		5,606
Hospital	1,326		1,664		3,863
Corporate	1,899		7,249		3,605
Total	$	3,114	$	13,913	$	14,089

Restructuring related costs
Plasma	$	9	$	281	$	1,050
Blood Center	(1)		154		286
Hospital	—		143		408
Corporate	97		6,667		7,755
Total	$	105	$	7,245	$	9,499

Total restructuring and restructuring related costs	$	3,219	$	21,158	$	23,588

GOODWILL AND INTANGIBLE ASSETS - Amortization Expense of Intangible Assets (Details) $ in Thousands	Mar. 28, 2026 USD ($)
Intangible Asset, Goodwill and Other [Abstract]
Fiscal 2027	$ 46,864
Fiscal 2028	44,781
Fiscal 2029	43,105
Fiscal 2030	41,836
Fiscal 2031	$ 40,359

INCOME TAXES (Schedule Domestic and Foreign Income Before Provision for Income Tax) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Income Tax Disclosure [Abstract]
Domestic	$ 87,236	$ 161,800	$ 112,563
Foreign	40,794	50,271	39,302
Income before provision for income taxes	$ 128,030	$ 212,071	$ 151,865

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

GOODWILL AND INTANGIBLE ASSETS - Schedule of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025
Goodwill [Roll Forward]
Goodwill, carrying amount	$ 604,269	$ 565,082
Divestitures		(6,381)
Acquisitions	50,478	69,542
Purchase accounting adjustments		(19,248)
Currency translation	1,621	(4,726)
Goodwill, carrying amount	656,368	604,269
Plasma
Goodwill [Roll Forward]
Goodwill, carrying amount	29,043	29,043
Divestitures		0
Acquisitions	0	0
Purchase accounting adjustments		0
Currency translation	0	0
Goodwill, carrying amount	29,043	29,043
Blood Center
Goodwill [Roll Forward]
Goodwill, carrying amount	26,967	33,484
Divestitures		(6,381)
Acquisitions	0	0
Purchase accounting adjustments		0
Currency translation	(79)	(136)
Goodwill, carrying amount	26,888	26,967
Hospital
Goodwill [Roll Forward]
Goodwill, carrying amount	548,259	502,555
Divestitures		0
Acquisitions	50,478	69,542
Purchase accounting adjustments		(19,248)
Currency translation	1,700	(4,590)
Goodwill, carrying amount	$ 600,437	$ 548,259

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

+ Details

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Change in Fair Value of Contingent Consideration (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisition date fair value of contingent consideration	$ 20,673	$ 25,000
Purchase accounting adjustments	(9)	$ 300
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]		Interest and other expense, net
Change in fair value	(1,879)	$ (23,022)
Fair Value, Measurements, Recurring
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	2,774
Ending balance	21,176	2,774
Level 3 \| Fair Value, Measurements, Recurring
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	2,278
Ending balance	21,063	2,278
Contingent Consideration \| Fair Value, Measurements, Recurring
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	2,278
Ending balance	21,063	2,278
Contingent Consideration \| Level 3 \| Fair Value, Measurements, Recurring
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	2,278	0
Ending balance	$ 21,063	$ 2,278

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value	$ 820,836	$ 959,959	$ 817,997
Other comprehensive income (loss)	17,470	(19,452)	(5,251)
Ending balance, value	796,320	820,836	959,959
Foreign currency
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value	(56,248)	(38,274)
Other comprehensive income before reclassifications	16,916	(17,974)
Amounts reclassified from accumulated other comprehensive income (loss)	0	0
Ending balance, value	(39,332)	(56,248)	(38,274)
Defined benefit plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value	1,149	1,748
Other comprehensive income before reclassifications	(403)	(599)
Amounts reclassified from accumulated other comprehensive income (loss)	0	0
Ending balance, value	746	1,149	1,748
Net Unrealized Gain (Loss) on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value	15	894
Other comprehensive income before reclassifications	2,097	(935)
Amounts reclassified from accumulated other comprehensive income (loss)	(1,140)	56
Ending balance, value	972	15	894
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value	(55,084)	(35,632)	(30,381)
Other comprehensive income before reclassifications	18,610	(19,508)
Amounts reclassified from accumulated other comprehensive income (loss)	(1,140)	56
Other comprehensive income (loss)	17,470	(19,452)	(5,251)
Ending balance, value	$ (37,614)	$ (55,084)	$ (35,632)

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-4

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-17

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

+ Details

- Definition

Amount after tax, before reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-17

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-4

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482739/220-10-55-15

+ Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

+ Details

- Definition

Amount after tax of reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-17

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-4

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482739/220-10-55-15

+ Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2

+ Details

CAPITAL STOCK (Schedule of Assumptions Used to Estimate Fair Value) (Details) - $ / shares	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	47.60%	29.30%	28.60%
Expected term	6 months	6 months	6 months
Risk-free interest rate	4.10%	4.90%	5.40%
Dividend Yield	0.00%	0.00%	0.00%
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	44.20%	43.90%	45.30%
Expected term	5 years 4 months 24 days	5 years 2 months 12 days	5 years 1 month 6 days
Risk-free interest rate	4.10%	4.40%	3.50%
Dividend Yield	0.00%	0.00%	0.00%
Fair value per option (in dollars per share)	$ 32.35	$ 43.56	$ 39.46
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant Date Fair Value (in dollars per share), Granted	70.52	95.09	89.21
Weighted Average Grant Date Fair Value (in dollars per share), Vested	$ 78.36	$ 75.04	$ 67.14
Performance Share Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	31.81%	35.35%	48.20%
Peer group stock price volatility	46.62%	35.95%	40.29%
Correlation of returns	27.81%	58.08%	59.93%
Weighted Average Grant Date Fair Value (in dollars per share), Granted	$ 87.66	$ 128.25	$ 128.83
Weighted Average Grant Date Fair Value (in dollars per share), Vested	$ 84.96	$ 72.35	$ 0

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

12 Months Ended

Mar. 28, 2026

Derivative Instruments and Hedging Activities Disclosure [Abstract]

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

The Company manufactures, markets and sells its products globally. For the fiscal years ended March 28, 2026, March 29, 2025 and March 30, 2024 the percent of the Company’s sales generated outside the U.S. in local currencies were 26.4%, 25.7% and 25.9%, respectively. The Company also incurs certain manufacturing, marketing and selling costs in international markets in local currency.

Accordingly, earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, the Company’s reporting currency. The Company has a program in place that is designed to mitigate the exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize, for a period of time, the impact on its financial results from changes in foreign exchange rates. The Company utilizes foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily Japanese Yen, Mexican Peso and Euro, and to a lesser extent Canadian Dollar, Swiss Franc and Chinese Yuan. This does not eliminate the impact of the volatility of foreign exchange rates. However, because the Company generally enters into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.

Designated Foreign Currency Hedge Contracts

All of the Company’s designated foreign currency hedge contracts as of March 28, 2026 and March 29, 2025 were cash flow hedges under ASC Topic 815, Derivatives and Hedging. The Company records the effective portion of any change in the fair value of designated foreign currency hedge contracts in other comprehensive income until the related third-party transaction occurs. Once the related third-party transaction occurs, the Company reclassifies the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. The Company had designated foreign currency hedge contracts outstanding in the contract amount of $30.1 million as of March 28, 2026 and $23.6 million as of March 29, 2025. As of March 28, 2026, a gain of $2.5 million, net of tax, will be reclassified to earnings within the next twelve months. Substantially all currency cash flow hedges outstanding as of March 28, 2026 mature within twelve months.

Non-Designated Foreign Currency Contracts

The Company manages its exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. It uses foreign currency forward contracts as a part of its strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC Topic 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. The Company had non-designated foreign currency hedge contracts under ASC Topic 815 outstanding in the contract amount of $75.3 million as of March 28, 2026 and $89.6 million as of March 29, 2025.

Interest Rate Swaps

Part of the Company’s interest rate risk management strategy includes the use of interest rate swaps to mitigate its exposure to changes in variable interest rates. The Company’s objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations.

To mitigate the interest rate risk on the Company’s senior unsecured term loan, in September 2022, the Company entered into four interest rate swaps, two of which expired in June 2023 and the remaining two were amended and extended in September 2024. The amendment and extension of the two interest rate swaps did not have a material impact on the consolidated financial statements.

Loans under the 2024 Revised Credit Facilities bear interest at an annual rate equal to the 1-month USD Term SOFR, plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio. As a result of the amendment and extension in September 2024, the two modified interest rate swaps have an average blended fixed interest rate of 3.31% plus the applicable rate on approximately 80% of the notional value of the unsecured term loan, until their maturity in April 2029. The Company has determined both of these interest rate swaps are effective and qualify for hedge accounting treatment.

The Company held the following interest rate swaps as of March 28, 2026:


Hedged Item	Original Notional Amount		Notional Amount as of March 28, 2026		Designation Date	Effective Date	Termination Date	Fixed Interest Rate	Estimated Fair Value Assets
	(Dollars in Thousands)
1-month USD Term SOFR	$	109,900	$	100,321	9/27/2024	9/30/2024	4/30/2029	3.3%	$	859
1-month USD Term SOFR	109,900		98,966		9/27/2024	9/30/2024	4/30/2029	3.3%	912
Total	$	219,800	$	199,287					$	1,771

For fiscal 2026, the Company recorded a loss of $0.4 million, net of tax, in AOCL within the consolidated balance sheets to recognize the effective portion of the fair value of the swaps that qualify as cash flow hedges.

Trade Receivables

In the ordinary course of business, the Company grants trade credit to its customers on normal credit terms. In an effort to reduce its credit risk, the Company (i) establishes credit limits for all customers, (ii) performs ongoing credit evaluations of customers’ financial condition, (iii) monitors the payment history and aging of customers’ receivables and (iv) monitors open orders against an individual customer’s outstanding receivable balance.

The Company’s allowance for credit losses is maintained for trade accounts receivable based on the expected collectability, the historical collection experience, the length of time an account is outstanding, the financial position of the customer and information provided by credit rating services. The Company has not experienced significant customer payment defaults or identified other significant collectability concerns.

The following is a roll forward of the allowance for credit losses:


	Allowance for Credit Losses (Recoveries)
	(Dollars in Thousands)
Balance as of April 1, 2023	$	4,932
Credit loss	840
Recoveries	(77)
Balance as of March 30, 2024	$	5,695
Credit loss	725
Recoveries	(120)
Balance as of March 29, 2025	$	6,300
Credit loss	615
Write-offs	(3,129)
Recoveries	(93)
Balance as of March 28, 2026	$	3,693

Other Fair Value Measurements

Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes the following three-level hierarchy used for measuring fair value:

•Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.

•Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.

•Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

The Company’s money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

Fair Value of Derivative Instruments


Derivative Instruments	Amount of Gain (Loss) Recognized in AOCL		Amount of Gain (Loss) Reclassified from AOCL into Earnings		Classification in Earnings	Amount of Gain (Loss) Excluded from Effectiveness Testing		Classification in Earnings
	(Dollars in Thousands)
Designated foreign currency hedge contracts, net of tax	$	2,540	$	1,145	Net revenues, COGS and SG&A	$	2,637	Interest and other expense, net
Non-designated foreign currency hedge contracts	$	—	$	—		$	(5,111)	Interest and other expense, net
Designated interest rate swaps, net of tax	$	(443)	$	(5)	Interest and other expense, net	$	—

The Company did not have fair value hedges or net investment hedges outstanding as of March 28, 2026 or March 29, 2025. As of March 28, 2026, no material deferred taxes were recognized for designated foreign currency hedges.

ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the consolidated balance sheets. The Company determines the fair value of its derivative instruments using the framework prescribed by ASC Topic 820, Fair Value Measurements and Disclosures, by considering the estimated amount it would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and its creditworthiness for liabilities. In certain instances, the Company may utilize financial models to measure fair value. Generally, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of March 28, 2026, the Company has classified its derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC Topic 815, as discussed below, because these observable inputs are available for substantially the full term of its derivative instruments.

The following tables present the fair value of the Company’s derivative instruments as they appear in its consolidated balance sheets as of March 28, 2026 and March 29, 2025:


	Classification	March 28, 2026		March 29, 2025
		(Dollars in Thousands)
Derivative Assets:
Designated foreign currency hedge contracts	Prepaid expenses and other current assets	$	1,245	$	193
Non-designated foreign currency hedge contracts	Prepaid expenses and other current assets	330		85
Designated interest rate swaps	Prepaid expenses and other current assets	823		1,305
Designated interest rate swaps	Other long-term assets	947		1,020
Total		$	3,345	$	2,603

Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	50	$	471
Non-designated foreign currency hedge contracts	Other current liabilities	63		25


Total		$	113	$	496

Fair Value Measured on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of March 28, 2026 and March 29, 2025.


	As of March 28, 2026
	Level 1		Level 2		Level 3		Total
	(Dollars in Thousands)
Assets
Money market funds	$	90,716	$	—	$	—	$	90,716
Designated foreign currency hedge contracts	—		1,245		—		1,245
Non-designated foreign currency hedge contracts	—		330		—		330
Designated interest rate swaps	—		1,770		—		1,770

Total	$	90,716	$	3,345	$	—	$	94,061

Liabilities
Designated foreign currency hedge contracts	$	—	$	50	$	—	$	50
Non-designated foreign currency hedge contracts	—		63		—		63

Contingent consideration	—		—		21,063		21,063
Total	$	—	$	113	$	21,063	$	21,176


	As of March 29, 2025
	Level 1		Level 2		Level 3		Total
	(Dollars in Thousands)
Assets
Money market funds	$	158,916	$	—	$	—	$	158,916
Designated foreign currency hedge contracts	—		193		—		193
Non-designated foreign currency hedge contracts	—		85		—		85
Designated interest rate swaps	—		2,325		—		2,325
Total	$	158,916	$	2,603	$	—	$	161,519

Liabilities
Designated foreign currency hedge contracts	$	—	$	471	$	—	$	471
Non-designated foreign currency hedge contracts	—		25		—		25

Contingent consideration	—		—		2,278		2,278
Total	$	—	$	496	$	2,278	$	2,774

Foreign currency hedge contracts - The fair value of foreign currency hedge contracts was measured using significant other observable inputs and valued by reference to over-the-counter quoted market prices for similar instruments. The Company does not believe that the fair value of these derivative instruments differs significantly from the amount that could be realized upon settlement or maturity, or that the changes in fair value will have a significant effect on its results of operations, financial condition or cash flows.

Interest rate swaps - The fair values of interest rate swaps are measured using the present value of expected future cash flows using market-based observable inputs, including credit risk and interest rate yield curves. The Company does not believe that the fair values of these derivative instruments differ significantly from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a significant effect on its results of operations, financial condition or cash flows.

Contingent consideration - The fair value of contingent consideration liabilities is based on significant unobservable inputs, including management estimates and assumptions, and is measured based on the probability-weighted present value of the payments expected to be made. Accordingly, the fair value of contingent consideration has been classified as level 3 within the fair value hierarchy.

The level 3 fair value measurements of contingent consideration liabilities include the following significant unobservable inputs:


	Fair Value as of
	March 28, 2026		Valuation Technique	Unobservable Input	Range
	(Dollars in Thousands)
Revenue-based payments	$	3,076	Monte Carlo Simulation Model	Discount rate	3.4%
				Projected fiscal year of payments	2028 - 2030



Event-based payments	$	390	Monte Carlo Simulation Model	Discount rate	5.8%
				Projected fiscal year of payment	2027 - 2028
	$	17,597		Discount Rate	3.0%
				Projected fiscal year of payment	2027

Fair Value as of

March 29, 2025

Valuation Technique

Unobservable Input

Range

(Dollars in Thousands)

Revenue-based payments

1,214

Monte Carlo Simulation Model

Discount rate

6.3%

Projected fiscal year of payments

2026 - 2028

Event-based payment

1,064

Monte Carlo Simulation Model

Discount rate

5.8%

Projected fiscal year of payment

2026 - 2028

The fair value of contingent consideration associated with acquisitions was $21.1 million and $2.3 million as of March 28, 2026 and March 29, 2025, respectively. There was $17.6 million included in other current liabilities as of March 28, 2026 and $3.4 million and $2.3 million included in other long-term liabilities as of March 28, 2026 and March 29, 2025, respectively.

A reconciliation of the change in the fair value of contingent consideration is included in the following table:


	Contingent Consideration
	(Dollars in Thousands)
Balance as of March 30, 2024	$	—
Acquisition date fair value of contingent consideration	25,000
Purchase accounting adjustments	300

Change in fair value	(23,022)

Balance as of March 29, 2025	$	2,278
Acquisition date fair value of contingent consideration	20,673

Payment of contingent consideration	(9)
Change in fair value	(1,879)

Balance as of March 28, 2026	$	21,063

Other Fair Value Disclosures

The fair value of the 2029 Notes was $662.4 million and $668.4 million as of March 28, 2026 and March 29, 2025, respectively, which was determined using the market price on the last trading day of the reporting period and is considered level 2 in the fair value hierarchy.

The senior unsecured term loan (which is carried at amortized cost), the revolving credit facility, accounts receivable and accounts payable approximate fair value.